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Abstract  
Background  
Skin cancers are the most common form of cancer occurring in white populations. They account for 
approximately 40% of all cancer cases globally, with the highest incidence in Australia. The three 
most common histological types of skin cancer are basal cell carcinoma (BCC), cutaneous 
squamous cell carcinoma (cSCC) and melanoma. The risk of developing skin cancer depends on 
both environmental and constitutional factors. Exposure to ultra-violet radiation (UVR) is the major 
environmental risk factor for BCC, cSCC and melanoma, and skin phenotypic characteristics are 
the major constitutional risk factors. 
 
Cigarette smoking, obesity and height have been shown to have an etiologic effect for many cancers 
in humans, but their associations with skin cancer are unclear. Studies examining the relationships 
between these factors and skin cancer have been limited by factors such as lack of information on 
established skin cancer risk factors, inadequate approach to statistical analyses, and lack of 
exploration of other potential sources of bias, such as detection bias.  
 
Aim 
The overall aim of this thesis was to assess whether cigarette smoking, obesity (estimated by body 
mass index (BMI)) and height are independent risk factors for BCC, cSCC and melanoma using 
various epidemiological and statistical techniques. In particular, the research aimed to address some 
of the limitations arising from previous studies.   
 
Methods  
This research was conducted using data from the QSkin Sun and Health Study (n=43,794), 
supplemented by linkage to various health databases including the Australian national health 
insurance scheme (Medicare), pathology laboratories and the Queensland Cancer Registry. 
Smoking history, BMI and height were self-reported at baseline, with nearly perfect repeatability. 
Hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between smoking, BMI 
and height were estimated using multivariable Cox proportional hazards regression, accounting for 
death as a competing event.  
  
ii 
 
Findings were summarised from 14 prospective cohort studies (including QSkin) with nearly 2.5 
million participants and over 17,000 cases (only for BMI and melanoma associations). Finally, 
summary data from recent GWAS meta-analyses of BMI, height and melanoma were used to 
perform Mendelian randomisation (MR) analyses. 
 
Results  
During a median follow-up period of 3.0 years (3.5 years for melanoma), 640 participants 
developed at least one histologically confirmed BCC, 193 developed at least one histologically 
confirmed invasive cSCC and 642 developed melanoma (253 invasive melanomas, 389 in situ 
melanomas). In the QSkin cohort, compared with never smokers, current smokers had significantly 
lower risks of BCC (HR: 0.6; 95% CI: 0.4-0.9) but significantly higher risks of cSCC (HR: 2.3; 
95% CI: 1.5-3.6). Current smoking was not associated with melanoma risk. Former smokers had 
similar risks for BCC and cSCC as never smokers, but had lower risks of melanoma (HR 0.76; 95% 
CI, 0.57-1.01). For all skin cancer subtypes, no dose-response trends were observed with duration 
of smoking, intensity, or time since quitting, except for melanoma where risks were lower with 
greater quantity of cigarettes smoked (HR 0.75; 95% CI, 0.56-0.98 per 10 cigarettes/day). On 
further analysis, current smokers had fewer skin examinations and procedures than never smokers, 
suggesting greater opportunities for detection among never smokers. 
 
BMI was not associated with melanoma in the QSkin cohort and the meta-analysis of prospective 
observational studies. In both analyses, no difference between men and women was found. The MR 
findings provided more compelling evidence that obesity does not alter risk of melanoma. However, 
using MR techniques, a significantly increased risk between genetically-predicted height and 
melanoma was found (OR: 1.06, 95% CI: 1.02-1.12), per 1SD (9.27 cm) increase in height. In the 
QSkin cohort, nonlinear associations were observed between height and melanoma risk overall (P-
nonlinearity=0.06). When stratified by sex, a significant non-linear association between increasing 
height and melanoma was found for men (P-nonlinearity < 0.001) but not women. 
 
Conclusion  
Smoking was associated with lower risk of BCC and melanoma. However, mixed findings relating 
to current and former smokers, and inconsistent evidence regarding dose-response relationships 
suggest that these associations are unlikely to be explained entirely by biological effects. For BCC, 
the lower risks were possibly a result of detection bias due to lower rates of skin examinations 
among smokers. The increased risk of cSCC among current smokers is possibly causal since the 
  
iii 
 
association is consistent with evidence from other cohort studies, providing another reason to cease 
smoking. Using three separate analyses, no evidence was found that higher BMI confers an 
increased risk of melanoma, although there remains some low-level uncertainty about a possible 
non-linear association between BMI and melanoma risk in women. Finally, strong evidence was 
found that height is a risk factor for melanoma, supporting earlier studies.  The mechanism remains 
unclear, and it is possible that the effects are mediated through hormonal and genetic pathways. 
Future studies should focus on understanding mechanisms underlying this association.   
  
  
iv 
 
Declaration by author 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly-authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, financial support and any other original research work used or reported in my thesis. The 
content of my thesis is the result of work I have carried out since the commencement of my higher 
degree by research candidature and does not include a substantial part of work that has been 
submitted to qualify for the award of any other degree or diploma in any university or other tertiary 
institution. I have clearly stated which parts of my thesis, if any, have been submitted to qualify for 
another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the policy and procedures of The University of Queensland, the thesis be made available 
for research and study in accordance with the Copyright Act 1968 unless a period of embargo has 
been approved by the Dean of the Graduate School.  
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis and have sought permission from co-authors for 
any jointly authored works included in the thesis. 
  
  
v 
 
Publications during candidature 
Publications included in this thesis  
1. Dusingize JC, Olsen CM, Pandeya N, Subramaniam P, Thompson BS, Neale RE, Green 
AC, Whiteman DC; QSkin Study. Cigarette Smoking and the Risks of Basal Cell Carcinoma and 
Squamous Cell Carcinoma. Journal of Investigative Dermatology. 2017; 137(8):1700-1708. 
 
2. Dusingize JC, Olsen CM, Pandeya N, Thompson BS, Webb PM, Green AC, Neale RE, 
Whiteman DC; QSkin Study. Smoking and Cutaneous Melanoma: Findings from the QSkin Sun 
and Health Cohort Study. Cancer Epidemiology Biomarkers Prevention. 2018; 27(8):874-881.  
 
Submitted manuscripts included in this thesis  
3. Dusingize JC, Olsen CM, An J, Pandeya N, Law MH, Thompson BS, Goldstein AM, Iles 
MM, Webb PM, Neale RE, Ong JS, MacGregor S, Whiteman DC. Body mass index and risk of 
cutaneous melanoma: Evidence from Observational and Mendelian randomisation analyses.  
 
4. Dusingize JC, Olsen CM, An J, Pandeya N, Law MH, Thompson BS, Goldstein AM, Iles 
MM, Webb PM, Neale RE, Ong JS, MacGregor S, Whiteman DC. Adult height and risk of 
cutaneous melanoma: findings from the QSkin Sun and Health cohort study and Mendelian 
randomisation.  
 
  
  
vi 
 
Other publications during candidature 
 
1. Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Green AC, Neale RE, Whiteman DC; 
QSkin Study. Association between phenotypic characteristics and melanoma in a large 
prospective cohort study. Journal of Investigative Dermatology. 2018; (18):32692-7.  
 
2. Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Green AC, Neale RE, Whiteman DC; 
QSkin Study. Physician Skin Checks before the Diagnosis of Melanoma Correlate with 
Tumour Characteristics. Journal of Investigative Dermatology. 2018; 138(10):2288-2291.  
 
3. Dusingize JC, Olsen CM, Pandeya N, Thompson BS, Webb PM, Green AC, Neale RE, 
Whiteman DC; QSkin Study. Smoking and Cutaneous Melanoma: Findings from the QSkin 
Sun and Health Cohort Study. Cancer Epidemiology Biomarkers Prevention. 2018; 27(8):874-
881.  
 
4. Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Webb PM, Green AC, Neale RE, 
Whiteman DC; QSkin Study. Risk Stratification for Melanoma: Models Derived and Validated 
in a Purpose-Designed Prospective Cohort. Journal of the National Cancer Institute. 2018; 
110(10):1075-1083.  
 
5. Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Subramaniam P, Nagle CM, Green AC, 
Neale RE, Webb PM, Whiteman DC; QSkin Study. Hormonal and reproductive factors and 
incidence of basal cell carcinoma and squamous cell carcinoma in a large, prospective cohort. 
Journal of the American Academy of Dermatology. 2018; 78(3):615-618. 
 
6. Dusingize JC, Olsen CM, Pandeya N, Subramaniam P, Thompson BS, Neale RE, Green AC, 
Whiteman DC; QSkin Study. Cigarette Smoking and the Risks of Basal Cell Carcinoma and 
Squamous Cell Carcinoma. Journal of Investigative Dermatology. 2017; 137(8):1700-1708. 
 
  
  
vii 
 
Contributions by others to the thesis 
Conception and design of the project: JC Dusingize, CM Olsen, DC Whiteman 
Development of methodology: JC Dusingize, CM Olsen, N Pandeya, DC Whiteman 
Acquisition of data: CM Olsen, BS Thompson, MH Law, S MacGregor, DC Whiteman 
Data management: BS Thompson, N Pandeya 
Analysis and interpretation of data: JC Dusingize, CM Olsen, N Pandeya, JS Ong, DC Whiteman 
Performed critical revision and editing of the manuscript: JC Dusingize, CM Olsen, N Pandeya, 
BS Thompson, P Subramaniam, J An, AM Goldstein, PM Webb, AC Green, RE Neale, MM Iles, S 
MacGregor, DC Whiteman 
Administrative, technical, or material support: CM Olsen, N Pandeya, BS Thompson, DC 
Whiteman 
General thesis advice and editing: CM Olsen, N Pandeya, DC Whiteman  
Thesis supervision: CM Olsen, N Pandeya, DC Whiteman 
 
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
No works submitted towards another degree have been included in this thesis. 
 
Research Involving Human or Animal Subjects 
This research was approved by the Human Research Ethics Committee of the QIMR Berghofer 
Medical Research Institute (approval number: P1309). Each participant provided written informed 
consent to take part.  
  
viii 
 
Acknowledgements  
 
Undertaking this PhD journey has been a truly life-changing experience for me and the work 
presented in this thesis would not have been possible without the support that I received from many 
people.  
 
I would like to express my special appreciation and thanks to my principal supervisor Professor 
David Whiteman. Thank you for giving me your time and support over the years. Your advice on 
both research as well as on my career have been invaluable. You have taught me how to think 
critically, communicate more clearly and concisely and become a better researcher.  Thank you for 
allowing me to pursue various projects without objection.  
 
I would like also to express my sincere gratitude to my associate supervisors Associate Professor 
Catherine Olsen and Dr Nirmala Pandeya for their guidance through this process; your discussion, 
ideas, and feedback have been absolutely inestimable. I would like to thank Professor Adele Green, 
Associate Professor Rachel Neale and Professor Penny Webb for their insightful comments and 
suggestions which prompted me to think about my research from various perspectives. To Professor 
Dallas English, thank you for linking me up with Professor Whiteman, you have instigated the 
beginning of this PhD journey.   
 
I would like to thank everyone in QSkin team who assisted with data collection and management: 
Lea Jackman, Rebekah Cicero, Padmini Subramaniam, Bridie Thompson and Brittany Wong. To 
the Statistical Genetics team, particularly Jue-Sheng Ong, I thank you for your expertise and taking 
the time out of your busy schedule to meet regularly and discuss this project.  
 
This work would not have been possible without the financial support of the QIMR Berghofer 
Medical Research Institute and the scholarship provided by the University of Queensland. 
 
  
ix 
 
To my fellow PhD buddies, Suzanne, Keren, Elizabeth, Azam, Sabir and Lena, thank you for the 
stimulating discussions. To my family, thank you for encouraging me in all of my pursuits and 
inspiring me to follow my dreams. I am especially grateful to my wife Adolyce and my son Travis 
for all of the sacrifices that you have made on my behalf, I am truly grateful to have you in my life. 
 
 
  
x 
 
Financial support  
This work was supported by a program grant from the National Health and Medical Research 
Council (NHMRC) of Australia (grant numbers APP1073898, APP1063061 and APP1123248). 
Part of the work in this thesis was conducted using the UK Biobank Resource (application number 
25331). The full acknowledgements for the melanoma meta-analysis can be found in the 
Supplementary Note of the 2015 melanoma GWAS meta-analysis. DCW and REN are supported by 
NHMRC Research Fellowships. SM is supported by the Australian Research Council Future 
Fellowship. The funders had no role in study design, data collection and analysis or decision to 
publish.  
  
  
xi 
 
Keywords and research classification 
Keywords 
epidemiology, skin cancer, smoking, obesity, height, Mendelian randomisation, causality, detection 
bias  
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
ANZSRC code: 111706, Epidemiology, 100% 
 
Fields of Research (FoR) Classification 
FoR code: 1117, Public Health and Health Services, 100% 
  
  
xii 
 
Table of contents  
Abstract ................................................................................................................................................ i 
Declaration by author ....................................................................................................................... iv 
Publications during candidature ...................................................................................................... v 
Acknowledgements.......................................................................................................................... viii 
Keywords and research classification ............................................................................................. xi 
Table of contents .............................................................................................................................. xii 
List of Figures .................................................................................................................................. xvi 
List of Tables ................................................................................................................................. xviii 
List of Abbreviations ....................................................................................................................... xx 
1 Introduction ................................................................................................................................ 1 
1.1 Anatomy and function of the skin ........................................................................................ 1 
1.1.1 The epidermis ................................................................................................................... 1 
1.1.2 The dermis........................................................................................................................ 2 
1.2 Skin cancer ........................................................................................................................... 2 
1.2.1 Squamous cell carcinoma and associated keratinocytic tumours .................................... 3 
1.2.2 Basal cell carcinoma ........................................................................................................ 7 
1.2.3 Rare nonmelanoma skin cancers ...................................................................................... 8 
1.2.4 Melanoma......................................................................................................................... 9 
1.3 Risk factors for keratinocyte carcinomas ........................................................................... 22 
1.3.1 Phenotypic factors .......................................................................................................... 22 
1.3.2 Environmental factors .................................................................................................... 24 
1.3.3 Clinical factors ............................................................................................................... 27 
1.3.4 Genetic factors ............................................................................................................... 28 
1.4 Risk factors for melanoma ................................................................................................. 28 
1.4.1 Phenotypic factors .......................................................................................................... 28 
1.4.2 Environmental factors .................................................................................................... 29 
1.4.3 Clinical factors ............................................................................................................... 31 
1.4.4 Genetic factors ............................................................................................................... 32 
1.5 The epidemiology of smoking and cancer ......................................................................... 32 
1.5.1 Smoking – epidemiology ............................................................................................... 32 
  
xiii 
 
1.5.2 Smoking and risk of KCs ............................................................................................... 33 
1.5.3 Smoking and risk of melanoma ..................................................................................... 33 
1.5.4 Proposed biological mechanisms linking smoking to cancer risk. ................................ 33 
1.6 Obesity - Epidemiology of obesity and cancer .................................................................. 34 
1.6.1 Obesity definition and measurements ............................................................................ 34 
1.6.2 Measurement of obesity ................................................................................................. 35 
1.6.3 Obesity – epidemiology ................................................................................................. 35 
1.6.4 Obesity and cancer risk .................................................................................................. 36 
1.6.5 Obesity and risk of melanoma ....................................................................................... 36 
1.6.6 Proposed biological mechanisms linking obesity to cancer........................................... 37 
1.7 Height and risk of melanoma ............................................................................................. 38 
1.7.1 Proposed biological mechanisms linking height and cancer risk .................................. 39 
1.8 Literature review summary ................................................................................................ 39 
2 Aims, Objectives and Hypotheses ........................................................................................... 41 
3 Materials and Methods ............................................................................................................ 43 
3.1 Study population ................................................................................................................ 43 
3.2 Ethical consideration .......................................................................................................... 43 
3.3 Exposure assessment .......................................................................................................... 43 
3.4 Validation of self-reported exposure information .............................................................. 44 
3.5 Follow-up ........................................................................................................................... 44 
3.6 Statistical methods ............................................................................................................. 45 
3.6.1 Descriptive Analyses...................................................................................................... 45 
3.6.2 Univariate Analyses ....................................................................................................... 46 
3.6.3 Multivariable analysis .................................................................................................... 46 
3.6.4 Competing risk analyses ................................................................................................ 47 
3.7 Meta-analysis of observational studies .............................................................................. 47 
3.8 Mendelian randomisation analyses .................................................................................... 48 
4 Cigarette smoking and the risk of skin cancer ...................................................................... 51 
4.1 Cigarette smoking and risk of keratinocytes carcinoma .................................................... 51 
4.1.1 Introduction .................................................................................................................... 51 
4.1.2 Contribution of candidate ............................................................................................... 51 
4.1.3 Manuscript: Cigarette smoking and the risks of basal cell carcinoma and squamous cell 
carcinoma ................................................................................................................................... 52 
4.2 Cigarette smoking and risk of cutaneous melanoma ......................................................... 82 
  
xiv 
 
4.2.1 Introduction .................................................................................................................... 82 
4.2.2 Contribution of Candidate .............................................................................................. 82 
4.2.3 Manuscript: Smoking and Cutaneous Melanoma: Findings from the QSkin Sun and 
Health Cohort Study .................................................................................................................. 83 
5 Body mass index and risk of cutaneous melanoma ............................................................. 106 
5.1 Introduction ...................................................................................................................... 106 
5.2 Contribution of Candidate ................................................................................................ 106 
5.3 Manuscript: Body mass index and risk of cutaneous melanoma: Evidence from 
Observational and Mendelian randomisation analyses ................................................................ 107 
6 Adult height and risk of cutaneous melanoma .................................................................... 132 
6.1 Introduction ...................................................................................................................... 132 
6.2 Contribution of Candidate ................................................................................................ 132 
6.3 Manuscript: Adult height and risk of cutaneous melanoma: findings from the QSkin Sun 
and Health cohort study and Mendelian randomisation ............................................................... 133 
7 Summary and Conclusions .................................................................................................... 153 
7.1 Introduction ...................................................................................................................... 153 
7.2 Summary of key findings ................................................................................................. 153 
7.2.1 Smoking and risk of skin cancer .................................................................................. 153 
7.2.2 Body mass index and risk of melanoma ...................................................................... 156 
7.2.3 Height and risk of melanoma ....................................................................................... 157 
7.3 Evaluating the causal role of smoking in cSCC ............................................................... 158 
7.3.1 Consistency with other studies ..................................................................................... 158 
7.3.2 The potential role of bias and confounding ................................................................. 159 
7.3.3 Potential mechanisms of action .................................................................................... 160 
7.4 Evaluating the causal role of height in melanoma ........................................................... 160 
7.4.1 Consistency with other studies ..................................................................................... 160 
7.4.2 The potential role of bias and confounding ................................................................. 161 
7.4.3 Potential mechanisms of action .................................................................................... 162 
7.5 Directions for future research .......................................................................................... 163 
7.6 Public health implications ................................................................................................ 164 
7.7 Conclusion ....................................................................................................................... 165 
8 References ............................................................................................................................... 166 
9 Appendixes .............................................................................................................................. 187 
9.1 Appendix A: QSkin cohort study questionnaire .............................................................. 187 
  
xv 
 
9.2 Appendix B: MBS item numbers for treatment of skin cancer........................................ 198 
9.3 Appendix C: Pathology reports data collection instrument ............................................. 199 
  
  
xvi 
 
List of Figures  
Figure 1-1. Anatomy and functions of the skin ............................................................................... 1 
Figure 1-2. World comparison of cSCC and BCC incidence rates ............................................... 5 
Figure 1-3. KC age-standardised mortality rate by year in Austrslia .......................................... 6 
Figure 1-4. Anatomy of the eye, showing the outside and inside of the eye including the sclera, 
cornea, iris, ciliary body, choroid, retina, vitreous humour, and optic nerve .................... 12 
Figure 1-5. Comparison of worldwide incidence of melanoma ................................................... 18 
Figure 1-6. Age-standardised incidence and mortality rates of melanoma by year for Australia
 .................................................................................................................................................... 19 
Figure 1-7. Age-standardized incidence rates of melanoma by sex, state and territory in 
Australia in 2015 ...................................................................................................................... 19 
Figure 1-8. Age-specific incidence rates of melanoma for 2011 in Australia ............................. 20 
Figure 1-9. Trends in the incidence rates of in situ and invasive melanomas by thickness and 
sex in Queensland, 1995–2014 ................................................................................................. 20 
Figure 1-10. The insulin-IGF hypothesis of obesity-related cancer ............................................ 38 
Figure 3-1. Directed acyclic graph illustrating instrumental variable assumptions .................. 49 
Figure 4-1. QSkin cohort flow diagram for BCC and cSCC incidence ...................................... 56 
Figure 4-2. Results of stratified analyses on the association between current smoking and risk 
of BCC ....................................................................................................................................... 65 
Figure 4-3. Results of stratified analyses on the association between current smoking and risk 
of cSCC ..................................................................................................................................... 68 
Figure 4-4. Relation of smoking intensity and its dose-response patterns with risk of BCC .... 74 
Figure 4-5. Relation of duration of smoking and its dose-response patterns with risk of BCC75 
Figure 4-6. Relation of time since quitting and its dose-response patterns with risk of BCC .. 75 
Figure 4-7. Relation of smoking intensity and its dose-response patterns with risk of cSCC .. 76 
Figure 4-8. Relation of duration of smoking and its dose-response patterns with risk of cSCC
 .................................................................................................................................................... 76 
Figure 4-9. Relation of time since quitting and its dose-response patterns with risk of cSCC . 77 
Figure 4-10. QSkin cohort flow diagram for melanoma incidence ............................................. 88 
Figure 4-11. Relation of duration of smoking and its dose-response patterns with risk of 
melanoma .................................................................................................................................. 98 
  
xvii 
 
Figure 4-12. Relation of smoking intensity and its dose-response patterns with risk of 
melanoma .................................................................................................................................. 98 
Figure 4-13. Relation of time since quitting smoking and its dose-response patterns with risk 
of melanoma ............................................................................................................................. 99 
Figure 5-1. Nonlinear relation of BMI and risk of melanoma for men..................................... 118 
Figure 5-2. Nonlinear relation of BMI and risk of melanoma for women ................................ 118 
Figure 5-3. PRISMA flow chart for studies included in the meta-analysis of BMI and 
melanoma ................................................................................................................................ 119 
Figure 5-4. Meta-analysis of the association between BMI and melanoma in women and men
 .................................................................................................................................................. 124 
Figure 5-5. BMI effect on melanoma for men ............................................................................. 125 
Figure 5-6. BMI effect on melanoma for women ........................................................................ 125 
Figure 5-7. Meta-analysis of the association between BMI and melanoma (women and men) in 
studies adjusted for sun-exposure ........................................................................................ 126 
Figure 5-8. Meta-analysis of the association between BMI and melanoma (women and men) in 
studies with measured weight and height ............................................................................ 126 
Figure 5-9. Funnel plot assessing symmetry of the distribution of individual variant estimates 
around the point estimate for BMI and melanoma association ......................................... 129 
Figure 6-1. Funnel plot assessing symmetry of the distribution of individual variant estimates 
around the point estimate for height and melanoma association ...................................... 139 
Figure 6-2. Nonlinear relation of height and risk of melanoma for men .................................. 148 
Figure 6-3. Nonlinear relation of height and risk of melanoma for women ............................. 148 
  
  
xviii 
 
List of Tables 
Table 1-1. AJCC 8th edition melanoma TNM definitions ........................................................... 15 
Table 1-2. Common classifications of body mass index in adults ................................................ 35 
Table 4-1. Baseline characteristics of 18,828 QSkin study participants included in the BCC 
and cSCC analyses, overall and stratified by smoking status .............................................. 59 
Table 4-2. The association between different dimensions of smoking and BCC, stratified by 
self-reported history of destructive treatments for skin lesions prior to baseline ............. 62 
Table 4-3. Smoking status and risk of BCC and cSCC, stratified by self-reported history of 
skin checks by a doctor (yes/no) in the past 3 years .............................................................. 66 
Table 4-4. The association between different dimensions of smoking and cSCC, stratified by 
self-reported history of destructive treatments for skin lesions at baseline ....................... 69 
Table 4-5. Analysis of dose effects simultaneous modelling of smoking status and individual 
quantitative smoking measures .............................................................................................. 71 
Table 4-6. Smoking status and risk cSCC, after excluding IEC/Bowen’s/ KA in control or 
using IEC/Bowen’s/ KA as cSCC cases .................................................................................. 73 
Table 4-7. Sensitivity analyses variously including participants with missing pathology as 
BCC/cSCC cases ....................................................................................................................... 78 
Table 4-8. Baseline characteristics of QSkin study participants included in the melanoma 
analysis by smoking status ...................................................................................................... 89 
Table 4-9. The association between measures of smoking and incidence of invasive melanoma
 .................................................................................................................................................... 93 
Table 4-10. The association between smoking status and incidence of invasive melanoma 
across strata of cumulative sun exposure .............................................................................. 95 
Table 4-11. The association between smoking and invasive melanoma: simultaneous modelling 
of qualitative and quantitative smoking measures ............................................................... 96 
Table 4-12. The association between smoking and all melanoma (invasive and in situ) ......... 100 
Table 4-13. The association between smoking and invasive melanoma –sensitivity analyses 
around the treatment of in situ melanoma arising during follow-up ................................ 102 
Table 5-1. Baseline characteristics of QSkin study participants by BMI categories (n=37,523).
 .................................................................................................................................................. 115 
  
xix 
 
Table 5-2. Hazard ratios (HRs) and 95% confidence intervals (CIs) of cutaneous melanoma 
according to body mass index in the QSkin cohort study .................................................. 117 
Table 5-3. Characteristics of prospective cohort studies included in the meta-analysis of BMI 
and melanoma ........................................................................................................................ 121 
Table 5-4. Association between increased BMI (per 4.6 units) and risk of melanoma using 
two-sample Mendelian randomisation (MR) ....................................................................... 128 
Table 5-5. Estimates of Egger intercept to evaluate evidence for directional pleiotropy in MR 
association ............................................................................................................................... 128 
Table 6-1. Association between increased height (per 9.27 cm) and risk of melanoma using 
two-sample Mendelian randomisation (MR) ....................................................................... 138 
Table 6-2. Estimates of Egger intercept to evaluate evidence for directional pleiotropy in MR 
association ............................................................................................................................... 139 
Table 6-3. Baseline characteristics of QSkin study participants by categories of height ........ 141 
Table 6-4. Hazard ratios (HR) and 95% CIs for the association between height and melanoma 
risk ........................................................................................................................................... 147 
Table 6-5. Hazard ratios (HR) and 95% CIs for the associations of height with melanoma (in 
situ + invasive) risk ................................................................................................................ 149 
  
  
xx 
 
List of Abbreviations 
ABS Australian Bureau of Statistics 
AIHW  Australian Institute of Health and Welfare 
AK   actinic keratosis 
BCC basal cell carcinoma 
BIA  bioelectrical impedance analysis 
BMI  body mass index 
CPS-II cancer prevention study II 
CSI  comprehensive smoking index 
CT  computed tomography 
DEXA  dual-energy X-Ray absorptiometry 
DNA  deoxyribonucleic acid 
EBW  excess body weight 
EV  epidermodysplasia verruciformis 
FFA  free fatty acids 
HAART  highly active antiretroviral therapy 
HC  hip circumference 
HIV human immunodeficiency virus 
HPFS  health professionals follow-up study 
HPV   human papilloma virus 
IARC International Agency for Research on Cancer 
ICC  intraclass correlation coefficient 
IEC     intra-epidermal carcinoma 
IGF1  insulin-like growth factor 1 
IGFBP1 insulin-like growth factor binding protein-1 
IGFBP2 insulin-like growth factor binding protein-2 
IGFs  insulin-like growth factors 
IR  insulin receptor 
KA keratoacanthoma  
KC     keratinocyte carcinoma  
MBS   medical benefits schedule  
MHT  menopausal hormone therapy  
  
xxi 
 
MRI  magnetic resonance imaging 
NBCCS  nevoid basal cell carcinoma syndrome  
NHS  Nurse’s Health Study 
NMSC  non-melanoma skin cancer 
NSAIDs  non-steroidal anti-inflammatory drugs  
OCs  oral contraceptives  
QCR   Queensland Cancer Registry  
cSCC   squamous cell carcinoma 
SD  standard deviation  
SSM  Superficial spreading melanoma  
TNFα  tumour-necrosis factor-α 
UR University of Rwanda 
USRT   United States Radiological Technologists  
UVR  ultra-violet radiations  
WC  waist circumference  
WCRF  World Cancer Research Fund  
WHI  Women’s Health Initiative 
WHO  World Health Organization 
WHR  waist hip ratio  
XP   xeroderma pigmentosum 
 
 
 
  
1 
 
1 Introduction 
1.1 Anatomy and function of the skin 
The skin is an organ that covers the entire external surface of the human body. It has several 
functions but the most important is to form a physical barrier to the external environment by 
protecting internal tissues from mechanical impacts, toxins, micro-organisms, radiation and 
chemicals. Additional functions include sensory perception, immunologic surveillance, 
thermoregulation, and prevention of excess water fluid loss from the body [1].The skin is composed 
of three layers [Figure 1-1]: the epidermis, the outermost layer of skin, the dermis (beneath the 
epidermis) and the deeper subcutaneous tissue (hypodermis) [1].  
 
 
Figure 1-1. Anatomy and functions of the skin 
  
Source: https://courses.candelalearning.com/olianp/chapter/integumentary-structures-and-
functions/ 
 
1.1.1 The epidermis 
The epidermis is the outer layer composed of stratified keratinised squamous epithelium. The 
epidermis has no blood vessels, and cells are exclusively nourished by diffusion from blood 
capillaries in the upper layers of the dermis. The majority of cells in this layer are keratinocytes 
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(95% of all skin cells) which are so named because they produce keratin. The main function of 
keratin is to protect the skin and underlying tissues from microbes, heat, ultraviolet radiation 
(UVR), water loss and many chemicals [2]. The remaining cells include melanocytes, Langerhans 
cells and Merkel cells [3].  Melanocytes are responsible for the production of the pigment melanin, 
the main natural pigment of the skin. Increased exposure to UVR stimulates an increase in melanin 
production which results in tanning of the skin, increasing the cell’s ability to absorb light and 
therefore protect the underlying skin cells from damaging radiation [1]. Langerhans cells are 
antigen presenting immune cells and are involved in T-cell responses to pathogens. Langerhans 
cells are responsible for the uptake of antigens deposited on skin and presenting them to naïve T-
cell of the epidermis [1, 4]. Merkel cells are mechanoreceptors which are in the basal layers of the 
epidermis and are thought to function in the sensation of touch [1, 5].  
 
The epidermis also has several appendages which include pilosebaceous follicles (which secrete the 
sebum to lubricate and waterproof the skin), sweat glands and nails [1]. These structures are 
connected to the surface epidermis but located mainly in the dermis or hypodermis.  
  
1.1.2 The dermis 
The dermis is the layer located beneath the epidermis and consists of connective tissues. The 
collagen and elastin proteins in the dermis make it tough and elastic [1]. The dermis harbors 
many mechanoreceptors (nerve endings) that provide the sense of touch and heat. It also contains 
lymphatic and blood vessels, hair follicles, sweat glands, sebaceous glands and apocrine glands. 
The epidermis and dermis are separated by a thin layer called the basement membrane. The role of 
the basement membrane is to control the traffic of molecules between dermis and epidermis as well 
as to serve as a reservoir for inflammatory and growth factors during physiological repair processes. 
The basement membrane forms the line of demarcation for in situ versus invasive skin cancers.  
 
1.2 Skin cancer  
Skin cancers are the most common form of cancer accounting for more than 40% of cases globally 
[6, 7]. The three most common types of skin cancer are basal cell carcinoma (BCC), cutaneous 
squamous cell carcinoma (cSCC) and cutaneous melanoma (hereafter referred to as melanoma). 
BCC and cSCC are also collectively known as non-melanoma skin cancer (NMSC) or keratinocyte 
carcinomas (KCs). Keratinocyte carcinoma is now the preferred term because it identifies the 
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shared cell of origin for these common cancers (i.e. the keratinocyte), and this terminology will be 
adopted throughout this thesis. 
 
1.2.1 Squamous cell carcinoma and associated keratinocytic tumours 
1.2.1.1 Clinical features  
Squamous cell carcinomas can develop on any cutaneous surface, but occur most commonly on 
sun-exposed skin, such as the scalp, the backs of the hands, ears and face [8]. However, a small 
proportion of cSCCs develops on sun-covered areas such as the genital region, buttocks and feet, 
consistent with a role for non-actinic factors in the development of cSCC.  Even though cutaneous 
cSCC is usually not fatal and is easy to treat in the early stages, it can be very complicated once it 
infiltrates nerves and deeper structures, and can re-occur locally and/or metastasize, leading to 
significant morbidity and mortality. The initial clinical presentation of cSCC includes plaques, 
papules or nodules and ulcerative or hyperkeratotic lesions.  
 
Some cSCCs arise in pre-malignant lesions called actinic keratoses (AKs) [9]. AKs (also known as 
solar keratoses) arise from neoplastic transformation of keratinocytes confined to the epidermis that 
have been exposed to UVR.  A community-based study in Queensland showed that AKs are labile 
lesions and the rate of progression is very low [10].  Even though a remarkable proportion of AKs 
may regress spontaneously with strict sun protective measures, treatment is indicated for lesions 
that are symptomatic or thick, or those occurring in immunosuppressed individuals [9].  
 
Intra-epidermal carcinoma (IEC) or squamous cell carcinoma in situ, sometimes referred to 
as Bowen’s disease, arise on any site of the skin but most cases are found on sun-exposed areas 
such as the head, neck and the dorsum of the hands [11].  IEC is regarded as a low-grade cSCC, and 
the majority of studies have reported that the likelihood of progression to invasive cSCC is ~3%–
8% [12, 13]. The most important risk factors for IEC include exposure to sun or arsenic [14], but 
other factors such as chemical carcinogens, inherited susceptibility and trauma also play an 
important role. 
 
Keratoacanthoma (KA) is characterised by rapid growth followed by spontaneous regression with 
residual tissue scarring [15]. Although most KAs regress spontaneously, some KAs have been 
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reported to have aggressive clinical behaviour leading to metastasis. Body sites that are chronically 
exposed to sunlight such as the face, forearms and hands are most commonly affected, but KAs may 
also occur on sites related to trauma, surgery or burns [15-17]. KA presents as dome-shaped, small 
papule that grow rapidly to form an erythematous nodule with a central keratotic plug, with features 
that are difficult to distinguish clinically from a cSCC [18]. Some arguments support classifying 
keratoacanthoma as a variant or a less aggressive form  of invasive cSCC  and in most pathological 
reports KA is referred to as "squamous cell carcinoma, keratoacanthoma-type”. However, due to 
lack of specific histopathologic characteristics that differentiate KA from cSCC, studies using 
specific molecular biomarkers suggest that KA is a distinct tumour and has a different pathogenesis 
from that of cSCC [19-21].  
 
1.2.1.2 Descriptive epidemiology  
Incidence 
Estimates of incidence of cSCC are imprecise because they are not routinely reported to cancer 
registries. Additionally, because a diagnosis of KC can be made based on its clinical appearance 
and commonly treated by general practitioners (GPs) with topical agents or destructively without 
submission of the specimen for histopathological confirmation, not all cases are recorded by 
pathology laboratories. The best reported Australian national incidence data come from 4 national 
surveys carried out in 1985, 1990, 1995 and 2002 [22]. The estimated cSCC incidence rates per 
100,000 person-years were 112 in 1985 and 387 in 2002 [22, 23] . Between 2011-2014, a study 
using data from a random sample of 10% of all persons registered with Medicare during 1997-2014 
estimated that the age standardised rate (ASR) for cSCC was 270 per 100,000 person years  during 
2011-2014 [24].  
 
Australia and New Zealand have the highest incidence of cSCC in the world [Figure 1-2] The 
incidence in Southwest United States of America is also very high, with a rate of 290/100 000 
person-years reported in Arizona and New Mexico [25, 26]. Incidence in the UK is much lower, 
with the registry reporting rates of 28.6/100 000 for cSCC [25]. One of the reasons for variations in 
the incidence rate around the world is the difference in UVR exposure; it is estimated that more 
than 90% of the KCs are due to UV radiation [27, 28].  
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Figure 1-2. World comparison of cSCC and BCC incidence rates 
 
All incidence rates are standardised to the world population.  
Source: Lomas et al. 2012; Pondicherry et al. 2018  
 
 
Mortality  
KC is the most commonly diagnosed cancer in Australia, although it is generally not life-
threatening. Approximately 560 Australians died from keratinocyte cancer in 2016, with two-thirds 
(~370) being male [29]. According to the Australian Institute of Health and Welfare (AIHW) data, 
the age-standardised mortality rates are relatively low at ~3-4 per 100,000 population for men and 1 
per 100,000 for women [Figure 1-3]. Overall, the mortality rates for KCs are dominated by deaths 
from cSCC and were estimated at ~0.3 per 100,000 population in the USA [30].  
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Figure 1-3. KC age-standardised mortality rate by year in Austrslia 
Source: Australian Institute of Health and Welfare  
 
1.2.1.3 Pathogenesis  
cSCC arises in epidermal keratinocytes that have undergone uncontrolled cell proliferation and loss 
of apoptosis due to mutations in key genes involved in either DNA repair, pigmentation or key 
signalling pathways. The mechanism leading to genomic instability in keratinocytes is UVB-
induced inactivation of p53, since approximately 60% of cSCC tumours harbour UVB-signature 
mutations (i.e. C→T and CC→TT transitions) [31, 32]. Mutations in p53 are also common in AKs 
and are more common in normal skin on sun exposed compared with non-sun exposed sites, [33, 
34]. Beside P53 mutations, other somatic mutations including NOTCH1 or NOTCH2 receptor 
mutations have been recently identified in approximately 75% of cutaneous cSCC and are believed 
to play a key role early in cSCC carcinogenesis [35, 36]. Several hereditary syndromes such as 
xeroderma pigmentosum, oculocutaneous albinism and epidermolysis bullosa are associated with an 
increased risk of cSCC. A detailed description of the most common inherited conditions that relate 
to cSCC are presented under section 1.3.2.6.  
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1.2.2 Basal cell carcinoma 
1.2.2.1 Clinical features. 
Basal cell carcinoma is predominantly found on the head (70%), (most frequently on the face and 
trunk (~25%) [37, 38]. BCC is rare at other body sites [39]. Basal cell carcinoma generally develops 
without a precursor lesion, unlike cSCC. BCCs are subdivided according to differences in 
histological presentation. The major histological subtypes are nodular, micronodular, superficial 
and morpheaform (or sclerosing) BCC. Nodular (60%) and superficial (25%) BCCs are considered 
less aggressive subtypes, whereas the more aggressive subtypes associated with higher risk of 
recurrence include morpheaform (~2%) and micronodular (~1.5%) BCCs [40]. BCC lesions can 
consist of more than one histological subtype. The most frequent combination of subtypes is 
nodular and micronodular.  
 
1.2.2.2 Descriptive epidemiology  
Incidence 
BCC is the most frequently occurring form of skin cancer accounting for approximately 80% of 
KCs [41]; it is the commonest of all cancers diagnosed in Australia. Similarly to cSCC, BCC cases 
are not routinely reported in the cancer registries and the only source of incidence data comes from 
4 national surveys carried out in 1985, 1990, 1995 and 2002 [22]. The incidence rate per 100 000 
person-years was estimated at 443 in 1985 and 884 in 2002 [22, 23]. A study conducted in the town 
of Nambour, Queensland, reported a BCC incidence rate of 1541 per 100,000 person-years [42], the 
highest incidence of BCC ever reported. Another recent study using data from a random sample of 
10% of all persons registered with Medicare during 1997-2014 reported that the estimated ASR for 
BCC was 770 per 100,000 person-years [24]. The incidence was much higher in Nambour than any 
other white-skinned population possibly because Nambour is a typical subtropical region at a high 
latitude [43].  
 
The incidence rates for BCC in Australia are comparable to those of Southern states of USA, with a 
rate of 936/100 000 person years reported for BCC in Arizona and New Mexico [25, 26]. The BCC 
incidence rate in Australia is almost 10 times the rate recorded in the UK, with the registry reporting 
rates of 100/100 000 person years for BCC [25] [44]. Lower rates of BCC were reported in Canada, 
Switzerland and the Scandinavian countries [Figure 1-2].  
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Mortality 
The prognosis for patients with BCC is generally very favourable. These lesions grow slowly and 
rarely metastasize. Men are more likely to develop metastatic disease than women, although the 
cause is not yet known. In the USA, the age-standardised mortality rates for BCC were 0.12 and 
0.05 per 100,000 respectively for men and women [30].   
 
1.2.2.3 Pathogenesis  
BCCs are slow growing tumours which arise from interfollicular epidermal stem cells [45]. BCC 
develops on sun-exposed skin surfaces with approximately 80% occurring on the head and neck 
[46]. Patients often present with a history of extended sun exposure that may be occupational 
(construction, farming) or recreational (outdoor sports, fishing). The epidermal DNA damage 
induced by UV radiation is thought to be the primary carcinogenic event in the development of 
BCC [47]. Recent studies suggest that intermittent sun exposure early in life may be important in 
BCC carcinogenesis [48]. 
 
Recently, there have been important developments in the understanding of the molecular 
pathogenesis of BCC.  There is evidence that mutations in the hedgehog (HH) signalling pathway 
are involved in BCC development [49]. The HH pathway influences differentiation of various 
tissues during foetal development. Impairment of this pathway is mostly due to mutations in the 
genes coding for PTCH1 and PTCH2 and is associated with various cancers including BCC.  Most 
of the PTCH mutations found in BCC (up to 70%) contain the dipyrimidine transition, a 
characteristic UV signature mutation (i.e., C to T or CC to TT transitions at dipyrimidine sites) [50]. 
 
1.2.3 Rare nonmelanoma skin cancers 
In this section, rare skin cancers are described for completeness, but are not separately analysed in 
this thesis.  
 
1.2.3.1 Merkel cell carcinoma 
Merkel cell carcinoma (MCC) is a highly aggressive, fast growing, rare type of skin cancer with a 
high propensity for recurring and metastasizing [51]. Because it arises in hormone-producing cells, 
it is also called a neuroendocrine carcinoma of the skin. MCC presents as rapidly growing, painless, 
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intracutaneous nodule commonly located on the head and neck [52, 53]. Data from the Queensland 
cancer registry indicate that between 2006 and 2014, the incidence of Merkel cell carcinoma was 
1.6/100,000 [54]. MCC often occurs in older patients but it also occurs at a younger age in 
immunosuppressed patients such as organ transplants recipients and HIV infected individuals [55, 
56]. Known risk factors include UV radiation, immunosuppression and infection with Merkel cell 
polyomavirus (MCPyV) [51, 53]. 
 
1.2.3.2 Kaposi Sarcoma 
 Kaposi sarcoma (KS) is an angioproliferative malignancy caused by infection with human 
herpesvirus-8 (HHV-8) [57]. Most people infected with HHV-8 do not get KS. People infected with 
HHV-8 are more likely to develop KS if their immune system is compromised ( for example: 
people living with human immunodeficiency virus (HIV)) or people taking immunosuppressive 
medications ( for example: organ transplant recipients) [58]. KS presents as purple, red or brown 
skin blotches or tumours on the skin most often on the legs and face. KS occurs most frequently in 
men than women with a male to female ratio of 3:1 [59]. Based on clinical and epidemiological 
features, KS is classified into 4 types: 1) classic (Elderly Mediterranean men); 2) endemic 
(Equatorial Africa); 3) transplant associated (after solid organ transplantation) and 4) AIDS related 
(most common HIV-associated malignancy worldwide) [60]. 
 
1.2.3.3 Dermatofibrosarcoma Protuberans  
Dermatofibrosarcoma Protuberans (DFSP) is a very rare cutaneous soft tissue sarcoma that arises in 
the deep layer of the skin (the dermis) [61]. It presents as flat or slightly raised patch usually on the 
torso but can also be found on the limbs, head and neck [62]. DFSP grows slowly and rarely spreads 
beyond the dermis. In the USA, the overall incidence of DFSP is estimated at 1 case per million per 
year [63]. The cause of DFSP is unclear, but the risk may increase with a scar that develops after a 
burn or surgery. African Americans and adults between 30 and 50 years old are at a higher risk of 
developing the disease [64]. 
 
1.2.4 Melanoma  
1.2.4.1 Clinical features 
Melanomas most often appear as pigmented tumours; their appearance depends on clinical stage 
and histological subtype. Early stage melanoma is difficult to distinguish from other frequently 
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encountered pigmented lesions such as solar lentigo, common moles (e.g. melanocytic, junctional, 
compound and intradermal nevi), and seborrheic keratosis . Visual inspection and recognition of 
patterns helps to assess whether a pigmented lesion presents suspicious features for melanoma. 
These features have been widely adopted as the ABCDE rule [65]. ABDCE stands for Asymmetry 
(the tumour cannot be divided in half), Border irregularity, Colour variability (uneven distribution 
of colour), Diameter (lesions are often greater than 6 mm in diameter) and Evolving (changes in 
colour and/or size of the lesion over time) [65].  The ABCDE criteria help to identify melanomas, 
especially the superficial spreading subtype. Dermoscopic examination is also used for clinical 
diagnosis of pigmented skin lesions and has been found to be superior to examination with the 
naked-eye [66]. 
 
1.2.4.2 Uncommon clinical presentations of melanoma 
 
Childhood melanomas 
 Childhood melanomas usually refer to melanomas diagnosed in individuals under the age of 18 
years [67]. They are rare and represent only 0.2% of all melanomas occurring in Australia [68]. 
Melanomas in children are classified in several categories including congenital melanoma, 
melanoma arising in congenital melanocytic naevus, melanomas with features of Spitz naevus, 
nodular melanoma and melanoma arising in blue naevus [69]. Nodular melanomas represent about 
50% of melanomas in children.  Childhood melanomas are frequently amelanotic and appear as red 
coloured nodule and are more likely to be thicker at diagnosis compared to melanomas in adults 
[70]. Because the clinical and histological features of childhood melanomas are poorly 
characterized, conventional ABCDE criteria used for melanoma diagnosis in adults may result in 
delays in diagnosis. Thus, an additional paediatric ABCD (Amelanotic; Bleeding;  Bump; Colour 
uniformity; De novo; any Diameter) and the CUP (Colour is pink/red or Changing; Ulceration or 
Upward thickening and Pyogenic granuloma-like lesions or Pop-up new lesions) detection criteria 
have been proposed to be used together with the conventional ABCDE to facilitate early detection 
of childhood melanoma [70].  
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Amelanotic melanoma 
Unlike most forms of melanoma that are typically pigmented, there exist uncommon melanoma 
characterised by the absence of pigmentation or making too little melanin and are described as 
amelanotic melanomas. The lesions present as pale pink or reddish plaques or nodules often with 
well-defined borders [71]. Compared to pigmented melanomas, amelanotic melanomas are very 
lethal because they often are not detected at an earlier stage [92].   
 
1.2.4.3 Noncutaneous melanoma  
Noncutaneous melanomas are also relatively rare compared to melanomas of the skin, representing 
approximately 5% of all melanoma cases occurring in the USA [72].  Noncutaneous melanomas are 
generally more aggressive than their cutaneous counterparts, with a 5-year survival rates of 25% 
compared with 80% for cutaneous melanomas. In this introduction, I have briefly described two 
most common types of noncutaneous melanoma which are “uveal melanoma” and “mucosal 
melanoma” although these subtypes are not included in the subsequent analyses.  
 
Uveal melanoma 
Uveal melanoma is the most common form of noncutaneous melanoma, although in comparison 
with the cutaneous melanomas, it is considered relatively rare [73]. It is also the most common 
intraocular form of melanoma representing about 70% of all ocular melanoma cases.  More than 
90% of uveal melanomas arise from the choroid (choroidal melanoma), while 10% arise from Iris 
and ciliary body [74] [Figure 1-4]. The risk of uveal melanoma is 10-fold higher in white 
population compared to other ethnicities [72].  The effect of sun exposure on the risk of developing 
uveal melanoma is still controversial. The mean age at diagnosis of uveal melanoma is about 60 
years [75]. The diagnosis of uveal melanoma is often made during routine eye examination. The 
most common symptoms include blurry vision and visual field defects.  
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Figure 1-4. Anatomy of the eye, showing the outside and inside of the eye including the sclera, 
cornea, iris, ciliary body, choroid, retina, vitreous humour, and optic nerve 
Source: https://www.umcure2020.org/en/uveal-melanoma/general-information/ (30/09/2019) 
 
 
Mucosal melanoma 
Mucosal melanomas arise from the mucosal epithelium of the body that contains melanocytes such 
as genitourinary, respiratory and alimentary tracts [76]. They make up only 1% of all melanoma and 
about 25% of noncutaneous melanoma [77]. While they also make up a greater proportion of 
melanoma diagnosed in the non-white population, the absolute incidence of mucosal melanomas is 
similar in all populations. Unlike most cutaneous melanomas, mucosal melanomas are not classified 
as UVR-related tumours and knowledge around their pathogenesis and risk factors is limited 
because of their extremely low incidence. Mucosal melanomas carry a poor prognosis because most 
cases are diagnosed at an advanced stage due to their less visible location, the lack of early and 
specific signs and symptoms and lack of pigmentation (they are often amelanotic) [76].  
 
1.2.4.4 Histological appearance  
 Based on histologic growth pattern, primary subtypes of melanoma include superficial spreading 
melanoma (the commonest subtype accounting for approximately 70% of all lesions), nodular 
melanoma, lentigo maligna melanoma, acral lentiginous melanoma, desmoplastic melanoma, 
Spitzoid melanomas and nevoid melanoma.  
 
Superficial spreading melanoma (SSM) 
SSM is the most common histologic subtype accounting for about 70% all melanoma cases [78]. 
SSM often arise from a pre-existing precursor lesion such as dysplastic nevus. SSM is also the 
subtype seen most often among young people. It arises as a superficial tumour confined to the 
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epidermis, where it may remain for several years. During this early stage (often referred to as the 
radial growth phase), surgical excision is a curable treatment option alone. However, tumours that 
have infiltrated into the dermis are considered to be in the vertical growth phase and have metastatic 
potential [79]. The presence of epithelioid melanocytes along the dermo-epidermal junction 
(pagetoid spread) is the most important feature of the SSM histology [80]. Architectural changes 
observed in SSM include poor circumscription of melanocytes, a predomination of single 
melanocytes over nests of melanocytes and haphazard distribution of melanocytes. 
 
Nodular melanoma 
Nodular melanoma is the second most common histologic subtype accounting for ~15% of all 
melanomas [81]. It appears often as a darkly pigmented nodule and is characterised by having no 
antecedent radial growth phase. Upon invading the dermis, it tends to grow more rapidly in 
thickness (vertical growth phase) than in diameter. Unlike the situation in most SSM, nodular 
melanomas do not demonstrate poor lateral circumscription. While only about 15% of all 
melanomas are nodular, they account for nearly half of all melanoma-associated deaths [82]. The 
prognosis of nodular melanoma is very poor because of their rapid growth; they most often appear 
sporadically and not associated with existing naevi, making early detection difficult [83, 84]. 
 
Lentigo maligna melanoma (LMM) 
LMM is a subtype of melanoma that arises from lentigo maligna. LMM represents 4-10% of all 
melanoma cases and occurs on chronically sun-damaged skin such as the face or forearms and the 
risk increases with age [85]. It has an initial prolonged radial growth phase followed by a 
potentially lethal vertical growth phase. LMM often appears as a flat or slightly raised brown patch 
or age spot. Atypical melanocytes arranged in form of spindle-shaped nests along the dermo-
epidermal junction are the most reported histopathologic features of LMM [86].  
 
Acral lentiginous melanoma (ALM) 
ALM is a rare type of melanoma which accounts for 2-3% of all melanoma cases. It occurs most 
frequently on non-hair bearing skin surfaces of the body such as palms of hands, soles of the feet, 
the nailbeds. ALM is rare among lighter skinned populations but is the most common melanoma 
subtype among people with darker skin [87]. ALM typically appears as an oddly shaped brown to 
black macule or patch. Histopathologic features of ALM include large junctional nests that consist 
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of atypical melanocytic proliferation scattered along the dermo-epidermal junction (pagetoid 
spread). Subungual melanomas are variants of acral lentiginous melanoma which generally arise 
from nail matrix [88].  One of the key sign of subungual melanoma is the “Hutchinson’s sign” 
which is characterised by the extension of the discolouration from the tip of the nail down to the 
nail bed [89]. 
 
Desmoplastic melanoma 
This rare melanoma typically appears as an amelanotic nodule that is frequently clinically mistaken 
as a scar. More than 50% of desmoplastic melanomas occur on sun-exposed areas of the head and 
neck among older adults [90].  The most commonly reported histopathologic features of 
desmoplastic melanomas include spindle-shaped malignant cells with a marked fibrogenic stromal 
response. Additional histopathological features that may help to confirm the diagnosis of 
desmoplastic melanoma include lentiginous melanocytic hyperplasia and neutropenic spindle-
shaped malignant melanocytes [91].  
 
Spitzoid melanoma 
Spitzoid melanomas are rare subtypes with clinical and histopathological features similar to a spitz 
nevus [92]. They can arise de novo or associated with a pre-existing naevus [93]. These lesions are 
usually amelanocytic nodule and generally arise on the head or extremities [94]. Spitzoid 
melanomas occur more commonly in adults but are also found in children [95]. Because they are 
often uniform in colour and present as round shaped, the diagnosis of spitzoid melanomas does not 
follow the commonly used ABCDE criteria for melanoma diagnosis [96]. They often go undetected 
because of their lack of pigmentation. 
 
Nevoid malignant melanoma (NMM) 
NMM is a rare variant of melanoma that appear as dome-shaped nodules frequently on the trunk or 
proximal limbs of young adults [97]. These tumours are named “nevoid” because of their clinical 
and histological features that resemble those of compound or intradermal melanocytic naevus [97].  
There are two variants of NMM; one is composed of small nevus-like cells when melanoma cells 
are small and the other, which often occurs in young children, is composed of epithelioid cells that 
mimic a Spitz nevus when melanoma cells are large [96]. Because many NMM lesions do not 
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present well-characterized features, the epidemiology and histologic diagnosis of NMM remain 
poorly understood.  
 
1.2.4.5 Stages of melanoma 
The prognosis and treatment options of melanoma depend on the stage at which the tumour is 
diagnosed. Stage refers to the extent to which a cancer has developed by growing and spreading 
[98]. The staging is based on the American Joint Committee on Cancer (AJCC) and it is a 
classification based on three main factors: tumour, node, and metastasis also known as TNM 
system. T stands for the primary tumour, its thickness and if it has ulcerated; N indicates whether 
the tumour has spread to regional lymphatics; and M indicates the metastatic potential to distant 
lymph nodes and organs. The eighth edition of the AJCC melanoma staging system is presented in 
the [Table 1-1] [99]. 
Table 1-1. AJCC 8th edition melanoma TNM definitions 
 
 
Primary tumour (T) 
T category               Thickness                                                Ulceration status 
TX: Primary tumour thickness 
cannot be assessed (e.g., 
diagnosis by curettage) 
Not applicable  Not applicable 
T0: No evidence of primary 
tumor (e.g., unknown primary 
or completely regressed 
melanoma) 
Not applicable Not applicable 
Tis (melanoma 
in situ) 
Not applicable Not applicable 
T1 ≤1.0 mm Unknown or unspecified 
T1a <0.8 mm                                                 Without ulceration 
T1b <0.8 mm                                                 With ulceration 
0.8 to 1 mm                                            With or without ulceration 
T2 >1 to 2 mm                                             Unknown or unspecified 
T2a >1 to 2 mm                                             Without ulceration 
T2b >1 to 2 mm                                             Without ulceration 
T3 >2 to 4 mm                                             Unknown or unspecified 
T3a >2 to 4 mm                                             Without ulceration 
T3b >2 to 4 mm                                             Without ulceration 
T4 >4 mm                                                    Unknown or unspecified 
T4a >4 mm                                                    Without ulceration 
T4b >4 mm                                                    Without ulceration 
 
Regional lymph nodes (N) 
 
N category 
Extent of regional lymph node and/or lymphatic metastasis 
Number of tumour-involved 
regional lymph node 
Presence of in-transit, satellite, 
and/or microsatellite metastases 
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NX Regional nodes not assessed 
(e.g., SLN biopsy not 
performed, regional node 
previously removed for another 
reason) 
 
Exception: Pathological N 
category is not required for T1 
melanomas, use cN. 
No 
N0 No regional metastases 
detected 
No 
N1 One tumour-involved node or 
in-transit, satellite, and/or 
microsatellite metastases with 
no tumour-involved nodes 
 
N1a One clinically occult (i.e., 
detected by SLN biopsy) 
No 
N1b One clinically detected No 
N1c No regional lymph node 
disease 
Yes 
N2 Two or three tumor-involved 
nodes or in-transit, satellite, 
and/or microsatellite metastases 
with one tumor-involved node 
 
N2a Two or three clinically occult 
(i.e., detected by SLN biopsy) 
No 
N2b Two or three, at least one of 
which was clinically detected 
No 
N2c One clinically occult or 
clinically detected 
Yes 
N3 Four or more tumor-involved 
nodes or in-transit, satellite, 
and/or microsatellite metastases 
with two or more tumor-
involved nodes, or any number 
of matted nodes without or with 
in-transit, satellite, and/or 
microsatellite metastases 
 
N3a Four or more clinically occult 
(i.e., detected by SLN biopsy) 
No 
N3b Four or more, at least one of 
which was clinically detected, 
or presence of any number of 
matted nodes 
No 
N3c Two or more clinically occult 
or clinically detected and/or 
presence of any number of 
matted node 
Yes 
 
Distant metastasis (M) 
  
M category M criteria 
Anatomic site LDH level 
M0 No evidence of distant 
metastasis 
Not applicable 
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M1 Evidence of distant metastasis See below 
M1A Distant metastasis to skin, soft 
tissue including muscle, and/or 
nonregional lymph node 
Not recorded or unspecified 
M1a(0) Not elevated 
M1a(1) Elevated 
M1b Distant metastasis to lung with 
or without M1a sites of disease 
Not recorded or unspecified 
M1b(0) Not elevated 
M1b(1) Elevated 
M1c Distant metastasis to non-CNS 
visceral sites with or without 
M1a or M1b sites of disease 
Not recorded or unspecified 
M1c(0) Not elevated 
M1c(1) Elevated 
M1d Distant metastasis to CNS with 
or without M1a, M1b, or M1c 
sites of disease 
Not recorded or unspecified 
M1d(0) Normal 
M1d(1) Elevated 
Suffixes for M category: (0) LDH not elevated, (1) LDH elevated. No suffix is used if LDH is not recorded 
or is unspecified. 
AJCC: American Joint Committee on Cancer; TNM: tumour, node, metastasis; SLN: sentinel lymph node; 
LDH: lactate dehydrogenase; CNS: central nervous system. 
 
1.2.4.6 Descriptive epidemiology 
Incidence  
Melanoma accounts for less than 5% of all skin cancers [7], but causes the most skin cancer related 
deaths [100]. Overall melanoma incidence and mortality continue to increase faster than any other 
cancer in Australia and elsewhere, making primary prevention a priority [101]. The incidence of 
melanoma varies significantly depending on the geographical location of the population as well as 
the racial and skin-colour differences. Among white-skinned populations, melanoma incidence 
increases with proximity to the equator [102].  The countries with the highest incidences are closest 
to the equator: Australia, New Zealand, and some parts of the USA [103]. In the USA, the age 
standardised incidence rate (ASR) was 16.2 /100,000 in 2018 [Figure 1-5].  
 
In Australia, the age standardised rates have increased from 26.7/100,000 in 1982 to 43.1/100,000 
in 2018 [Figure 1-6]. However, a recent study has reported that melanoma incidence in Australia 
has been declining since 2005 [104]. While the ASR continues to increase in older people, the 
reported decrease is likely driven by declines in younger people. Because Australia covers a wide 
latitudinal range, melanoma incidence rates differ by states and territories with higher rates in 
tropical and subtropical jurisdiction. The incidence rates range from 38/100,000 in South Australia 
to 70/100,000 in Queensland [Figure 1-7]. Men are generally more likely to develop melanoma 
than women. For example, the lifetime cumulative probabilities of being diagnosed with melanoma 
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is 1 in 14 for men whereas women have a 1 in 24 cumulative lifetime probability of being 
diagnosed with melanoma before the age of 85 [Figure 1-8].  According to data from the AIHW, 
the mean age for development melanoma in Australia is 63 years for men and 60 years for women. 
While only a small proportion of melanoma cases are diagnosed before the age of 35, Australia has 
the highest incidence of melanoma among adolescent and young adults in the world [105]. A 
Queensland study has reported a recent decline in melanoma incidence among young people, 
however, mostly likely due to the comprehensive primary prevention programs that were instigated 
in the early 1980’s [106]. 
 
Most melanoma cases in Australia (~ 90%) are diagnosed at early stage (Stage 1 or Stage 2) and a 
lower proportion of cases (~5%) are diagnosed at advanced stage (Stage 3 or Stage 4). 
 
Melanoma in situ presents at a higher incidence than invasive melanoma. Over the last 20 years, the 
incidence of melanoma in situ increased at a faster rate than that of invasive melanoma, from 31 to 
113/100,000 for men and from 28 to 83/100,000 for women [107] [Figure 1-9].  Improved 
awareness of the importance of early detection and treatment among the public and clinicians could 
explain these trends at least in part. 
 
 
Figure 1-5. Comparison of worldwide incidence of melanoma 
Source: GLOBOCAN 2018 (IARC) (9.12.2018) 
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Figure 1-6. Age-standardised incidence and mortality rates of melanoma by year for Australia 
 
 
 
Figure 1-7. Age-standardized incidence rates of melanoma by sex, state and territory in 
Australia in 2015 
 
 
 
Source: Australian Institute of Health and Welfare 
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Figure 1-8. Age-specific incidence rates of melanoma for 2011 in Australia 
 
 
Figure 1-9. Trends in the incidence rates of in situ and invasive melanomas by thickness and 
sex in Queensland, 1995–2014  
Source: Aitken et al, 2018 
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Mortality  
In 2012, melanoma ranked 8
th
 highest in terms of number of deaths from cancer in Australia [108]. 
From 1968 to 2012, the number of deaths due to melanoma increased from 315 to 1515  [108], 
representing an increase in the age standardised mortality rate of 3.3 deaths per 100,000 persons in 
1968 to 5.9  deaths per 100,000 in 2012 [Figure 1-6]. It is estimated that in 2015 the age-
standardised mortality rate will be 6.1 deaths per 100,000 persons (9.2 for males and 3.5 for 
females). The 5-year relative survival for patients with melanoma is higher when compared to other 
types of malignancies and survival rates are higher in countries where there is good melanoma 
awareness due to earlier detection [109]. In Australia, women diagnosed with melanoma have a 
94% cumulative lifetime probability of surviving for 5 years after their diagnosis while men have a 
90% chance [109], confirming a survival advantage for women. The survival rate, however, is 
strongly and inversely correlated with tumour thickness, with 5-year survival almost 100% for thin 
tumours (1mm or less) and approximately 55% for tumours thicker than 4mm [109].   
 
1.2.4.7 Pathogenesis 
Melanoma develops from the pigment-producing cells known as epidermal melanocytes and can 
occur in any tissue containing these cells [100]. Melanoma develops predominantly on the skin 
(cutaneous melanoma), but can also be found in the eyes, ears, gastro-intestinal tract, and oral and 
genital mucous membranes [77]. Recent data suggest multiple pathways of melanoma pathogenesis, 
but exposure to UVR is the major environmental cause [110]. Experimental studies have suggested 
that exposure to UVR often leads to DNA mutations such as the formation of pyrimidine dimers or 
C to T transitions [111]. The base mutation rate in melanoma samples is much higher than mutation 
rates found in solid cancers, providing additional evidence of mutagenic role of UVR in melanoma 
pathogenesis [112]. Melanoma that occurs in chronically sun-exposed areas such as face or forearm, 
and melanomas occurring on older-aged individuals, exhibit  high load of UVR signature mutations 
such as B-Raf proto-oncogene (BRAF), neurofibromin 1 (NF1) and NRAS [113, 114]. Melanoma 
that occurs on less sun-exposed areas such as proximal extremities or trunk or found in younger-
aged individuals are often associated with intermittent sun-exposure and usually exhibits lower 
levels of BRAF mutations [115, 116]. 
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Melanoma can also arise from existing precursor lesions such as melanocytic nevi [114]. More than 
80% of common and dysplastic nevi harbor BRAF mutations [117]. However, nevi rarely progress 
to melanoma, indicating that these mutations alone are not enough to induce melanogenesis [117]. 
Sustained expression of BRAF mutations however, together with acquisition of additional  
mutations in the prominent  genes such as TERT and CDKN2A could induce growth of 
melanocytes [118]. In contrast, melanomas arising in chronically sun-exposed skin usually do not 
arise from a pre-existing nevi but from other dysplastic lesions such as melanoma in situ [118] and 
exhibit different type of mutations.  
 
1.3 Risk factors for keratinocyte carcinomas 
This thesis will focus primarily on relatively understudied risk factors for skin cancer, namely 
cigarette smoking, obesity and height. The following sections included in this chapter will review 
briefly the other factors that are known or suspected to be associated with skin cancer development. 
 
1.3.1 Phenotypic factors  
1.3.1.1 Skin pigmentation and tanning tendency  
People with certain types of skin are at higher risk of developing sunburn and skin cancer.  
Depending on the ethnic group, remarkable differences in melanoma incidence have been 
documented. For example, a higher incidence of melanoma has been reported among people of 
Celtic descent compared to other ethnic groups [119]. However, people of Celtic ancestry did not 
have a significantly increased risk after adjusting for the confounding effect of skin type and 
phenotypic characteristics [120]. In people with dark skin, the large numbers of melanosomes in 
keratinocytes provide a higher level of sun protection than occurs among people with light skin 
[121], and this difference in sun protection level largely explains the difference in skin cancer 
incidence across populations. People with light skin colour have increased risk of both BCC and 
cSCC compared to those with dark skin [122, 123].   
 
Variations in constitutional factors such as eye and hair colour have been linked to the risk of skin 
cancer. People with light eye colour have a higher risk of developing BCC and cSCC compared to 
those with dark eyes [122, 124, 125]. Compared to dark hair colour, light red and blond hair is 
significantly associated with increased risk of BCC and cSCC [122, 125, 126].  
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Fitzpatrick created a comprehensive method to classify skin types according to their burning and 
tanning responses to UVR. The 6 categories range from type I (always burn, never tan: palest; 
freckles) to type VI (tan, never burn: deeply pigmented dark brown to darkest brown) [127]. 
Individuals with a skin that always burns and never tan have a greater than 2-fold increased risk of 
BCC and cSCC compared to those with a skin that tan and never burns [122, 125, 128].  
 
1.3.1.2 Obesity  
There is strong evidence for the role of obesity in the development of cancer [129] where it is 
hypothesised to act through hormonal and inflammatory pathways [130, 131]. However, limited 
information is available on the potential role of obesity in the development of KCs.  Several large 
prospective cohort studies, namely the Nurses' Health Study (NHS) [132], the United States 
Radiological Technologists’ Study (USRT) [133], the Women’s Health Initiative (WHI) [134] and 
the Danish Diet, Cancer and Health Cohort Study [135] reported that women in the obese range had  
10% to 30% lower risk of developing BCC and cSCC compared to those in the normal BMI range. 
In contrast, the Nambour cohort (conducted in Queensland, Australia) reported non-significant 
associations between BMI and risk of BCC in women [136]. In cohort studies of men, the USRT, 
the Danish Diet, Cancer and Health Cohort Study and Nambour study found no significant 
associations between obesity and BCC or cSCC (although the point estimates tend to show a 
possible negative effect).  
 
1.3.1.3 Height 
There is growing evidence suggesting that taller people are more likely to develop cancers at 
different anatomical sites [137, 138] where the effect is believed  to be mediated through hormonal 
and genetic pathways [139] [140]. A pooled analysis of more than 500,000 participants from 
Australia, Norway and Sweden reported that height (per 5cm increment) was significantly 
associated with a 10% increased risk of KCs [141] in men and women combined. However, that 
study did not report separate risk estimates for cSCC and BCC. Another prospective study in 
Australia reported that height  was significantly associated with a 60% increased risk of cSCC for 
men (4
th
  quartile vs. 1
st
  quartile ), but not for women, while a 50% increased risk of cSCC was 
seen for women but not for men [142]. In contrast to findings from observational studies, a very 
recent Mendelian randomisation study found that genetically predicted height was not associated 
with cSCC or BCC [143]. 
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1.3.2 Environmental factors  
1.3.2.1 Ultraviolet radiation  
Exposure to sunlight is generally accepted to be the major environmental risk factor for most types 
of skin cancer [144]. Epidemiological studies implicate UVR exposure as the main cause of cSCC 
[126, 145]. cSCC is associated with total lifetime sun exposure [146-148] and with occupational sun 
exposure [147]. High levels of sun exposure in childhood and adolescence were found to be 
strongly associated with cSCC compared to adult sun exposure [126]. Artificial UVR sources 
include lamps used in medicine (e.g. extracorporeal phonophoresis), and for cosmetic purposes (e.g. 
UVA lamps used in tanning) and a recent meta-analysis found a significant association between 
indoor tanning and cSCC; ever exposure to indoor tanning increased the risk of cSCC by 67% 
[149]. The presence of markers of actinic damage such as solar keratosis, telangiectasia and 
lentigines is also associated with cSCC [122]. 
 
With regards to BCC, previous studies confirmed a link between intermittent sun exposure (non-
occupational or recreational sun exposure) and the risk of developing BCC [125, 150].  However, 
results from a meta-analysis showed that occupational UVR exposure is an independent risk factor 
not only for cSCC as previously reported but also for BCC [151]. Findings from a cohort of US 
women suggest that the risks of BCC are associated with sun exposure in both adulthood and early 
life [126].  Exposure to artificial UV radiation (e.g. tanning beds) also increases the risk of BCC and 
a meta-analysis found that ever exposure to indoor tanning increased the risk of BCC by 
approximately 30% [149].  
 
1.3.2.2 Tobacco smoking 
A detailed literature review on smoking and BCC and cSCC is provided in section 1.5.2 and in 
Chapter 4, new findings on the association between smoking and cSCC and BCC using the QSkin 
cohort data are discussed.  
 
1.3.2.3 Dietary factors  
Diet plays a role in the development of many cancers and there is strong evidence linking the 
consumption of specific foods and decreased risk of certain cancers including the consumption of 
fruits and vegetables [152]. A systematic review investigating the relationship between dietary 
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factors and the development of KC reported a positive association between fat intake and BCC and 
cSCC [153]. Recent findings from the phase 3 ONTRAC skin cancer prevention study indicated 
that taking 500 mg of  vitamin B3 supplement (also called nicotinamide) twice daily, reduced the 
incidence of KCs by 23% [154]. Nicotinamide supplementation was also found to be effective in 
reducing the risk of developing other skin lesions such as actinic keratoses. However, there was no 
consistent evidence that intakes of other dietary or supplemental nutrients such as retinol, β-
carotene, Vitamin C, Vitamin E play a role in preventing BCC or cSCC [153].  A systematic review 
of 10 trials also reported no convincing evidence of the role of dietary factors in the prevention of 
KCs [155].  
 
Alcohol consumption has also been shown to be associated with several cancers [156, 157]. The 
WHI cohort study reported 20% increased risk of KCs among people who consume 7+ drinks per 
week compared to non-drinkers [158]. The NHS also reported  that people who consume >30 grams 
of alcohol from liquor have a 25%  increased risk of BCC compared to non-drinkers [159], while 
three large cohort studies in USA found that each daily alcohol drink (equivalent to 1.28 grams of 
alcohol) increased the risk of cSCC by 22% [160]. 
 
1.3.2.4 Human papilloma virus (HPV) infection 
Globally, it was estimated that 4.8% of the new cancer cases in 2008 were attributed to HPV 
infection [161]. So far, the IARC has identified more than 200 different HPV genotypes [162]. The 
association between cutaneous HPVs that frequently affect the dry skin (HPV5 and HPV8) and 
cSCC is well established among people with epidermodysplasia verruciformis (EV) [162, 163]. EV 
is a rare inherited condition  commonly located at sun-exposed anatomical sites  with  propensity to 
progress to cutaneous SCC [164]. However, the role of cutaneous HPVs in cSCC development in 
the general population is not well understood [165]. A recent study using whole transcriptome 
sequencing to look at the presence of viral DNA in tumour tissue, found no difference in HPV viral 
load between cSCC tumours and normal skin tissue [166]. In contrast, the presence of higher levels 
of HPV viral load found in actinic keratoses than in cSCC, suggest that HPV infection may play a 
role at early stage of carcinogenesis but not involved in cSCC progression [167]. Thus, it is possible 
that viruses facilitate the accumulation of DNA damage induced by UVR exposure. For example, 
individuals with SCC on sun exposed areas, and those with fair skin phenotype were more likely to 
be HPV seropositive compared to those with SCC at other sites [168, 169]. Finally, higher 
proportions of HPV DNA seropositivity found among immunocompromised individuals compared 
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to their   immunocompetent counterparts, suggest that HPV may not play a direct role in cSCC 
development, but rather act as a marker of immunosuppression [170]. 
 
Based on epidemiological and biological evidence mucosal HPV types (HPV16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58 and 59) have been classified as high-risk (HR) phenotypes because of their 
association with cervical cancer [162, 171]. Some types of HPVs have also been associated with 
increased risk of anogenital cancer and some head and neck SCCs [172, 173].  
 
In 2007, the Australian government commenced a free National HPV Vaccination Program. Since 
the introduction of the quadrivalent HPV vaccine against infection with HPV types 6, 11, 16 and 
18, the prevalence of HPV16 and HPV18, which cause more than 80% of cervical cancer in 
women, declined significantly [174]. However, the impact on skin cancer incidence remains 
unknown, but is likely to be small since cutaneous HPVs are not among the targeted genotypes. 
 
1.3.2.5 Oral contraceptives and postmenopausal hormone therapy  
Exogenous hormonal factors such as menopausal hormone therapy and oral contraceptives are 
widely used among women in many high-income countries to prevent chronic conditions such as 
osteoporosis, or to treat symptoms related to menopause, or control fertility [175]. Preclinical 
studies have found that oestrogen receptors are present in keratinocytes and may play a role in skin 
cancer carcinogenesis [176]. It has been shown that use of oral contraceptives and menopausal 
hormone therapy affect the skin, including acting as photosensitising agents by increasing the skin's 
reaction to UVR, the leading risk factor for skin cancer [177, 178].  The prospective "Diet, Cancer 
and Health" cohort study indicated that ever user of menopausal hormone therapy   but not oral 
contraceptives had a 15% and 35% increased risk of being diagnosed with a new BCC or new 
cSCC, respectively, compared with never users [179].  In the USRT [180] and the QSkin cohort in 
Australia [181], the use of any menopausal hormone therapy significantly increased the risk of BCC 
and cSCC approximately by 20% and 40%, respectively, compared with never users. The 
randomised trials within the Women’s Health Initiative (WHI) Study [182] however, found that 
menopausal hormone therapy did not affect overall incidence of KC. Recently, findings from the 
QSkin cohort in Queensland, Australia, also found no evidence that use of OCs significantly 
influenced risk of cSCC or BCC [181]. 
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1.3.2.6 Chronic arsenic exposure  
Exposure to arsenic may occur as a result of ingesting contaminated drinking water [183], 
medication or eating seafood [184, 185]. A case control study including ~500 BCC cases and ~ 500 
controls in Eastern Europe (Hungary, Romania and Slovakia) found a positive association between 
BCC and exposure to inorganic arsenic through drinking water [186]. In Queensland, increased risk 
of BCC was also reported among patients who reported having ingested arsenic-containing 
medication (“Bell’s Asthma tonic”) during childhood [184]. In Taiwan, a two-fold increased risk of 
cSCC was reported among residents who lived in settings with high levels of arsenic concentration 
in drinking well water compared with those who had access to clean water [187]. A two-fold 
increased risk of cSCC was also reported among individuals with highest toenail arsenic 
concentration compared with those with moderate levels of exposure in New Hampshire, USA 
[188].    
 
1.3.3 Clinical factors  
1.3.3.1 Personal history of KCs  
Personal history of a KC is a strong predictor of developing subsequent KC [189]. Patients with a 
BCC had a 17-fold increased risk of a subsequent BCC and a 3-fold increased risk of a subsequent 
cSCC compared to the general population [189]. In the USA, it was estimated that approximately 
40 percent of patients who have had one BCC will develop another lesion within five years [190].  
 
1.3.3.2 Immunosuppression  
There is growing evidence suggesting that chronic immunosuppression may increase the incidence 
of cutaneous cSCC, and to a lesser extent, BCC [191-193].  Infection with the Human 
Immunodeficiency Virus (HIV), exposure to certain medicines used for preventing graft-versus-
host disease after organ transplantation, or long-term corticosteroid use can suppress the immune 
system, leading to higher incidence of various tumours.  For example, the incidence of cSCC was 
65 to 250 times higher in organ transplant recipients than in the general population and the 
incidence of BCC was 10-40-fold higher [194-198]. Compared with the general public, people 
living with HIV have approximately  4-fold increased risk of developing KCs [199]. Increased risk 
of KCs has also been reported among people taking corticosteroids to treat certain auto-immune 
diseases compared to nonusers [200, 201], [202].  
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A number of mechanisms through which immunosuppressive medications may induce the 
development of skin cancer has been proposed, although none of them had, as yet, yielded 
conclusive results. First, chronic immunosuppression may create a state of decreased 
immunosurveillance against precancerous changes resulting in increased susceptibility to various 
malignancies [203, 204]. Second, the drug used as immunosuppressive agent may have direct 
carcinogenic effects [205, 206]. For example, azathioprine, an immunosuppressant used to prevent 
rejection after organ transplants or to treat autoimmune diseases such as rheumatoid arthritis, has 
properties to sensitises DNA to ultraviolet A (UVA), the major risk factor for skin cancer [207]. 
 
1.3.4 Genetic factors 
Certain inherited disorders may also increase KCs susceptibility. The most common conditions that 
relate to KC risk include Xeroderma pigmentosum and familial Gorlin syndrome (XP) [208-210].  
 
Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder characterised by extreme 
increase in photosensitivity and impaired ability to repair DNA damage [210].  The genes related to 
XP are part of a DNA-repair process known as nucleotide excision repair (NER) and people with 
XP lose their ability to repair UV specific photolesions [210]. This condition mostly affects the eyes 
and areas of skin exposed to the sun. Individuals with XP are approximately 1000 times more likely 
to develop cSCC and BCC compared to the general population before their 20
th
 birthday [211].  
 
Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal 
dominant disorder characterised by mutations of the human patched gene (PTCH) leading to BCC 
predisposition at an earlier age compared to the general population  [208, 212]. Other inherited 
disorders include oculocutaneous albinism and epidermodysplasia verruciformis for cSCC [213, 
214] and Bazex-Dupre-Christol syndrome and Rombo syndrome for BCC [215, 216]. 
 
1.4 Risk factors for melanoma  
1.4.1 Phenotypic factors 
1.4.1.1 Skin pigmentation and tanning tendency  
Factors that increase sensitivity to sunlight including light skin pigmentation, poor tanning 
tendency, freckling tendency, light eye colour (blue or green) and red or blond hair are well 
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established risk factors for melanoma [125]. In a meta-analysis of observational studies, light skin 
colour vs. medium or dark skin; red hair colour vs. dark hair colour; fair eyes vs. dark eyes, were 
associated with a 2-4 fold increased risk of melanoma [125]. The pooled relative risk also doubled 
in individuals with higher density of freckles compared to individuals with no or few freckles, and 
increased susceptibility to UV-induced skin damage, such as those with skin type that burns rather 
than tans after sun exposure, conferred an increased risk of more than 2-fold.  
 
1.4.1.2 Common and atypical nevi 
 The presence and number of common and dysplastic nevi (or atypical moles) are markers of 
increased risk of melanoma [217], and they can also be precursors. The risk of melanoma increases 
by 10-fold among individuals with one or more atypical nevi [218].  Common nevi  also confer an 
increased risk, with a significant increase in risk per increase in nevus count by one; presence of 50 
or more common nevi is associated with approximately 5-fold increased risk of developing 
melanoma [219]. A meta-analysis of observational studies reported that approximately one-third of 
melanoma arises from pre-existing nevi [220]. 
 
1.4.1.3 Obesity and height 
While obesity and height have been linked to several human cancers [129, 135, 138], their role in 
the development of skin cancer remains unclear. In section 1.6.5 and section 1.7, I have 
comprehensively summarised the current evidence regarding these associations, and in Chapter 6 
and Chapter 7, I have presented new findings from additional analyses on the associations between 
obesity, height and melanoma risk using data from the QSkin cohort and consortium data from the 
BMI, height and melanoma genome-wide association studies (GWAS) meta-analyses. 
 
1.4.2 Environmental factors  
1.4.2.1 Ultraviolet radiation 
Exposure to UVR from sunlight is accepted as the main environmental risk factor for melanoma in 
white-skinned populations [221, 222]. In reference to patterns of sun exposure, intermittent sun-
exposure was found to be associated with melanoma whereas an inverse association was found 
between high chronic sun exposure and melanoma [125]. However, the association between sun 
exposure and melanoma differs by body site, with melanoma of the head and neck more strongly 
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associated with a continuous pattern of sun exposure and melanoma arising on the trunk more 
strongly associated with an intermittent pattern of sun exposure [223], supporting the hypothesis of 
different etiological pathways to melanoma development. The effect of UVR on melanoma 
development has already been described in more detail above (see section 1.3.1.1).   
 
Artificial UVR from sunbeds also increases of melanoma; indoor tanning is a well-established class 
I carcinogen based on its effect on melanoma [221, 224].  There is also evidence that childhood and 
adolescence are important periods for the initiation and development of melanoma in adulthood 
with a dose-response relationship and higher risk associated with younger age at first use [225].  
 
1.4.2.2 Tobacco smoking  
The association between cigarette smoking and melanoma remains unclear despite extensive 
investigation. The evidence regarding the potential role of cigarette smoking in the development of 
melanoma is summarised under section 1.5.3 and, in Chapter 5, new findings from the QSkin cohort 
are discussed and contrasted against the current body of evidence. 
 
1.4.2.3 Dietary factors  
Studies assessing the role of dietary factors such as antioxidants, vitamin C and vitamin E and risk 
of melanoma have yielded inconsistent findings. A large meta-analysis including 2 prospective 
cohorts, 1 nested case-control study and 6 randomised controlled trials found little evidence that 
intake of fruits and vegetable or antioxidant nutrients alters risk of melanoma [226]. However, 
because melanoma was not the primary outcome of interest for the most studies included in the 
meta-analysis, information regarding melanoma risk factors were not collected, resulting in 
inadequate control of confounding factors. The Nurse’s Health Study found a modestly increased 
risk of melanoma associated with high dietary intake of citrus fruits or juice after adjusting for 
potential confounding factors. However, weaknesses in study design limit causal interpretation 
[227]. Findings from the European Prospective Investigation into Cancer and Nutrition (EPIC) 
study including 500 000 participants reported an inverse association between caffeinated coffee or 
tea and melanoma among men but not among women [228].  This finding was confirmed by two 
large meta-analyses of cohort and case-control studies that suggested that coffee consumption may 
reduce risk of melanoma [229, 230].  
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1.4.2.4 Oral contraceptives and menopausal hormone therapy  
The association between long term use of oral contraceptives and menopausal hormone therapy and 
risk of melanoma has been examined in several studies including two meta-analyses.  The first 
meta-analysis reported no increased risk of CM with the use of oral contraceptives and hormone 
replacement therapy [231].  The second meta-analysis including 18 case-control studies also found 
no evidence that oral contraceptives use is a risk factor for melanoma [232]. Only two studies, 
reported an increased melanoma risk among menopausal hormone therapy users. However, the first 
study [233] which used linked data between pharmacy and pathology databases in Netherlands 
found no evidence of dose response relationship, while the second study [234] did not adjust for 
potential confounding factors such as sun exposure.  
 
1.4.3 Clinical factors  
1.4.3.1 Personal history of melanoma and other skin cancer  
A personal history of melanoma is a risk factor for developing a second primary melanoma [219, 
235]. The relative risks of developing an invasive melanoma after an invasive or in situ melanoma 
were 12- and 26-fold respectively compared with the general population [236].  The increased risk 
of developing a subsequent melanoma among melanoma survivors is likely a result of cumulative 
lifetime exposure to UVR along with a background of genetic susceptibility. Past history of KCs 
and actinic keratoses, are also strongly associated with melanoma development [189].  For example, 
patients who have had BCC or cSCC have a 2.2-fold increased risk of melanoma compared with the 
general population [237].  
 
1.4.3.2 Immunosuppression 
 Increased risk of melanoma has been reported among immunosuppressed populations including 
solid organ transplant recipients; patients with lymphoproliferative disorders, specifically non-
Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia; and patients with human 
immunodeficiency virus (HIV) infection [238]. A number of studies have shown that organ 
transplant recipients had 2-fold to 8-fold increased risk of melanoma compared with the general 
population [239-242].  Patients with NHL or with a history of NHL also have 1.3 to 2.7-fold 
increased risk of developing melanoma compared to the general population [235, 243-245]. 
Moreover, a systematic review and meta-analysis of cohort studies reported that patients with HIV 
infection have 1.5- to 2-fold increased risk of melanoma relatively to HIV-uninfected [246].  
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1.4.4 Genetic factors  
1.4.4.1 Inherited susceptibility 
Mutations in germline CDKN2A (tumour suppressor gene), were the first heritable mutations found 
in familial melanoma [247]. Increased frequency of CDKN2A mutations is associated with familial 
melanoma and early age at melanoma diagnosis [248]. Other high penetrance melanoma 
susceptibility genes include CDK4, BAP1, POT1, ACD and TERF2IP [249]. There are also 
intermediate and low-risk melanoma susceptibility genes, some associated with pigmentary risk 
factors (SLC45A2, TYR, MC1R and ASIP), nevus count (MTAP, PLA2G6 and TERT), DNA 
maintenance pathways (PARP1 and ATM) and others with unknown functions (ARNT-
SETDB1, CASP8, FTO and MX2) [250]. 
 
1.4.4.2 Family history of melanoma 
Familial melanoma (also known as familial melanoma syndrome, B-K mole syndrome or dysplastic 
nevus syndrome) is an inherited condition generally defined as presence of melanoma in two or 
more first degree relatives such as parents or siblings and characterised by atypical nevi and 
multiple inherited melanomas. About 10% of all melanomas are familial [251]. Two meta-analyses 
found a significant association between familial predisposition to melanoma and risk of developing 
melanoma in siblings [125, 252] and estimated that the proportion of melanoma attributable to 
familial predisposition was around 7% [252].  
 
1.5 The epidemiology of smoking and cancer  
1.5.1 Smoking – epidemiology  
Currently, there are 1.3 billion tobacco smokers worldwide and this number is expected to reach 1.6 
billion by 2025 [253, 254]. Smoking rates of adults in the USA have dropped by half, from 42% in 
1965 to 20.8 % in 2006 [255]. In Australia, 14.5% (2.6 million) were current smokers in 2015 
[256], a decline from 28% in 1990 [257] which is likely due to increased public health interventions 
including increased taxation on tobacco products. The prevalence was much higher among the 
indigenous population with 50% of men and 44% of women reported to be current smokers in 2008 
[258]. Smoking remains a leading cause of mortality and morbidity in Australia, killing an 
estimated 20,933 people annually [259].  
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Tobacco smoking is the single largest risk factor for several cancers worldwide [260]. In the UK, it 
was estimated that, in total, 23% of the total cancer burden in men and 15% of the total burden of 
cancer in women was attributable to smoking [261]. In Australia an estimated 16% of all cancer 
cases in men and 10% of cancers in women (excluding BCC and cSCC of the skin) were 
attributable to tobacco smoking in 2010 [262].  
 
1.5.2 Smoking and risk of KCs 
New evidence continues to add to the existing list of tobacco-related cancers, however, the 
association between smoking and cutaneous malignancies has not been well established. Two recent 
meta-analyses including both cohort and case-control studies assessed for a possible link between 
smoking and KCs risk and came to different conclusions. The first reported that ever smokers of 
both sexes had slightly higher risks of both BCC and cSCC compared with never smokers [263]; the 
study did not provide separate pooled estimates for current and former smokers. The second found 
that current smoking was associated with an approximately 50% increased risk of cSCC but not 
BCC [186]. More recently, the Million Women Study showed that current smokers had about a 
20% increased risk of cSCC and a 20% lower risk of BCC than never smokers [264]. 
 
1.5.3 Smoking and risk of melanoma 
The association between smoking and melanoma remains unclear despite extensive investigations. 
Two previous meta-analyses both reported moderate inverse associations between smoking and 
melanoma. The first meta-analysis, which was limited to prospective cohort studies, reported that, 
compared with never smokers, ever smokers had a 30% lower risk of melanoma for men but not for 
women [263]. Separate pooled estimates for current and never smokers were not reported. The 
second meta-analysis comprising cohort and case-control studies also reported a 30% decreased risk 
of melanoma among current smokers compared with never smokers, but did not report sex-specific 
estimates [265].  Former smokers had a slightly decreased but non-significant risk relatively to 
never smokers.  
 
1.5.4 Proposed biological mechanisms linking smoking to cancer risk.   
The mechanisms through which cigarette smoking cause cancer are complex [266]. Tobacco smoke 
contains a number of carcinogenic compounds and has been shown to have an aetiological effect in 
several types of cancer [260]. Each puff of cigarette smoke contains mixtures of compounds 
including 70 which has been listed by the International Agency for Research on Cancer as 
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carcinogenic in humans and animals [267]. Carcinogens in cigarette smoke require a metabolic 
activation process which is catalysed by cytochrome P-450 enzymes (P-450s) to convert the 
carcinogens to forms that can easily bind to DNA [268]. DNA methylation is one of the best 
characterised epigenetic modifications induced by carcinogens in cigarette smoke and form the 
central basis of the carcinogenic process [269].  Persistent epigenetic modifications can inhibit 
transcription factors, resulting in transcription suppression [269]. Impaired transcription can cause 
the loss of control of normal cellular functions and growth, resulting in abnormal cellular 
proliferation and cancer [270]. Decreased risk of cancer after quitting smoking supports the role of 
epigenetic factors in tobacco carcinogenesis [271]. 
 
1.6 Obesity - Epidemiology of obesity and cancer 
1.6.1 Obesity definition and measurements  
The term obesity refers to the abnormal or excess accumulation of fat in adipose tissue [272]. There 
are two main types of adipose tissue, namely subcutaneous and visceral.  Subcutaneous adipose 
tissue is largely found in the skin and muscles whereas visceral adipose tissue is found in the main 
cavities especially in the abdominal cavity [272]. The most common causes of obesity are excessive 
food energy intake and insufficient physical activity [273]. Other contributing factors include 
genetic susceptibility, increased use of antipsychotics, some illness such as hypothyroidism and 
smoking cessation (smoking suppresses appetite) [274, 275].   
 
Obesity is classified as peripheral, central or a combination of both, depending on the distribution of 
fat [276]. Peripheral obesity is defined as accumulation of excess fat in the hips, thighs and around 
the buttocks whereas in central obesity (also known as visceral or male-pattern obesity), the fat is 
located inside the peritoneal cavity. Central obesity is the most dangerous form because the fat 
builds up is closely located to the vital organs and their blood supply and thus fat can be easily 
released into the blood stream causing many of the negative health effects associated with obesity. 
Central obesity is associated with significantly increased risks of developing health conditions such 
as metabolic syndrome, type 2 diabetes, heart disease and the majority of obesity-associated cancers 
[277, 278].  
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1.6.2 Measurement of obesity 
There are several techniques available to estimate body composition and fat distribution namely 
underwater weighing (hydrodensitometry), dilution methods (hydrometry), Bioelectrical Impedance 
Analysis, Dual-Energy X-Ray Absorptiometry, measurement of skinfolds, computed tomography 
(CT) or magnetic resonance imaging among others [279].  However, these methods are expensive 
and technically not available in daily practice and routine examinations. Therefore, anthropometric 
measures such as body mass index (BMI), waist circumference, hip circumference, waist-to-hip 
ratio have been widely used in epidemiological studies as surrogate markers to estimate body fat 
[280]. However, the cost of waist circumference, hip circumference and waist-to-hip ratio 
measurements and their technical requirements limit their use in large-scale epidemiological 
studies. BMI is defined as body weight (in kilograms) divided by the height (in meters) squared and 
is expressed in units of kg/m
2
. Adults with a BMI between 25 and 30 kg/m
2
 are considered 
overweight; those with a BMI ≥30 kg/m2 are considered obese [281]. Combined overweight and 
obesity may be expressed as excess body weight. Obesity in adults is subcategorised as class I (BMI 
≥30 to 35), class II (BMI ≥35 to 40), and class III (BMI ≥40) [Table 1-2]. BMI estimates total body 
fatness (combined central and peripheral adipose tissues).  
 
Table 1-2. Common classifications of body mass index in adults 
 
Body Mass Index Classification 
< 18.5 Underweight 
18.5–24.9 normal weight 
25.0–29.9 Overweight 
30.0–34.9 
 
class I obesity 
35.0–39.9 
 
class II obesity 
≥ 40.0 
 
class III obesity 
 
1.6.3 Obesity – epidemiology  
Over the last two decades, the prevalence of overweight and obesity has increased worldwide [282, 
283]. The estimated total number of overweight and obese adults in 2005 was 937 million (23.2% 
of the world’s adult population) and 396 million (9.8% of the world’s adult population), 
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respectively [284]. Furthermore, if the trend continues, by 2030 an estimated 3.3 billion people 
(58% of the world’s adult population) could be either overweight or obese [284].  
 
In 2016, the prevalence of obesity in the USA was 35% among adults aged 20 to 40 years, and 40% 
among old adults aged 60 years and older [285]. In Australia, the prevalence of overweight and 
obesity has increased over time, from 56.3% in 1995 [286] to 63% in 2015 [287]. Nearly 36% of 
Australians aged 18 and over were overweight and 28% were obese in 2015 [287]. Overweight and 
obesity varies with age, with 36.4% of people aged 18-24 years being overweight or obese, 
compared with 74.9% of people aged 65-74 years [286]. A recent study on the projected 
progression of the prevalence of obesity in Australia showed that the adult population prevalence of 
obesity will be 33.9% by 2025 [288]. 
 
1.6.4 Obesity and cancer risk 
Worldwide, it was estimated that 481 000 or 3.6% of all new cancer cases in adults aged 30 years 
and older (excluding KC) were attributable to high BMI in 2012 [289]. In Australia, a recent study 
found that an estimated 3,917 cancer cases (or 3.4% of all cancer cases excluding KC) diagnosed in 
2010 could be attributed to excess body weight [290].  In 2002, the International Agency for 
Research on Cancer (IARC) reported convincing evidence that excess body weight is associated 
with increased risk of developing cancers of the postmenopausal breast, colon, endometrium, 
kidney and oesophageal adenocarcinoma [291].  In 2007, the World Cancer Research Fund 
(WCRF) supported the IARC’s previous findings [292]. The WCRF report presented data 
supporting evidence for rectal and pancreatic cancer and a probable causal association with 
gallbladder cancer. An inverse association was reported between excess body weight and 
premenopausal breast and lung cancer. In 2008, Renehan and colleagues published a meta-analysis 
and included large cohort studies and less common cancers that were not included in the 2007 
WCRF review [129].  This meta-analysis supported previous reports by IARC and WCRF and also 
reported probable causal associations between excess body weight and malignant melanoma, 
leukaemia, thyroid, multiple myeloma and non-Hodgkin lymphoma.  
 
1.6.5 Obesity and risk of melanoma 
Numerous studies have evaluated whether obesity is a causal factor for melanoma, but findings 
have been heterogeneous. Two meta-analyses that synthesised prospective observational studies and 
case control studies reported a significant association between obesity (measured by BMI) and 
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melanoma among men but not women [129, 293]. However, it remains unclear whether these 
associations represent a true causal relationship or are explained by bias or confounding by other 
factors. For example, many epidemiological studies rely on self-reported weight and height 
measurements which are subject to sex-specific misclassification [294, 295].  Obesity may also be 
associated with other unknown or unmeasured lifestyle factors, and the possibility of residual 
confounding by such factors remains as a limitation of all observational studies. In this thesis, I 
have investigated these associations (estimated by BMI) using three separate analytical techniques. 
A detailed methodological approach and findings are presented in Chapter 6. 
 
1.6.6 Proposed biological mechanisms linking obesity to cancer  
A number of biological mechanisms have been proposed to explain the relationship between obesity 
and cancer risk. Excess body weight and adiposity result in insulin signalling impairment (insulin 
resistance), which is consequently compensated for by stimulation of pancreas insulin secretion 
resulting in chronic hyperinsulinemia [296]. The insulin cancer hypothesis suggests that chronic 
hyperinsulinemia decreases the concentration of IGF binding protein-1(IGFBP1) and IGF binding 
protein-2 (IGFBP2) [Figure 1-10] [297]. This mechanism leads to higher plasma levels and 
bioavailability of free insulin-like growth factor 1 (IGF1).  Both insulin and IGF1 have been shown 
to act as growth factors that promote cell proliferation and inhibits apoptosis by inhibiting tumour 
suppressor gene p53 which has an anticancer function [130].  
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Figure 1-10. The insulin-IGF hypothesis of obesity-related cancer 
Source: Calle et al, 2004 
Further studies have hypothesised that obesity-induced hypoxia may also influence cancer 
development [298, 299]. Adipose tissue hypoxia is associated with systemic insulin resistance and 
chronic inflammation [300]. During chronic inflammation, accumulation of pro-inflammatory 
mediators such as cytokines may induce epigenetic alterations that inhibit tumour suppressor genes 
[301] and promote tumour growth [302]. Finally, with the recent discovery of new loci associated 
with BMI [303], it has been suggested that the genetic factors that predispose to obesity may also be 
implicated in the development of certain malignancies (shared genetic susceptibility) [304, 305]. 
1.7 Height and risk of melanoma 
The association between height and melanoma risk has been reported in numerous observational 
studies [138, 306-309]. In a large cohort study in Norway with an average follow-up of 27 years 
and nearly 3000 cases, it was reported that men and women in the highest quintile of height had a 
50% increased melanoma risk compared to the first quintile [309]. In the UK Million Women Study 
with more than 3500 melanoma cases, it was found that melanoma risk had increased by 30% for 
every 10cm increase in height [138]. A pooled analysis including 8 case-control studies (with a total 
of 2,083 melanoma cases) also found a 30% increased risk of melanoma for women in the highest 
quartile of height compared with those in the lowest quartile even after adjusting for potential 
confounding factors related to sun exposure [307]. The Nambour study in Queensland, reported that 
taller men and women are 1.3 and 2.5 times more likely to develop melanoma, respectively, but the 
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study was underpowered to detect significant associations [142]. However, it is still unclear whether 
height is associated with melanoma through underlying biological mechanisms or whether some of 
the observed associations arise as result of residual confounding effects from those factors. For 
example, none of these studies have adjusted for the confounding effect of factors related to 
childhood nutrition status and illnesses which have been reported as important environmental 
factors influencing growth [310, 311].  
 
1.7.1 Proposed biological mechanisms linking height and cancer risk  
There are a number of plausible biological pathways through which height might confer an 
increased risk of cancer.  The first pathway links height to the total number of cells in the body 
[139]. Larger body contains more cells, and it has been suggested that within species, the more cells 
one has the greater the chance for increased mitotic activities leading to malignant transformation 
[312]. The second pathway links body size to the levels of circulating growth hormones such as 
insulin-like growth factor (IGF)-I [313] [314]. It has been demonstrated that the levels of IGF-1 are 
positively associated with adult height [315, 316]. IGFs have been reported to regulate cell turnover 
and apoptosis [140, 312], and thus could be implicated in cancer development. Finally, although 
adult height is largely genetically determined, early life environmental factors may also play an 
important role. Studies have shown that height acts as surrogate marker for childhood nutritional 
status and caloric intake [317]. Excess caloric intake may promote carcinogenesis while calorie-
restricted diet inhibits the development of various tumours [318, 319].  Therefore, people of shorter 
stature may have experienced food restriction during childhood, which decreases not only their 
height but also their risk of cancer.  
 
1.8 Literature review summary  
Cigarette smoking, obesity and height have been shown to cause several cancers in humans, but 
their associations with skin cancer are not well understood. Studies examining the relationships 
between these factors and skin cancer have had numerous limitations including lack of information 
on established skin cancer risk factors which limited the ability to control for important potential 
confounding factors, inadequate approach to statistical analyses and use of data from case-control 
studies which are prone to several biases. In addition, most studies have not explored other potential 
sources of bias, such as detection biases that appear to underlie skin cancer surveillance in high-
incidence populations. 
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 In my PhD, I have comprehensively investigated these associations by using various 
epidemiological and statistical techniques aiming to overcome some of the limitations arising from 
previous studies.  In particular, I used prospective observational data from a cohort that from its 
inception, was specifically designed to evaluate skin cancer outcomes. This cohort captured detailed 
information at baseline on phenotype, sun exposure, and medical history, in addition to other items 
necessary to explore potential detection biases and to allow greater control of confounding than 
earlier prospective investigations. To strengthen my causal inferences and minimise biases inherent 
to observational studies, I conducted Mendelian randomisation analyses using summary data from 
the recent GWAS meta-analyses of BMI, height and melanoma. 
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2 Aims, Objectives and Hypotheses 
The overall aim of this thesis was to assess whether cigarette smoking, obesity and height are 
independent risk factors for basal cell carcinoma, squamous cell carcinoma and melanoma using 
data from various large epidemiological data sets.  
 
AIM 1. To assess the effect of various dimensions of smoking on the risk of developing first 
invasive BCC and cSCC using data from the QSkin cohort, supplemented by linkage to Medicare 
and pathology laboratories in Queensland. 
 OBJECTIVES 
1. To estimate the effect of smoking status (current/former and never) on the risk of incident   
BCC and cSCC. 
2. To perform stratified analyses according to self-reported history of actinic lesions reported 
at baseline (high-risk vs. low risk of KCs). 
3. To assess whether linear or non-linear dose-response relationships exist between continuous 
measures of smoking (smoking duration, smoking intensity and time since quitting) and risk 
incident BCC or cSCC.  
HYPOTHESES  
1. Cigarette smoking is positively associated with risk of cSCC (but not BCC). 
2. Time since smoking cessation is inversely associated with risk of cSCC (but not BCC).  
3. Smoking duration and intensity are associated with increased risk of cSCC (but not BCC). 
 
AIM 2. To assess the effect of various dimensions of smoking on the risk of developing first 
invasive melanoma in the QSkin cohort  
OBJECTIVES 
1. To assess the effect of smoking status (current/former and never) on the risk of incident 
invasive melanoma.  
2. To assess whether linear or non-linear dose-response relationships exist between continuous 
measures of smoking (smoking duration, smoking intensity and time since quitting) and 
melanoma risk.  
HYPOTHESES 
1. Cigarette smoking is positively associated with risk of melanoma. 
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2. Time since smoking cessation is inversely associated with risk of melanoma.  
3. Smoking duration and intensity are associated with increased risk of melanoma. 
 
AIM 3. To assess the effect of obesity (as measured by BMI) on the risk of developing first 
invasive melanoma. 
OBJECTIVES 
1. To investigate whether BMI is an independent risk factor for melanoma using observational 
data from the QSkin cohort. 
2. To summarise evidence from previous prospective observational studies and QSkin by use 
of meta-analysis, to determine whether obesity is an independent risk factor for melanoma in 
observational studies. 
3. To assess whether genetically predicted BMI is associated with risk of melanoma using 
summary data from recent GWAS meta-analyses of obesity and melanoma using Mendelian 
randomisation techniques.  
HYPOTHESES  
1. Increased BMI is positively associated with increased risk of melanoma. 
2. Genetically predicted BMI is associated with an increased risk of melanoma. 
 
AIM 4. To assess whether height is an independent risk factor for melanoma. 
OBJECTIVES 
1. To investigate whether height is an independent risk factor for melanoma using 
observational data from the QSkin cohort. 
2. To assess whether genetically predicted height is associated with risk of melanoma using 
summary data from recent GWAS meta-analyses of height and melanoma using Mendelian 
randomisation techniques.  
HYPOTHESES  
1. Increased height is positively associated with increased risk of melanoma. 
2. Genetically predicted height is independently associated with increased risk of 
melanoma. 
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3 Materials and Methods 
In this chapter, I have provided a general methodology adopted to address the aims of the thesis. In 
particular, I have described the source of data, data collection instruments, inclusion/exclusion 
criteria and participants follow-up. Specific methodological details pertaining to some of the more 
specialised approaches are covered in their respective chapters.  
 
3.1 Study population 
The predominant source of data for this thesis was the QSkin Sun and Health Study (QSkin) [320]. 
The QSkin cohort is a population based prospective cohort study purpose designed to evaluate the 
role of genetic and environmental factors on the risk of developing various types of skin cancer. 
Briefly, between November 2010 and November 2011, a random sample of 193,344 men and 
women aged between 40 to 69 years at study entry and with their primary residential address in the 
State of Queensland were randomly sampled from the Australian Electoral Roll (voter registration 
is mandatory in Australia). Of the 193,344 people invited, 43,794 (~23%) who accepted to 
participate, were then invited to complete a baseline survey.  
 
3.2 Ethical consideration  
The QSkin study received ethical approval from the human research ethics committee of the QIMR 
Berghofer Medical Research Institute and been approved for record linkage activities by 
Queensland Health, the Australian Institute of Health and Welfare, Medicare Australia and other 
agencies. Each QSkin participant provided written informed consent for their records to be linked to 
external databases including Medicare, cancer registries, pathology laboratories and the National 
Death Index. 
 
3.3 Exposure assessment  
Exposure data were collected at baseline through a self-reported questionnaire which elicited 
information about demographic items (e.g.: age, gender, marital status, place of birth, private health 
insurance, ancestry/ethnicity, education and employment status) anthropometric factors (weight, 
height, trouser/dress size), general medical history, pigmentary characteristics (skin colour, skin 
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type, eye and hair colour, freckling on face and moles on skin), past and recent history of sun 
exposure and sunburns, sun protection behaviours, and past history of skin cancer (Appendix A). 
Participants were asked: “About how many separate skin cancers (but not moles or warts) have you 
ever had cut off your skin?”; and separately “About how many sunspots or skin cancers have you 
ever had frozen or burnt off your skin?” They were also asked to report the number of times they 
had their skin deliberately checked by a doctor during the past 3 years.  Among other items, each 
participant was asked questions about past medical history, including medical conditions that 
required treatment from a specialist physician and cancers other than skin cancer.  
 
With respect to smoking, participants were asked whether they had ever smoked tobacco daily for at 
least 6 months. Ever smokers were then asked additional questions about the current smoking 
status, the average number of cigarettes smoked per day while smoking, their age at initiation, and 
the total number of years during which they had smoked. Former smokers were asked the age at 
which they had stopped smoking. Anthropometric measurements were obtained from self-reported 
information on height and weight. BMI was calculated as weight in kilograms divided by height in 
meters squared.  
 
3.4 Validation of self-reported exposure information 
In 2012, a validation study was conducted where 114 subjects were randomly surveyed to validate 
the self-reported survey items against physician examination [321] and to examine the repeatability 
of the survey instrument. Items relating to phenotype had moderate to very high repeatability 
(kappa coefficients = 0.51-0.87); agreement was also high for the questions on past surgical and 
nonsurgical treatments of skin cancer (weighted kappa = 0.79 and 0.83, respectively).  Repeatability 
for smoking status (current, former, and never smoker) was almost perfect (weighted kappa = 0.97, 
95% CI = 0.92-1.00), as were other smoking parameters. With respect to anthropometric measures, 
repeatability for height (Intraclass Correlation Coefficient=0.99, 95% CI: 0.99-0.99), weight 
(Intraclass Correlation Coefficient=0.98, 95% CI: 0.97-0.99) and current BMI (Intraclass 
Correlation Coefficient=0.97, 95% CI 0.96-0.98) were also near perfect.   
 
3.5 Follow-up 
The outcomes of interest were diagnosis with histologically confirmed cSCC, BCC and melanoma. 
The QSkin cohort is followed-up passively through linkage to health databases. Because KCs 
events are not reported in the Queensland cancer registry (QCR), BCC and cSCC endpoints were 
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obtained through linkage with Medicare Australia and pathology laboratories servicing the 
Queensland population; melanoma endpoints were obtained through linkage with the QCR [322]. 
Medicare is Australia’s universal healthcare scheme that subsidises all citizens and permanent 
residents [323].  
 
 Linkage to Medicare data was conducted using participant Medicare number, name, address and 
date of birth. From the linked Medicare dataset, we identified QSkin participants who had at least 
one claim for any of Medical Benefits Schedule (MBS) item numbers to identify episodes of care 
describing treatments related to skin cancer.  The MBS is a listing of Medicare services such as 
consultations, procedures and tests subsidised by the Australian government.  Eight MBS item 
numbers indicating the first surgical excision for BCC and cSCC were used to define a KC case 
(Appendix B). These items require the diagnosis of BCC and cSCC to be histologically confirmed 
before the Medicare claim is lodged. Histological details of skin cancers identified through 
Medicare were obtained through linkage to the pathology laboratories servicing the Queensland 
population. Information abstracted included diagnosis of BCC (including the most common 
subtypes), cSCC (including IEC), keratoacanthoma, melanoma (including lentigo maligna) and 
actinic keratosis. Additional information collected included anatomical location of the lesion, 
procedures used for biopsy or treatment, and the date the procedure was performed. A complete list 
of the coding scheme for each lesion is provided in appendix C.  
 
For melanoma endpoints, participants were followed prospectively for the first occurrence of 
histologically confirmed in situ or invasive melanoma by record linkage to the Queensland Cancer 
Registry (notification has been mandatory since 1982 and is virtually complete). The surveillance 
commenced from date of enrolment (2010-2011) through 30 June 2014 for KCs outcomes and 
through 31 December 2014 for melanoma endpoints. Finally, deaths in the cohort were identified 
through linkage with the National Death Index which records the date and cause of all deaths 
occurring in Australia.  
 
3.6 Statistical methods 
3.6.1 Descriptive Analyses 
Range and logic checks of each of the primary exposure variables were conducted by checking their 
frequency distribution, missing values and outliers. Continuous exposures were summarised using 
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mean standard deviation when normally distributed and median and interquartile range for skewed 
distribution. Categorical exposures were summarised by presenting the frequencies and percentage 
in each category. 
 
3.6.2 Univariate Analyses  
We calculated each person’s follow-up duration as the time from the date of consent through until 
either the date of first histologically confirmed BCC or invasive cSCC or melanoma, or the date of 
death, or the end of follow-up, whichever occurred first. Univariate analyses were performed to 
assess the association between each exposure factor and the outcome using chi-squared tests for 
categorical variables and Student’s t-test for continuous variables or non-parametric tests when the 
exposure was not normally distributed.  
 
3.6.3 Multivariable analysis 
Time to first incident outcome was analysed using Cox proportional hazards regression models to 
examine the association between the various exposure factors and the outcome of interest. This 
model assumes a log-linear relationship between the exposure and the outcome. Non-linearity in the 
dose effect estimates of continuous exposure measures was estimated using the standard approach 
where continuous measures are categorised into ordinal categories based on the distribution or 
quartiles of exposure to ensure equal numbers of people in each category. Additional analyses were 
then performed by fitting Cox regression with generalised additive models (GAMs) for non-linear 
dose response of continuous exposure measures. These models avoid arbitrary choice of cut-off 
values and are estimated based on dose effect relationship without assuming linearity. GAMs use 
regression splines, which are smoothly joined piecewise regression to allow flexibility in estimating 
the non-linearity in the dose effect. These models have the advantage of using all information on 
risk variation within categories.  
 
Using the DAGitty program [324], we constructed directed acyclic graphs (DAGs)  to identify a 
minimum sufficient adjustment set of confounding factors in estimating the independent effect of 
various risk factors on the outcome. Covariates for inclusion in the DAG were defined a priori 
based on known and hypothesised confounders. Potential confounders included self-reported factors 
from the baseline questionnaire as well as other factors identified through record linkage to health 
databases. We used R software for generalised additive models, and SAS version 9.4 (SAS Institute, 
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Cary, NC) for all other analyses. All tests were two-sided and a P<0.05 was used to denote 
statically significance associations. 
 
3.6.4 Competing risk analyses 
In epidemiology, competing risks refers to the situation whereby the event of interest may be 
preceded by other events, the occurrence of which prevents or modifies the probability of observing 
the event of interest [325]. When the individuals exposed are at risk of more than one type of 
competing event or failure, the traditional Cox proportional hazards (PH) regression methods are 
not suitable to analyse survival or time to event data [325] because individuals with competing 
events are censored at the time of competing event which may violate the assumption of 
independent censoring [326]. To circumvent this limitation, Fine and Grey proposed a new model 
based on the cumulative incidence function that estimates the probability of developing an event of 
interest prior to a specific time [327].  In contrast to the proportional hazards model, the competing 
risk model accounts for other causes of failure when estimating the regression parameters. In our 
data, because of possible selective mortality by which exposed individuals (e.g. smokers, obese 
participants) may die at a younger age than non-exposed individuals (i.e. before developing the 
outcome of interest), competing risks regression analyses were implemented.  
 
3.7 Meta-analysis of observational studies  
The findings from multiple small studies are sometimes heterogeneous which can make it 
challenging to form an overall impression of the state of knowledge.  Meta-analysis is based on 
thorough literature searches and aims to provide unbiased summary estimates [328]. It offers an 
opportunity to statistically combine estimates from several independent studies [329]. Its main 
advantages are to increase the number of observations and statistical power, explore potential 
sources of heterogeneity and improve the precision of estimates of the effect.  In Chapter 6, I have 
summarised the evidence from observational studies by conducting a meta-analysis of the 
association between BMI and melanoma.  The literature search was limited to prospective studies 
and no restriction on participants’ sex or language was used. Firstly, prospective cohort studies 
reported by Sergentanis and colleagues [293] on the association between BMI and melanoma risk 
were identified and retrieved. The search strategies employed by Sergentanis retrieved all scientific 
studies published through 31
st
 October 2011. Secondly, the search strategies employed by 
Sergentanis et al. was replicated by one investigator (JCD) to retrieve studies published from 
January 2010 through to December 2017.  A random-effects model was used to pool risk estimates 
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across studies [329]. The Cochran’s Q statistic was used to test for statistical heterogeneity [330], 
and the I
2
 statistic to quantify heterogeneity across studies [331]. The meta-analysis was conducted 
using Stata version 15.1 (StataCorp LLC, College Station, TX, 2017). 
 
3.8 Mendelian randomisation analyses 
In classical epidemiology, observational data are often used to test scientific hypotheses. However, 
statistical inferences from observational data are often based on implausible assumptions such as 
the absence of residual confounding (no measurement error, no unmeasured confounders) and 
absence of reverse causality. Even though many of these limitations can be accounted for in 
multivariable regression analyses, it is very difficult to know if all of them have been identified, or 
if those identified were measured without error.  Therefore, if may be hard to distinguish between 
correlation and causation from observational data.  
 
Randomised controlled trials (RCTs) are, in principal, regarded as the “gold standard” to test 
scientific hypotheses in medical research. In RCTs, exposure is randomly assigned to individuals, 
and the average outcomes in each of the treatment arms of the trial are compared. While, RCTs are 
generally the best design to determine the causal relationship between a particular risk factor and a 
disease, they also present some potential limitations. RCTs are expensive and time-consuming, 
especially when the outcome is rare or requires a long follow-up period to observe the outcome. In 
addition, some risk factors cannot be randomly allocated for ethical reasons. For example, in 
assessing the effect of smoking on melanoma, it would be unethical to recruit subjects to be 
randomly assigned to either smoking or abstinence from smoking. Consequently, alternative 
approaches are important to better understand the nature of the relationship between an exposure 
and the disease.  
 
Mendelian randomisation (MR) is an alternative technique to classical epidemiological methods; it 
uses genetic variants as potential instrumental variables (IV) to assess for causal relationship 
between a modifiable (non-genetic) risk factor and the disease [332]. The recent advances in 
genotyping technologies, which rendered the cost of DNA sequencing affordable [333], and public 
availability of summary data from the genome-wide association studies (GWAS) has facilitated the 
development of several genetic instruments. Because a person's genotype is randomly assigned at 
conception, according to Mendel’s law of independent assortment, genetic variants that are 
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associated with BMI are less likely to be confounded by other traits, with reverse causality ruled out 
because disease status cannot alter germline genotype [334]. Single nucleotide polymorphisms 
(SNP) are generally used as potential IVs for MR analyses [335]. 
 
To be used as a valid IV, a genetic variant must satisfy three fundamental MR assumptions: 1) The 
variant (SNP) must be associated with the measured risk factor (exposure), 2) the variant must not 
be associated with confounding factors of risk factor-outcome association and 3) the risk factor 
must be associated with the outcome only via their association with measured risk factor (exclusion 
restriction assumption) [336] [Figure 3-1].  
 
Figure 3-1. Directed acyclic graph illustrating instrumental variable assumptions 
 
For the case of only a single genetic variant as IV, the causal association is estimated using Wald-
type ratio estimator [337] as follows:  
?̂?𝐼𝑉𝑊 =  ?̂?𝑧𝑦/?̂?𝑧𝑥 , with a standard error of 𝜎𝐼𝑉𝑊 = 𝜎𝑧𝑦 /|?̂?𝑧𝑥|.   
When more than one genetic variant is used as IV, individual Wald ratios are combined across all 
instruments using fixed effect inverse variance weighted method (IVW) as follows: 
β̂IVW =
∑ β̂zxz β̂zyσzy
−2
∑ β̂zx
2
z
 
σzy
−2   
The standard error of the estimate is estimated as follows: 
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σIVW = √
1
∑ β̂zx
2 σzy
−2
z
  
 
Here ?̂?𝑧𝑦 refers to the magnitude of association of the instrument variable, on the binary outcome  
 ?̂?𝑧𝑥 refers to the magnitude of association of the genetic variant (SNP) on the modifiable risk factor 
(exposure).  In Chapter 6 and Chapter 7, we have applied MR techniques to assess for possible 
causal associations between obesity, height and melanoma risk and more detailed information 
including source of data, and statistical methods for MR are illustrated in these specific chapters.   
  
51 
 
4 Cigarette smoking and the risk of skin cancer 
4.1 Cigarette smoking and risk of keratinocytes carcinoma 
4.1.1 Introduction  
The aim of this analysis was to assess the effect of various dimensions of smoking on the risk of 
developing first invasive BCC and cSCC using linked data between the QSkin cohort, Medicare and 
pathology laboratories in Queensland. This chapter consists of a peer-reviewed manuscript that was 
published in the Journal of Investigative Dermatology in 2017. 
 
Dusingize JC, Olsen CM, Pandeya N, Subramaniam P, Thompson BS, Neale RE, Green AC, 
Whiteman DC; QSkin Study. Cigarette Smoking and the Risks of Basal Cell Carcinoma and 
Squamous Cell Carcinoma. Journal of Investigative Dermatology. 2017; 137(8):1700-1708. 
 
4.1.2 Contribution of candidate 
The concept of the study was formulated by my supervisors DCW and CMO and my co-author 
Professor Adele Green. I contributed in data collection by abstracting information from 
approximately 10,000 pathology reports. I was involved in data cleaning and coding. I wrote the 
data analysis plan and performed the statistical analysis with the assistance of my supervisors. I was 
responsible for the writing of the manuscript, taking into account the comments and suggestions 
from all co-authors. I participated in the peer review process by preparing the final draft of the 
manuscript and submitted it to the journal for publication. I was responsible for writing the response 
to reviewer comments, and prepared the revised manuscript with input from all the co-authors. 
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4.1.3 Manuscript: Cigarette smoking and the risks of basal cell carcinoma and squamous 
cell carcinoma 
 
ABSTRACT 
Sunlight is the principal environmental risk factor for keratinocyte cancers, but other carcinogens 
have also been implicated, including tobacco smoke.  Findings have been conflicting however. We 
investigated associations between cigarette smoking and incidence of BCC or cSCC in QSkin, a 
prospective study of skin cancer (n=43,794). Smoking history was self-reported at baseline; newly 
diagnosed BCCs and cSCCs were ascertained through data linkage and verified by histopathology 
reports. We restricted analyses to white participants who at baseline reported no past history of skin 
cancer excisions and no more than 5 destructively-treated actinic skin lesions. We fitted Cox 
proportional hazards models, adjusted for known confounders. Compared with never smokers, 
current smokers had significantly lower risks of BCC (HR 0.6; 95% CI, 0.4-0.9) but significantly 
higher risks of cSCC (HR 2.3; 95% CI, 1.5-3.6). Former smokers had similar risks for BCC and 
cSCC as never smokers. Among smokers, we observed no dose-response trends with duration of 
smoking, intensity or time since quitting. On further analysis, current smokers had fewer skin 
examinations and procedures than never smokers, suggesting greater opportunities for detection 
among never smokers. Strengths include large sample size, prospective design and virtually 
complete follow-up, however histologic details were missing for a proportion of excised tumours. 
In conclusion, current smokers had lower incidence of BCC (possibly due to detection bias), but 
higher rates of cSCC.   
 
INTRODUCTION 
Basal cell carcinoma (BCC) and squamous cell carcinoma (cSCC), collectively named keratinocyte 
carcinomas (KCs), are the most common malignancies worldwide [6]. Whilst ultraviolet radiation 
(UVR) exposure is established as the major causal factor for KCs, the role of smoking, which is the 
strongest modifiable risk factor for many human cancers [221], is not yet understood.   New 
evidence continues to expand the list of tobacco-related cancers; however, the potential role of 
cigarette smoking in relation to cutaneous malignancies remains inconclusive, with previous 
epidemiological studies reporting both positive and negative associations.  
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Two meta-analyses reported pooled estimates of the association between smoking and the risk of 
KCs and drew different conclusions. The first reported that ever smokers of both sexes had slightly 
increased risks of both BCC and cSCC compared with never-smokers [263].  The second concluded 
that smoking increases the risk of cSCC but not BCC [186].  More recently, the findings from a 16-
year prospective study of 1621 adults residing in Nambour, Queensland were published, reporting a 
non-significant inverse association between current smoking and BCC compared to never-smokers 
[338], but no association with cSCC [339].  
 
Possible reasons for the inconsistencies between previous studies include using different approaches 
to analyse smoking exposure (ever vs. never; current vs. former vs. never), failure to account for 
various dimensions of smoking history (e.g. duration; intensity), inadequate control of potential 
confounding factors, and loss to follow-up in prospective studies. In addition, most studies have not 
explored other potential sources of bias, such as detection biases that appear to underlie BCC 
surveillance in high-incidence populations [340].  
Given the uncertainty of these associations, we sought to investigate the relationship between 
cigarette smoking and risk of BCC and cSCC using data from a large, population-based cohort 
study which captured detailed information at baseline on phenotype, sun exposure and medical 
history, in addition to other items necessary to explore potential detection biases.  
 
METHODS 
Study population 
The QSkin Sun and Health Study (QSkin) comprises a cohort of 43,794 men and women aged 
between 40 to 69 years sampled randomly from the Queensland population in 2011.  Detailed 
information of participant recruitment has been described elsewhere [320]. 
 
This study was approved by the Human Research Ethics Committee of the QIMR Berghofer 
Medical Research Institute. Each participant provided written informed consent to take part in the 
study 
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Exposure assessment  
At baseline participants completed a questionnaire about demographic items, general medical 
history, pigmentary characteristics, history of sun exposure, sun protection behaviours and history 
of skin cancer. Participants were asked: “About how many separate skin cancers (but not moles or 
warts) have you ever had cut off your skin?”; and separately, “About how many sunspots or skin 
cancers have you ever had frozen or burnt off your skin?”. They were also asked to report the 
number of times they had their skin deliberately checked by a doctor during the past three years. 
Items relating to phenotype had moderate to very high repeatability (kappa coefficients 0.51 to 
0.87); agreement was also very high for the questions on past surgical and non-surgical treatments 
of skin cancer (weighted kappa 0.79 and 0.83 respectively) [321]. With respect to smoking, 
participants were asked whether they had ever smoked tobacco daily for at least 6 months.  Ever 
smokers were then asked questions about the average number of cigarettes smoked per day while 
smoking, their age at initiation, and the total number of years during which they had smoked. 
Former smokers were asked the age at which they had stopped smoking. Repeatability for smoking 
status (current, former and never-smoker) was almost perfect (weighted kappa = 0.97, 95% CI: 
0.92-1.00), as were other smoking parameters [321]. 
 
Follow-up 
Participants were followed for the first occurrence of histologically confirmed invasive cSCC or 
BCC through record linkage to health databases. We first linked the dataset to the Australian 
national health insurance scheme (Medicare) to identify participants who had received treatment for 
skin cancer, including biopsies and excisions. We then linked this list of treated participants to data 
held by the pathology laboratories servicing the Queensland population to obtain detailed histology 
reports for the skin lesions so identified. All pathology reports were reviewed and coded by 
qualified investigators.  
 
BCC and cSCC end-points were recorded from the date of consent through to June 30, 2014. We 
excluded lip cSCC from our analyses (n=51) as these lesions have a different aetiology from 
cutaneous cSCC [341]. People with common low-grade lesions such as keratoacanthoma (KA) or 
intraepidermal carcinoma (IEC) or Bowen’s disease, which individually have a very small risk of 
progressing to cSCC [342, 343], were included in the non-case group in our primary analyses, 
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however we also included them in the cSCC case group in sensitivity analyses. We obtained 
mortality data for the cohort through linkage with the National Death Index that records the date 
and cause of all deaths occurring in Australia. 
 
Statistical analysis 
The aims of the analyses were to quantify the association between smoking and risk of first incident 
BCC or cSCC. We restricted our analysis to white participants who met the following inclusion 
criteria: (a) no reported past history of excisions for skin cancer, (b) no more than 5 ‘sunspots or 
skin cancers’ (hereafter actinic skin lesions) treated by freezing or burning reported and (c) no 
record of melanoma in the Queensland Cancer Registry at time of recruitment. The final sample for 
analysis numbered 18,828 participants [Figure 4-1].   
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Figure 4-1. QSkin cohort flow diagram for BCC and cSCC incidence 
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We used Cox proportional hazards regression analysis to examine the association between various 
measures of smoking and risk of first BCC or first invasive cSCC. We calculated each person’s 
follow-up duration as the time from the date of consent up until either the date of first histologically 
confirmed BCC or invasive cSCC, or the date of death, or the end of follow up (June 30, 2014), 
whichever occurred first.  In our primary analysis, we excluded those participants who had a 
Medicare claim for at least one KC event, but for whom no confirmatory histopathological reports 
were obtained (“missing pathology cases”). We performed three sets of sensitivity analyses by 
firstly assigning those with missing pathology as non-cases, secondly assigning them as cases, and 
finally by randomly assigning 75% of participants with missing pathology as BCC cases and 25% 
as cSCC cases (based on the BCC to cSCC ratio 3:1 observed in our data).  
 
We modelled BCC and cSCC separately.  We first analysed the association between smoking status 
(never, ex- and current) and risk of incident BCC or incident cSCC. Potential confounders included 
self-reported factors from the baseline questionnaire as well as other factors identified through 
record linkage to health databases. Using the DAGitty program [324], we constructed directed 
acyclic graphs (DAGS) to identify a minimum sufficient adjustment set of confounding factors to 
estimate the total effect of smoking on BCC or cSCC. Our final models were adjusted for age, sex, 
private health insurance, education status, natural skin colour, tanning ability, number of freckles, 
history of sunburn as a child and cumulative sun exposure. 
 
Because smoking is a multi-dimensional exposure, statistical models that only examine the 
association between smoking status and health outcome, and that fail to consider important 
contributors to total smoking exposure have been deemed inefficient [344]. Therefore, we also 
investigated possible effects of smoking duration and intensity and time since quitting. We first 
used a standard approach in which never smokers were included as the reference category and 
continuous measures of smoking were categorised into ordinal categories at their approximate 
quartile cut-points. The tests for linear trend for ordinal categorical variables (restricted to ever 
smokers) were assessed by assigning a median value to each category and modelling as continuous 
variables in the model. 
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To further assess possible effects of smoking intensity, duration and time since quitting 
independently of the effects of ‘ever smoking’, we fitted models which included a term for smoking 
status (current/never smoker) as well as a term for the centred (rescaled to the mean) continuous 
measures of either duration or intensity of smoking [345]. This approach avoids multi-collinearity. 
We also assessed potential non-linear associations with dose by fitting generalised additive models 
(GAMs) with smoothed functions for the continuous measures of duration and intensity of smoking. 
We used SAS 9.4 software (SAS Institute, Cary, NC) for all statistical analyses except GAM 
models, which were conducted using R software (CRAN package mg).  
 
RESULTS 
Baseline demographic characteristics of the study cohort according to smoking status are presented 
in [Table 4-1]. Ten percent and 35% of the study cohort were current and ex-smokers respectively; 
data for smoking status were missing for 61 people.  Current smokers were younger (mean age, 53 
years vs. 54 years respectively), more likely to be men (46% vs. 37% respectively), less likely to 
have private health insurance (39% vs. 73%) and less likely to hold a university degree (13% vs. 
33%) than never smokers. Current smokers were also less likely than never smokers to report 
having undergone destructive treatments for actinic skin lesions or skin cancers (p<0.001) and less 
likely to have had their skin checked by a doctor prior to baseline.  
 
 
Table 4-1. Baseline characteristics of 18,828 QSkin study participants included in the BCC and cSCC analyses, overall and stratified by 
smoking status 
 
Parameter 
  
Smoking status 
 
 
Total (n= 18828) Never (n=10,222) Former (n=6,675) Current (n=1,870) Chi-Square 
P-value  
N (%) 
 
N (%) 
 
N (%) 
 
N (%) 
      
Age at entry (Mean, SD) 54.2 (8.2) 53.8 (8.2) 55.3 (8.2) 52.8 (7.6) < 0.001** 
Age group           
40-49 6535 (34.7) 3771 (36.9) 1965 (29.5) 772 (41.3) < 0.001 
40-59 7134 (37.9) 3797 (37.2) 2574 (38.6) 733 (39.2)  
60-69 5159 (27.4) 2654 (25.9) 2126 (31.9) 365 (19.5)  
Sex          
Females 10983 (58.3) 6472 (63.3) 3472 (52.1) 1007 (53.6) < 0.001 
Males 7845 (41.7) 3750 (36.7) 3193 (47.9) 873 (46.4)  
Further Education          
No school certificate 1315 (7.5) 524 (5.4) 542 (8.8) 244 (14.5) < 0.001 
School certificate 2607 (14.8) 1351 (13.9) 949 (15.4) 298 (17.6)  
Higher school  3470 (19.7) 1872 (19.3) 1197 (19.4) 386 (22.9)  
Trade/certificate/diploma 5434 (30.8) 2743 (28.2) 2133 (34.5) 541 (32.0)  
University degree 4808 (27.3) 3224 (33.2) 1359 (22.9) 219 (12.9)  
Private Health Insurance          
No 6442 (34.3) 2798 (27.5) 2474 (37.3) 1141 (60.9) <0.001 
Yes 12324 (65.7) 7393 (72.5) 4168 (62.7) 732 (39.1)  
Skin colour          
Fair  9981 (53.3) 5584 (54.9) 3445 (51.9) 923 (49.4) <0.001 
Medium 7054 (37.7) 3746 (36.9) 2569 (38.7) 715 (38.3)  
Olive/Dark 1688 (9.0) 833 (8.2) 619 (9.3) 229 (12.3)  
Eye colour          
Blue/Grey 6886 (37.0) 3720 (36.8) 2445 (37.2) 695 (37.4) 0.68 
Green/hazel 7137 (38.4) 3932 (38.9) 2480 (37.8) 706 (38.0)  
Brown/black 4573 (24.6) 2460 (24.3) 1642 (24.98 457 (24.6)  
Hair colour           
Dark brown/black 8372 (44.70 4603 (45.3) 2952 (44.5) 789 (42.2) 0.01 
Light brown 7106 (37.9) 3833 (37.7) 2545 (38.4) 704 (37.7)  
Blonde  2602 (13.9) 1366 (13.4) 924 (13.9) 304 (16.3)  
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Parameter 
  
Smoking status 
 
 
Total (n= 18828) Never (n=10,222) Former (n=6,675) Current (n=1,870) Chi-Square 
P-value  
N (%) 
 
N (%) 
 
N (%) 
 
N (%) 
      
Red/auburn 658 (3.5) 371 (3.6) 214 (3.2) 73 (3.9)  
 Burning tendency          
No burns 2066 (11.0) 967 (9.5) 777 (11.7) 313 (16.7) <0.001 
Burns a little 8874 (47.4) 4704 (46.2) 3228 (48.7) 908 (48.5)  
Burns moderately 5853 (31.2) 3338 (32.8) 2002 (30.2) 500 (26.7)  
Burns badly 1947 (10.4) 1171 (11.5) 621 (9.4) 150 (8.0)  
Tanning tendency          
No tan 702 (3.8) 420 (4.1) 210 (3.2) 70 (3.8) <0.001 
Tan lightly 3205 (17.1) 1963 (19.3) 937 (14.1) 300 (16.1)  
Tan moderately 9755 (52.1) 5379 (52.9) 3477 (52.5) 870 (46.6)  
Tan deeply 5066 (27.0) 2411 (23.7) 2005 (30.3) 626 (33.6)  
Freckles at age 21 years (face)          
None 9981 (53.2) 5169 (50.8) 3732 (56.2) 1041 (55.6) <0.001 
A few 5726 (30.5) 3274 (32.2) 1889 (28.4) 544 (29.0)  
Some 2320 (12.4) 1325 (13.0) 7786(11.7) 217 (11.6)  
Many 720 (3.8) 404 (4.0) 244 (3.7) 71 (3.8)  
Sunburns as a child           
Never 4178 (24.3) 2311 (24.7) 1427 (23.7) 428 (24.8) <0.001 
1-5 8086 (47.1) 4469 (47.7) 2809 (46.6) 785 (45.6)  
6-10 2761 (16.1) 1517 (16.2) 982 (16.3) 254 (14.7)  
11+ 2155 (12.5) 1073 (11.5) 815 (13.5) 256 (14.9)  
AKs/ skin cancers destructively treated prior to 
baseline 
         
None 13322 (62.7) 7065 (61.0) 4718 (62.3) 1501 (74.2) <0.001 
1-5  5506 (25.9) 3157 (27.3) 1947 (25.7) 379 (18.7)  
6 + 2413 (11.4) 1359 (11.7) 906 (12.0) 144 (7.1)  
 Numbers may not sum to total due to missing data 
 **P value for significant difference using Ryan-Einot-Gabriel-Welsch multiple range test 
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During a median follow-up period of 3.0 years, 640 participants developed at least one 
histologically confirmed BCC and 193 developed at least one histologically confirmed invasive 
cSCC. In addition, there were 316 participants with a Medicare claim for at least one KC event, but 
for whom no confirmatory histopathological reports were obtained. BCCs occur mainly on the 
head/neck (48%), with 35% occurring on the trunk and 17% on the limbs, whereas most cSCCs 
occurred on the limbs (47%) and head/neck (42%) with 11% on the trunk. Compared to never 
smokers, current smokers at baseline had significantly lower risks of developing BCC (HR: 0.64, 
95% CI: 0.44-0.93); ex-smoking was not significantly associated [Table 4-2]. We observed no 
significant linear trend in risk of BCC with increasing smoking intensity or duration (p trend=0.06 
and 0.11 respectively) among smokers. Because individuals with a past history of actinic skin 
damage have markedly higher risks of subsequent KC [346] which may modify any association 
between smoking and KC risk, we also performed analyses stratified by past history of treatment for 
actinic skin lesions (none n=13,322 vs. 1-5, n=5,506). Among those with no history of destructive 
treatments for skin lesions, current smoking had a non-significant but inverse association with BCC 
compared to never smoking (HR: 0.85; 95% CI: 0.54-1.33). Among those with 1-5 skin lesions, 
however, the risks of BCC were significantly lower among current smokers compared to never 
smokers (HR: 0.43, 95%: 0.21-0.88). The interaction between smoking status and history of 
destructive treatments for skin lesions did not reach statistical significance, however. 
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Table 4-2. The association between different dimensions of smoking and BCC, stratified by self-reported history of destructive treatments for 
skin lesions prior to baseline 
Parameter   
Total   
 (n=18,828) 
No destructive treatments for skin 
lesions prior to baseline  
(n= 13,322) 
1-5 destructive treatments for skin 
lesions prior to baseline 
 (n=5,506) 
  
Case /Person-years 
 
HR (95% CI) 
 
Cases/Person years 
 
HR (95% CI) 
 
Cases /Person years 
 
HR (95% CI)  
Smoking status*       
Never smoker 384/30199 1.00 187/21003 1.00 197/9196 1.00 
Ever smoker  255/25259 0.81 (0.68-0.97) 142/18447 0.87 (0.68-1.12) 113/6813 0.79 (0.61-1.03) 
Ex-smoker  217/19684 0.85 (0.71-1.03) 112/14005 0.88 (0.68-1.14) 105/5680 0.86 (0.66-1.12) 
Current smoker 38/5575 0.64 (0.44-0.93) 30/4442 0.85 (0.54-1.33) 8/1133 0.43 (0.21-0.88) 
p-value                   <0.001    <0.001                 0.075                   
Age (years) at starting smoking        
Never  384/30199 1.00 187/21003 1.00 197/9196 1.00 
<15 29/3303 0.85 (0.56-1.26) 15/2528 0.81 (0.46-1.41) 14/775 0.97 (0.54-1.76) 
15-16 71/7457 0.78 (0.58-1.03) 37/5462 0.79 (0.53-1.17) 34/1994 0.79 (0.53-1.21) 
>16 151/14268 0.83 (0.68-1.03) 87/10269 0.93 (0.70-1.24) 64/3999 0.77 (0.56-1.05) 
p-trend  0.942                     0.503                     0.449                   
Duration (years) of smoking       
Never  384/30199 1.00 187/21003 1.00 197/9196 1.00 
≤10 70/5441 1.05 (0.79-1.38) 34/3627 1.09 (0.73-1.62) 36/1814 0.97 (0.66-1.43) 
11-20 49/6063 0.66 (0.47-0.91) 23/4377 0.59 (0.37-0.95) 26/1686 0.75 (0.48-1.18) 
21-30 66/5946 0.90 (0.67-1.22) 36/4556 0.97 (0.65-1.44) 30/1389 0.92 (0.58-1.45) 
>30 66/7514 0.71 (0.53-0.96) 46/5650 0.90 (0.62-1.31) 20/1864 0.54 (0.33-0.91) 
p-trend  0.115                     0.976                      0.064                   
Intensity of smoking (cigarettes/day)       
Never 384/30199 1.00 187/21003 1.00 197/9196 1.00 
≤10 90/7903 0.98 (0.76-1.25) 45/5661 1.01 (0.71-1.43) 45/2242 0.99 (0.69-1.41) 
11-20 98/10117 0.76 (0.59-0.98) 59/7411 0.86 (0.61-1.20) 39/2706 0.70 (0.47-1.02) 
21-30 45/4610 0.75 (0.52-1.06) 21/3386 0.66 (0.39-1.10) 24/1228 0.88 (0.54-1.43) 
>30 19/2098 0.59 (0.34-1.04) 15/1629 0.93 (0.51-1.70) 4/470 0.13 (0.01-0.97) 
p-trend                    0.064  0.505                    0.972                   
Pack-years of smoking       
Never 384/30199 1.00 187/21003 1.00 197/9196 1.00 
≤10 90/8059 0.93 (0.72-1.19) 43/5619 0.93 (0.64-1.32) 47/2440 0.93 (0.65-1.32) 
11-20 61/5619 0.92 (0.69- 1.24) 29/4069 0.89 (0.58-1.35) 32/1550 0.99(0.66-1.49) 
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Parameter   
Total   
 (n=18,828) 
No destructive treatments for skin 
lesions prior to baseline  
(n= 13,322) 
1-5 destructive treatments for skin 
lesions prior to baseline 
 (n=5,506) 
  
Case /Person-years 
 
HR (95% CI) 
 
Cases/Person years 
 
HR (95% CI) 
 
Cases /Person years 
 
HR (95% CI)  
21-30 33/4117 0.66 (0.44- 0.98) 22/3104 0.81 (0.49-1.34) 11/1014 0.53(0.27-1.04) 
>30 64/6692 0.70 (0.51- 0.96) 43/5103 0.87 (0.58-1.28) 21/1589 0.56 (0.33-0.97) 
p-trend 
 
 0.075                     0.765                    0.985                   
Years since quitting  
(past smokers) 
      
Never  384/30199 1.00 187/21003 1.00 197/9196 1.00 
≤10 47/5297 0.82 (0.59-1.14) 26/4081 0.80 (0.51-1.26) 21/1215 0.95 (0.58-1.53) 
11-20 56/5387 0.83 (0.61-1.14) 33/3946 1.01 (0.68-1.52) 23/1441 0.66 (0.39-1.10) 
21-30 65/5546 0.88 (0.66-1.19) 27/3856 0.74 (0.47-1.17) 38/1690 1.04 (0.70-1.54) 
>30 48/3355 0.86 (0.61-1.23) 25/2039 0.98 (0.60-1.61) 23/1316 0.76 (0.46-1.25) 
p-trend                    0.546  0.709                    0.958                                                      
* One person with BCC had missing smoking status.  
 Models were adjusted for age, sex, private health insurance, education status, natural skin colour, tanning ability, number of freckles, history of sunburn as a child, cumulative 
sun exposure. 
 ‘Never smoker’ was the reference category for all analyses. 
 p-Trend values do not include reference group. (p-value for the exact Cochran-Armitage trend test) 
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We conducted further stratified analyses to evaluate other potential instances of effect modification. 
We found the association between current smoking and BCC differed by body site, with lower risks 
observed for BCC occurring on trunk and limbs compared to the head/neck [Figure 4-2]. 
Stratification by self-reported history of skin checks by a doctor in the past 3 years showed a 
significant inverse association between current smoking and BCC in people who reported one or 
more skin checks but a null association in people who reported never having their skin checked 
([Table 4-3]; [Figure 4-2]). None of the interactions described above (i.e. by body site of BCC or 
history of skin checks by a doctor) reached statistical significance, however. We found no 
differences in risk of BCC by sex, age, skin colour, tanning tendency, freckles at age 21 or having a 
skin biopsy during follow up.  
  
65 
 
 
. 
 
 
Figure 4-2. Results of stratified analyses on the association 
between current smoking and risk of BCC 
The square represents the HR of the association between current smoking and risk 
of basal cell carcinoma, and the lines represent the 95% confidence intervals of the 
association. CI, confidence interval; HR, hazard ratio 
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Table 4-3. Smoking status and risk of BCC and cSCC, stratified by self-reported history of skin checks by a doctor (yes/no) in the past 3 years 
 
 
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; HR, hazard ratio; cSCC, squamous cell carcinoma. 
1
Models were adjusted for age, sex, private health insurance, education status, natural skin colour, tanning ability, number of freckles, history of sunburn as a child, and cumulative 
sun exposure. 
 SKIN NEVER CHECKED BY A DOCTOR 
 
SKIN EVER CHECKED BY A DOCTOR
 
Parameter  BCC cSCC  BCC cSCC 
 Cases HR
1
 (95% CI) Cases HR
1
 (95% CI)  Cases HR
1
 (95% CI) Cases HR
1
 (95% CI) 
        
Smoking status among people with less than 5 
destructive treatments for skin lesions prior to 
baseline  
 
         
Never smoker  101 1.00 27 1.00  283 1.00 59 1.00 
Former smoker  64 0.83 (0.58-1.18) 27 1.05 (0.55-1.83)  153 0.88 (0.71-1.10) 46 1.07 (0.70-1.64) 
Current smoker  19 0.99 (0.57-1.72) 16 2.77 (1.37-5.68)  19 0.49 (0.29-0.84) 18 2.08 (1.14-3.79) 
Smoking status among people with no history of 
destructive treatments for skin lesions prior to 
baseline  
 
        
Never smoker  61 1.00 19 1.00  126 1.00 26 1.00 
Former smoker 46 0.97 (0.63-1.50) 17 0.82 (0.39-1.74)   66 0.83 (0.59-1.26) 25 1.33 (0.71-2.47) 
Current smoker 16 1.16 (0.62-2.20) 13 2.61 (1.15-5.91)   14 0.66 (0.34-1.27) 11 2.24 (0.95-5.28) 
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We found that current smokers at baseline had significantly higher cSCC incidence compared with 
never smokers (HR: 2.30 95% CI: 1-46-3.62) [Table 4-4], and the risks remained significantly 
elevated after adjusting for the independent effects of duration and intensity [Table 4-5]. Unlike 
BCC, the risks of cSCC associated with smoking varied only modestly according to self-reported 
history of destructive treatments for skin lesions. The association between current smoking and 
cSCC varied slightly according to self-reported history of skin checks, and consistent with the 
pattern seen for BCC, risk of cSCC was lower amongst people with a history of skin checks ([Table 
4-3]; [Figure 4-3]. Stratified analyses by body site showed a significantly increased risk of cSCC 
on the limbs, but not on the trunk or head/neck amongst current smokers [Figure 4-3]. Again, the 
interaction terms did not reach statistical significance.  Sensitivity analyses including IEC/KA as 
cSCC cases did not result in any material difference to the associations we observed between 
smoking status and cSCC [Table 4-6].  
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Figure 4-3. Results of stratified analyses on the association between current smoking and risk 
of cSCC 
The square represents the HR of the association between current smoking and risk of basal cell carcinoma, and the lines 
represent the 95% confidence intervals of the association. The upper range of the confidence interval for some strata 
was too large and was truncated while trying to keep the same scale. CI, confidence interval; HR, hazard ratio 
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Table 4-4. The association between different dimensions of smoking and cSCC, stratified by self-reported history of destructive treatments for 
skin lesions at baseline 
 
Parameter   
Total  
 (n=18,828) 
No history of destructive treatments for 
skin lesions prior to baseline  
(n=13,322) 
History of 1-5 destructive treatments for 
skin lesions prior to baseline 
 (n=5,506) 
  
Cases /Person years 
 
HR (95% CI) 
 
Cases/Person years 
 
HR (95% CI) 
 
Cases/Person years 
 
HR (95% CI) 
Smoking status       
Never smoker 86/30654 1.00 45/21224 1.00 41/9430 1.00 
Ever smoker  107/25480 1.26 (0.92-1.73) 66/18542 1.36 (0.88-2.09) 41/6938 1.20 (0.75-1.92) 
Ex-smoker  73/19889 1.05 (0.74-1.48) 42/14086 1.10 (0.68-1.77) 31/5803 1.03 (0.62-1.71) 
Current smoker 34/5591 2.30 (1.46-3.62) 24/4456 2.49 (1.38-4.47) 10/1135 2.21 (1.07-4.56) 
          p-value   <0.001  <0.001  0.001 
Age (years) at starting smoking        
Never  86/30654 1.00 45/21224 1.00 41/9430 1.00 
<15 12/3322 0.98 (0.48-1.98) 5/2538 0.55 (0.16-1.80) 7/784 1.70 (0.69-4.10) 
15-16 36/7505 1.42 (0.92-2.18) 23/5471 1.70 (0.96-3.00) 13/2033 1.17 (0.59-2.32) 
>16 59/14416 1.26 (0.87-1.18) 38/10340 1.41 (0.86-2.30) 21/4076 1.14 (0.66-1.97) 
p-trend  0.664  0.240  0.438 
Duration (years) of smoking       
Never  86/30654 1.00 45/21224 1.00 41/9430 1.00 
≤10 16/5518 1.12 (0.64-1.95) 8/3659 1.25 (0.58-2.70) 8/1858 0.96 (0.42-2.16) 
11-20 17/6109 0.87 (0.49-1.56) 10/4394 0.94 (0.43-2.02) 7/1715 0.79 (0.33-1.90) 
21-30 23/6015 1.24 (0.74-2.09) 15/4585 1.37 (0.69-2.71) 8/1430 1.18 (0.51-2.67) 
>30 50/7538 1.60 (1.07-2.40) 33/5662 1.74 (1.01-2.98) 17/1876 1.61 (0.88-2.97) 
p-trend  0.117  0.239  0.219 
Intensity of smoking 
(cigarettes/day) 
      
Never 86/30654 1.00 45/21224 1.00 41/9430 1.00 
≤10 32/7982 1.51 (0.98-2.32) 20/5688 1.73 (0.97-3.09) 12/2294 1.32 (0.69-2.54) 
11-20 35/10212 1.04 (0.67-1.60) 19/7467 1.04 (0.57-1.89) 16/2745 1.08 (0.58-2.04) 
21-30 19/4657 1.03 (0.57-1.84) 14/3391 1.22 (0.58-2.56) 5/1265 0.82 (0.32-2.13) 
>30 16/2103 1.32 (0.67-2.61) 10/1636 1.25 (0.51-3.04) 6/467 1.76 (0.61-5.07) 
p-trend  0.546  0.897  0.897 
Pack-years of smoking       
  
70 
 
Parameter   
Total  
 (n=18,828) 
No history of destructive treatments for 
skin lesions prior to baseline  
(n=13,322) 
History of 1-5 destructive treatments for 
skin lesions prior to baseline 
 (n=5,506) 
  
Cases /Person years 
 
HR (95% CI) 
 
Cases/Person years 
 
HR (95% CI) 
 
Cases/Person years 
 
HR (95% CI) 
Never 86/30654 1.00 45/21224 1.00 41/9430 1.00 
≤10 25/8150 1.15 (0.71-1.85) 14/5654 1.26 (0.65-2.42) 11/2496 1.03 (0.51-2.08) 
11-20 21/5679 1.32 (0.80-2.18) 15/4087 1.81 (0.97-3.35) 6/1592 0.82 (0.34-1.95) 
21-30 14/4149 1.04 (0.55-1.97) 8/3124 1.06 (0.44-2.53) 6/1025 1.12 (0.43-2.87) 
>30 41/6731 1.24 (0.79-1.94) 26/5123 1.16 (0.62-2.15) 15/1609 1.51 (0.78-2.93) 
p-trend  0.953  0.505  0.367 
Years since quitting  
(ex- smokers) 
      
Never  86/30654 1.00 45/21224 1.00 41/9430 1.00 
≤10 16/5337 1.08 (0.59-1.96) 11/4095 1.19 (0.54-2.58) 5/1242 1.09 (0.42-2.81) 
11-20 12/5455 0.62 (0.31-1.25) 6/3983 0.50 (0.17-1.41) 6/1472 0.79 (0.31-2.05) 
21-30 26/5615 1.34 (0.83-2.17) 15/3876 1.35 (0.70-2.62) 11/1740 1.33 (0.65-2.69) 
>30 18/3382 0.96 (0.54-1.70) 10/2048 1.16 (0.54-2.46) 8/1333 0.77 (0.32-1.86) 
p-Trend  0.664  0.597  0.975 
 Abbreviations: CI, confidence interval; HR, hazard ratio. 
 Models were adjusted for age, sex, private health insurance, education status, natural skin colour, tanning ability, number of freckles, history of sunburn as a child, 
cumulative sun exposure. 
 ‘Never smoker’ was the reference category for all analyses. 
 p-Trend values do not include reference group. (p-value for the exact Cochran-Armitage trend test) 
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Table 4-5. Analysis of dose effects simultaneous modelling of smoking status and individual quantitative smoking measures 
 
Model
1,2 
 Total sample 
(n=18,828) 
 
 
 
No AKs/ skin cancers treated destructively prior to 
baseline (n=13,322) 
  Basal cell carcinoma 
 
Squamous cell carcinoma 
 
Basal cell carcinoma 
 
Squamous cell carcinoma  
 
    
HR
 
(95% CI)
 
 
HR
 
(95% CI)
 
 
 
 
HR
 
(95% CI)
 
 
HR
 
(95% CI)
 
    
 
A 
 
Current smoker 
 
0.65 (0.44-0.96) 
 
2.52 (1.52-4.18) 
 
 
 
0.85 (0.54-1.37) 
 
3.09 (1.68-5.69) 
 Duration of smoking (per 10 years) 1.01 (0.67-1.53) 0.94 (0.59-1.48)  0.91 (0.57-1.45) 0.65 (0.39-1.06) 
       
B Current smoker 0.66 (0.45-0.97) 1.98 (1.18-3.30)  0.91 (0.57-1.43) 2.29 (1.21-4.35) 
 Intensity of smoking (per 10 
cigarettes/day) 
1.12(0.78-1.60) 1.25 (0.85-1.83)  1.11 (0.75-1.66) 0.97 (0.57-1.64) 
       
C Current smoker 0.65 (0.44-0.97) 2.05 (1.18-3.56)  0.89 (0.56-1.42) 2.58 (1.35-4.92) 
 Intensity of smoking (per 10 
cigarettes/day) 
1.13 (0.78-1.63) 1.26 (0.85-1.85)  1.14(0.75-1.72) 1.07 (0.64-1.79) 
 Duration of smoking (per 10 years) 0.95 (0.62-1.45) 0.94 (0.57-1.56)  0.89 (0.56-1.44) 0.59 (0.34-1.01) 
       
D Ex-smoker 0.86 (0.71-1.04) 1.01 (0.71-1.44)  0.88 (0.68-1.15) 1.05 (0.65-1.70) 
 Duration of smoking (per 10 years) 0.97 (0.85-1.11) 0.95 (0.77-1.19)  1.04 (0.86-1.24) 0.94 (0.70-1.26) 
       
E Ex-smoker 0.84 (0.69-1.02) 1.03 (0.73-1.46)  0.87 (0.67-1.14) 1.06 (0.66-1.71) 
 Intensity of smoking (per 10 
cigarettes/day) 
0.86 (0.75-0.98) 0.83 (0.66-1.04)  0.91 (0.77-1.08) 0.88 (0.67-1.14) 
       
F Ex-smoker 0.88 (0.65-1.18) 1.07 (0.66-1.74)  0.84 (0.55-1.30) 1.24 (0.64-2.38) 
 Time since quitting smoking (per 10 
years) 
1.02 (0.99-1.16) 1.05 (0.84-1.31)  0.98 (0.81-1.18) 1.12 (0.84-1.51) 
       
G Ex-smoker 0.85 (0.70-1.03) 1.02 (0.72-1.45)  0.88 (0.67-1.14) 1.08 (0.67-1.75) 
 Duration of smoking (per 10 years) 1.02 (0.89-1.17) 1.00 (0.80-1.25)  1.08 (0.90-1.31) 0.98 (0.73-1.31) 
 Intensity of smoking (per 10 
cigarettes/day) 
0.85 (0.73-0.78) 0.84 (0.67-1.06)  0.89 (0.74-1.06) 0.88 (0.67-1.16) 
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Model
1,2 
 Total sample 
(n=18,828) 
 
 
 
No AKs/ skin cancers treated destructively prior to 
baseline (n=13,322) 
  Basal cell carcinoma 
 
Squamous cell carcinoma 
 
Basal cell carcinoma 
 
Squamous cell carcinoma  
 
    
HR
 
(95% CI)
 
 
HR
 
(95% CI)
 
 
 
 
HR
 
(95% CI)
 
 
HR
 
(95% CI)
 
    
       
H Ex-smoker 0.84 (0.55-1.29) 1.06 (0.53-2.11)  0.92 (0.50-1.70) 1.54 (0.60-3.94) 
 Duration of smoking (per 10 years) 0.96 (0.78-1.19) 0.98 (0.65-1.47)  1.05 (0.78-1.42) 1.19 (0.67-2.12) 
 Time since quitting smoking (per 10 
years) 
0.99 (0.70-1.22) 1.03 (0.68-1.56)  1.02 (0.76-1.38) 1.32 (0.73-2.37) 
  
 
     
I Ex-smoker 0.83 (0.61-1.12) 1.05 (0.64-1.70)  0.81 (0.52-1.25) 1.25 (0.65-2.40) 
 Intensity of smoking (per 10 
cigarettes/day) 
0.85 (0.74-0.98) 0.84 (0.67-1.06)  0.90 (0.76-1.28) 0.88 (0.68-1.16) 
 Time since quitting smoking (per 10 
years) 
0.99 (0.86-1.13) 1.02 (0.82-1.27)  0.96 (0.79-1.15) 1.11(0.83-1.49) 
       
J Ex-smoker 0.88 (0.57-1.34) 1.14 (0.57-2.26)  0.96 (0.52-1.79) 1.69 (0.66-4.34) 
 Intensity of smoking (per 10 
cigarettes/day) 
0.85 (0.73-0.98) 0.84 (0.66-1.05)  0.88 (0.73-1.06) 0.86 (0.65-1.14) 
 Duration of smoking (per 10 years) 1.04 (0.83-1.29) 1.06 (0.70-1.62)  1.13 (0.83-1.54) 1.29 (0.71-2.35) 
 Time since quitting smoking (per 10 
years) 
1.02 (0.82-1.26) 1.08 (0.71-1.63)  1.04 (0.78-1.43) 1.39 (0.77-2.50) 
1
Models were adjusted for age, sex, private health insurance, education status, natural skin colour, tanning ability, number of freckles, history of sunburn as a child, 
cumulative sun exposure. 
2
Continuous measures were centred and estimates of hazard ratio were obtained using separate models that each included an indicator of current/never smoking or ex-/never 
smoking  
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Table 4-6. Smoking status and risk cSCC, after excluding IEC/Bowen’s/ KA in control or using IEC/Bowen’s/ KA as cSCC cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter  
 
cSCC (Model excluding IEC/Bowen’s/ KA 
in controls) 
  
cSCC (IEC/Bowen’s/ KA as cSCC cases) 
Smoking status among people with less than 5 destructive 
treatments for skin lesions prior to baseline  
 
   
 HR (95% CI)  HR (95% CI) 
  
Never smoker  1.00  1.00 
Former smoker 1.03 (0.73-1.46)  0.86 (0.44-1.70) 
Current smoker 
 
2.32 (1.47- 3.65)  2.03 (0.79-5.18) 
Smoking status among people with no history of destructive 
treatments for skin lesions prior to baseline  
   
Never smoker  1.00  1.00 
Former smoker 0.98 (0.68-1.42)  1.46 (0.52-4.01) 
Current smoker 2.24 (1.39-3.60)  3.80 (1.14-12.61) 
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We found no evidence of dose-response effects for any of the continuous measures of smoking with 
respect to BCC or cSCC once the qualitative effect of smoking was incorporated in the model 
[Table 4-5]. Furthermore, using nonlinear terms of smoking measures did not improve the model fit 
[Figure 4-4 – Figure 4-9].  
 
Finally, we conducted sensitivity analyses to test the possible effects of missing pathology data on 
the association between smoking and risks of BCC and cSCC. The directions of association were 
unchanged, although the magnitude varied depending on whether we assigned all missing pathology 
as “BCC cases” (adjusted HR, current vs. never smoker: 0.84, 95% CI: 0.63-1.11) or “non-cases” 
(adjusted HR, current vs. never smoker: 0.64, 95%CI: 0.44-0.93), or else randomly assigned 75% of 
all the missing pathology as “BCC cases” (adjusted HR, current vs. never smoker: 0.81, 95% CI: 
0.61-1.08) [Table 4-7]. We performed similar sensitivity analysis for cSCC; the positive 
associations between current smoking and cSCC remained significant under each scenario [Table 
4-7]. 
 
 
Figure 4-4. Relation of smoking intensity and its dose-response patterns with risk of BCC 
The solid line represents log hazard, and the dashed line represents its 95% confidence Intervals 
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Figure 4-5. Relation of duration of smoking and its dose-response patterns with risk of BCC 
 The solid line represents log hazard, and the dashed line represents its 95% confidence Intervals. 
 
 
 
Figure 4-6. Relation of time since quitting and its dose-response patterns with risk of BCC 
The solid line represents log hazard, and the dashed line represents its 95% confidence Intervals 
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Figure 4-7. Relation of smoking intensity and its dose-response patterns with risk of cSCC 
The solid line represents log hazard, and the dashed line represents its 95% confidence Intervals 
 
 
 
Figure 4-8. Relation of duration of smoking and its dose-response patterns with risk of cSCC 
The solid line represents log hazard, and the dashed line represents its 95% confidence Intervals. 
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Figure 4-9. Relation of time since quitting and its dose-response patterns with risk of cSCC 
The solid line represents log hazard, and the dashed line represents its 95% confidence Intervals 
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Table 4-7. Sensitivity analyses variously including participants with missing pathology as BCC/cSCC cases 
 
  
All missing histology as BCC or cSCC 
cases 
 
All missing histology as BCC or cSCC 
control 
 
75% of missing histology as BCC and 25% 
as cSCC 
Parameter        BCC       cSCC      BCC      cSCC      BCC      cSCC 
HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI) 
           
SMOKING STATUS 
0-5 destructive treatments for skin 
lesions prior to baseline 
 
           
      Never smoker  1.00  1.00  1.00  1.00  1.00  1.00 
Former smoker 0.85 (0.73-1.00)  0.92 (0.75-1.14)  0.86 (0.71-1.04)  1.05 (0.75-1.49)  0.87 (0.74--1.02)  1.02 (0.76-1.36) 
      Current smoker 0.84 (0.63-1.11)  1.66 (1.22-2.24)  0.64 (0.44-0.93)  2.30 (1.46-3.62)  0.81 (0.61-1.08)  1.88 (1.25-2.81) 
SMOKING STATUS 
No destructive treatments for skin 
lesions prior to baseline 
  
           
Never smoker  1.00  1.00  1.00  1.00  1.00  1.00 
Former smoker 0.89 (0.73-1.11)  0.98 (0.75-1.31)  0.88 (0.68-1.14)  1.10 (0.68-1.78)  0.89 (0.72-1.11)  1.08 (0.75-1.57) 
Current smoker 0.99 (0.71- 1.40)  1.70 (1.16-2.50)  0.84 (0.53-1.33)  2.50 (1.39-4.51)  0.95 (0.66-1.36)  1.80 (1.08-3.00) 
 
 Models were adjusted for age, sex, private health insurance, education status, natural skin colour, tanning ability, number of freckles, history of sunburn as a child, 
cumulative sun exposure. 
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DISCUSSION 
We have prospectively investigated the association between smoking and the risk of developing a 
first BCC or cSCC in a large population-based cohort while taking account of the potential 
confounding influence of demographic and phenotypic characteristics and sun exposure history. 
Overall, we found that current smokers with no prior history of any excisions for skin cancer were 
significantly less likely than never smokers to be diagnosed with a new BCC during follow-up but 
were significantly more likely to be diagnosed with a new cSCC. We found no significant 
associations between former smoking and BCC or cSCC. Contrary to other cancers where clear 
dose-response relationships with increasing duration and intensity of smoking exposure have been 
observed [347], we saw no trends with duration of smoking, intensity or time since quitting in our 
cohort.  
 
Our findings of lower risk of BCC among current smokers are similar to previous cohort studies 
that reported null or inverse associations [263] , [348], [338] . Case-control studies have been 
heterogeneous and reported both positive and negative associations [349-352]. It is unlikely that the 
associations reported here are due to confounding, as we controlled for sun exposure, phenotypic 
and other skin cancer risk factors, although some analyses suggested differences according to health 
promoting behaviours. When we stratified by recent history of skin checks, we saw no effect of 
current smoking on BCC risk among those who never had their skin checked, but we saw a 
significantly protective effect of current smoking among those who had undergone a skin check. 
Our assessment is that the inverse association between current smoking and BCC is likely 
explained, at least in part, by detection bias, in which never smokers who undergo regular skin 
checks are more likely to be diagnosed with indolent BCCs than current smokers. This fits with the 
baseline data presented in [Table 4-1]. Never smokers were more highly educated, more likely to 
have private health insurance and more likely to have skin checks than current smokers; thus, more 
likely to have health promoting behaviours. This is consistent with previous research which has 
shown that incidence of BCC varies according to the methods of surveillance [340].  
 
In our cohort we found a strongly positive significant  association between current smoking and 
cSCC, consistent with earlier reports from the female Nurses’ Health Study [263], male Health 
Professional Follow up Study [263] and others [350] [353]. The Nambour cohort in Queensland 
[339] and the Swedish Construction Workers cohort [354] reported non-significant increased 
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associations between smoking and cSCC. The association may not have reached significance in the 
Nambour study because of the relatively small sample size, and the Swedish Construction Workers 
study did not control for potential confounding effects of sun exposure and phenotypic factors.  
Other possible sources of inconsistency across studies include using different approaches to define 
smoking status and failing to account for potential sources of bias (particularly detection bias). In 
addition, most previous studies did not analyse different dimensions of smoking, nor did they adjust 
for skin cancer risk factors at baseline.  
 
We found little evidence of confounding, as the risk estimates remained stable after adjustment and 
stratification. Moreover, the observed association between smoking and cSCC is not likely due to 
information bias as follow-up was high and our sensitivity analyses, in which we variously included 
participants with missing pathology data as cases or non-cases, resulted in similar risk estimates. 
We cannot, however, exclude the possibility of detection bias which may have resulted in an 
underestimate of the effect. The risks of cSCC associated with smoking were modestly lower 
among those who had ever had their skin checked by a doctor (HR: 2.08) than among those with no 
prior history of skin checks (HR: 2.77). The difference between these estimates was not statistically 
significant however. Thus, while there may be some detection effect for cSCC, the magnitude 
appears less than that observed for BCC. This accords with the known differences between BCC 
and cSCC detection, since it has been shown previously that incidence of BCC (but not cSCC) 
varies according to the methods of surveillance [340] . 
 
There are several possible biological mechanisms for how smoking may induce cutaneous 
malignancies, although none explains why the effect would be restricted to current smokers or be 
specific for cSCC but not BCC. While toxic constituents of tobacco products have been reported to 
down-regulate gene expression of the Notch pathway (an important gene inhibiting the growth of 
KCs) [355, 356] why this would differentially influence cSCC and BCC development is unclear. 
Nicotine, the main constituent of cigarette smoke, acts systemically to suppress the immune system 
[357] which might conceivably be associated more strongly with cSCC than BCC. These 
mechanistic explanations remain entirely speculative however. 
 
A limitation of our study is reliance on self-reported exposure information and smoking history 
which is potentially subject to misclassification. Arguing against this is our previous demonstration 
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of a very high degree of repeatability for smoking measures in this cohort [321]. A further 
limitation was the reasonably high level of missing pathology data among participants who were 
known to have undergone treatment for a keratinocyte carcinoma. We addressed this in a series of 
sensitivity analyses in which participants with missing pathology data were randomly assigned 
various states. In none of these sensitivity analyses were our conclusions markedly altered. Our 
study has several strengths. The large sample size allowed us to restrict our analyses to participants 
with no prior history of treatment for any skin lesion. We captured comprehensive data at baseline 
on key phenotypic and exposure variables for skin cancer which permitted careful control of 
confounders and reduced potential recall bias. Further strengths were the complete follow-up of 
skin cancer events in the cohort through data linkage, and pathology confirmation for most 
diagnoses. We were also able to conduct stratified analyses, including for health promoting 
behaviours reported previously to be associated with smoking status [358]. Finally, our analyses 
enabled the assessment of associations with a range of smoking dimensions measures independently 
of the effects of ‘ever smoking’. 
 
In conclusion, our data accord with the emerging consensus that BCC and cSCC have very different 
associations with smoking. We found that current smoking is associated with lower risk of BCC, 
possibly as a result of detection bias due to lower rates of screening among smokers, although a 
lower risk of BCC in smokers cannot be ruled out.  As our findings for BCC may be influenced by 
screening practices that are specific to Queensland, our findings may not be generalisable to other 
population. The significantly increased risk of cSCC amongst current smokers we report may be 
causal as the association is consistent with evidence from other cohort studies, and we have 
demonstrated temporality and specificity. However, due to the lack of association amongst ex-
smokers, the lack of a dose-response relationship with intensity and duration of smoking and no 
compelling biologic mechanism, we urge cautious interpretation of our findings. 
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4.2 Cigarette smoking and risk of cutaneous melanoma 
4.2.1 Introduction  
The aim of this analysis was to assess the effect of various dimensions of smoking on the risk of 
developing first invasive melanoma using linked data between the QSkin cohort and the 
Queensland cancer registry. This chapter consists of a peer-reviewed manuscript that was published 
in the Journal of Cancer Epidemiology, Biomarkers & Prevention in 2018. 
 
Dusingize JC, Olsen CM, Pandeya N, Thompson BS, Webb PM, Green AC, Neale RE, Whiteman 
DC; QSkin Study. Smoking and Cutaneous Melanoma: Findings from the QSkin Sun and Health 
Cohort Study. Cancer Epidemiology Biomarkers Prevention. 2018; 27(8):874-881. 
 
4.2.2 Contribution of Candidate 
The concept of the study was formulated by my supervisors DCW and CMO. I participated in data 
collection and cleaning with the help from NP and CMO. I wrote the data analysis plan and 
performed the statistical analysis with the assistance of my supervisors. I was responsible for 
writing the first draft of the manuscript and worked on revisions taking into account the comments 
and suggestions from all co-authors. I prepared the final draft of the manuscript and submitted it to 
the journal for publication. I was responsible for writing the response to reviewer comments and 
prepared the revised manuscript with input from all the co-authors. 
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4.2.3 Manuscript: Smoking and Cutaneous Melanoma: Findings from the QSkin Sun and 
Health Cohort Study 
 
ABSTRACT 
Background: Previous studies suggest that smokers have lower risks of cutaneous melanoma than 
non-smokers, but data from population-based prospective studies are scarce. We investigated 
associations between smoking and melanoma in a cohort study purpose-designed to investigate skin 
cancer outcomes.  
Methods: Participants with no prior history of melanoma (n=38,697) completed a risk factor survey 
at baseline (2011). Patients were followed through linkage to the cancer registry. We estimated 
hazard ratios and 95% confidence intervals for associations between smoking (including intensity, 
duration, time since quitting) and melanoma using multivariate Cox proportional hazards 
regression, accounting for death as a competing event.  
Results: During a mean follow-up of 3.5 years, invasive melanomas developed in 247 participants. 
Compared with never smokers, former smokers (but not current smokers) had lower risks of 
invasive melanoma (HR: 0.76; 95%CI 0.57-1.01).  Among former smokers, risks were lower with 
greater quantity of cigarettes smoked (HR: 0.75; 95%CI 0.56-0.98 per 10 cigarettes/day). No 
association was observed with duration of smoking while longer time since quitting was associated 
with a relative risk of melanoma that was not significantly different from the null (HR: 1.18; 
95%CI: 0.91-1.51, for every 10 years since quitting).  
Conclusions: We observed complex associations between smoking and melanoma, with some 
suggestion that former smokers had lower risks than never or current smokers. The apparent inverse 
association among former smokers may be due to residual confounding, although surveillance bias 
or biological effects cannot be excluded entirely.  
Impact: Smoking does not increase the risk of cutaneous melanoma. 
 
INTRODUCTION   
The International Agency for Research on Cancer (IARC) has declared smoking as a cause of 18 
cancers [260].  The confirmed cancer types include cancer of oral cavity, oropharynx, nasopharynx, 
esophagus (both adenocarcinoma and squamous-cell carcinoma), stomach, colorectum, liver, 
pancreas, nasal cavity, larynx, lung, uterine, cervix, ovary, bladder, kidney, ureter, bone marrow. 
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Although no cancers of the skin are currently included in this list, there is strengthening evidence 
that smoking is a cause of cutaneous squamous cell carcinoma (cSCC) [359]. The association 
between smoking and melanoma remains unclear despite considerable investigation. Two previous 
meta-analyses reported moderate inverse associations between smoking and melanoma, although 
both noted important limitations with the literature. The first used a dichotomised measure of 
smoking (ever vs. never) which failed to separate the effect of current and former smoking [263]. 
The second reported significant publication bias due to selective reporting in the included studies 
[265].   
 
Cohort studies have reported mixed findings.  Blakeley and colleagues reported inverse associations 
between current smoking and melanoma, but that study did not report any findings for former 
smokers [360]. The Swedish Construction Workers and the US Radiologic Technologists study 
cohort reported inverse associations between both current and former smoking and melanoma [348, 
361]. A prospective cohort study of cancer mortality and incidence showed a significant inverse 
association between current smoking and melanoma incidence in women but not in men, while a 
null association was reported among former smokers in both sexes[362]. The Health Professionals 
Follow-up Study reported an inverse association between current and former smoking and 
melanoma in men [263], whereas the Nurses’ Health Study (women only) [263] reported null 
associations in both current and former smokers. Findings from case-control studies have been 
mixed, reporting both positive and negative associations [350, 363].  
 
Several design and analysis features of previous prospective studies exploring this potential 
association have rendered the findings open to questions of bias and confounding, meaning that the 
question of whether smoking increases or decreases the risk of melanoma has not been answered 
definitively. For example, no previous cohorts have collected information on potentially important 
factors such as skin phototype (burning/tanning).  In terms of analysis, various studies have shown 
that analysing multiple measures of smoking history individually is inefficient and may lead to 
over- or under-estimation of risk by failing to account for variability in smoking history [364, 365]. 
Moreover, the influence of various sources of bias have rarely been investigated, despite their 
acknowledged importance [366, 367]. For example, detection bias could arise if smokers underwent 
fewer physician skin checks than non-smokers, resulting in apparently lower melanoma incidence 
among smokers. Similarly, smokers have higher all-cause mortality than non-smokers, which might 
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contribute to an apparent lower melanoma incidence among smokers due to competing risks of 
death. 
 
We sought to investigate further the role of cigarette smoking in the development of cutaneous 
melanoma using data from a large population-based cohort study purpose-designed to investigate 
skin cancer outcomes. In particular, we aimed to explore possible dose–response relationships with 
duration or intensity of smoking, and time since quitting smoking, while taking full account of the 
potential confounding effects of established risk factors for melanoma.  
 
MATERIALS AND METHODS  
Study population  
The QSkin Sun and Health Study (QSkin) is a prospective cohort study of 43,794 men and women 
randomly sampled from the Queensland population in 2011 who were aged between 40 to 69 years 
at study entry. Detailed information regarding participant recruitment and other study characteristics 
has been reported elsewhere [320]. We restricted our analysis to participants of European ancestry 
who completed the smoking questions in the baseline questionnaire. Prior to baseline, we excluded 
those with a confirmed diagnosis of both in situ and invasive melanoma (n=126); or invasive 
melanoma only (n=867); or in situ melanoma only (n=764), leaving 38,697 participants for 
analysis. 
This study has received approval from the Human Research Ethics Committee of the QIMR 
Berghofer Medical Research Institute. Each participant provided written informed consent to take 
part in the study. 
 
Exposure assessment  
At baseline participants self-completed a questionnaire asking about demographic items, general 
medical history, pigmentary characteristics, history of sun exposure, sun protection behaviour and 
history of skin cancer. They were further asked to report the number of times they had undergone 
regular skin checks by a doctor over the past three years.  Participants were asked to report their 
smoking history; those who had smoked daily for at least 6 months were asked further questions 
including age at smoking initiation, the age at which they stopped smoking permanently (among 
former smokers), the amount they smoked per day while smoking, and the total number of years 
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during which they had smoked. Repeatability for smoking measures was nearly perfect (weighted 
kappa = 0.97, 95% CI: 0.92-1.00) [321].  
 
Follow-up 
In addition to historical data obtained from the cancer registry prior to baseline, participants were 
followed prospectively for the first occurrence of histologically confirmed in situ or invasive 
melanoma by record linkage to the Queensland Cancer Registry (notification has been mandatory 
since 1982 and is virtually complete). Surveillance commenced from date of enrolment (2010-2011) 
through 30 June 2014. Deaths in the cohort were identified through linkage with the National Death 
Index.  
 
Statistical Analysis 
The primary outcome was incident invasive melanoma. Participants contributed person-years to the 
analysis from date of consent until one of the following endpoints: histologically confirmed in situ 
or invasive melanoma, death or end of follow-up (June 30, 2014), whichever occurred first. In our 
primary analysis, in situ melanomas occurring during follow-up were censored on the date of 
diagnosis. However, we performed sensitivity analyses by 1) including in situ melanoma in the case 
group (i.e. cases = any diagnosis of melanoma, in situ or invasive) and 2) by treating history of in 
situ melanoma as a time-varying covariate, whereby participants so diagnosed remained at risk for a 
subsequent invasive melanoma but were treated as a different risk set post in situ diagnosis.  
 
We performed competing risks regression analyses to account for possible increased mortality 
hazards among smokers. We used the Fine-Gray approach to calculate overall and gender-specific 
sub-distribution hazard ratios and corresponding 95% confidence intervals (CI) for the association 
between measures of smoking and risk of melanoma in the presence of death as a competing risk 
[327]. We selected potential confounders based on prior knowledge and the published literature, but 
we also looked at pairwise associations in our data. Our final multivariate models were adjusted for 
age, sex, natural skin colour, tanning tendency, number of moles at age 21, history of excised skin 
cancers, history of destructive skin cancer treatments, family history of melanoma, history of 
sunburn as a child and cumulative lifetime sun exposure. 
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To test for trends in dose response, we included categorical smoking variables (intensity, duration 
and time since quitting) in each model as continuous terms and assigned a value to each ordinal 
category equal to the median of its continuous distribution within that category and then modelled 
each categorical dimension as a continuous term. We performed additional analyses assessing each 
measure of smoking as a continuous variable while simultaneously adjusting for other measures of 
smoking. To avoid multi-collinearity, we centred all continuous measures of smoking (rescaled to 
the mean)[345]. Pack-years smoked was used to adjust for dose smoked while estimating the effect 
of time since quitting due to strong correlation between duration and time since quitting. To explore 
possible nonlinear dose effects of continuous measures of smoking, we employed generalised 
additive models with cubic splines fixed at 3 degrees of freedom. We used R software for these 
generalised additive models (CRAN package mgcv) and SAS 9.4 software (SAS Institute, Cary, 
NC) for all other statistical analyses.  
 
RESULTS 
The average follow-up duration was 3.5 years (minimum 2.4 years, maximum 3.6 years). Of the 
38,697 eligible participants, 247 developed a first incident invasive melanoma during follow-up 
(139 men; 108 women) and 394 developed a first incident in situ melanoma (236 men, 158 
women); 445 participants died [Figure 4-10]. The mean age at study entry was 56 years, 10% were 
current smokers and 36% former smokers. Compared with never smokers, current smokers were 
younger (mean 54 years vs 56 years), more likely to be males and less likely to have achieved 
higher levels of education [Table 4-8]. Current smokers were also less likely than never smokers to 
report having a skin type that burns easily and were more likely to report having skin that tans 
deeply. On average, current smokers smoked for a significantly longer duration than former 
smokers (mean, 36.5 years vs. 19.8 years, respectively), but both groups reported similar smoking 
intensity (mean 18 vs. 19 cigs/day, respectively).       
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Figure 4-10. QSkin cohort flow diagram for melanoma incidence 
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Table 4-8. Baseline characteristics of QSkin study participants included in the melanoma analysis by smoking status 
Parameter  Smoking status at baseline  
 Total (n=38,697) Never (n= 21,035) Former (n=13,935) Current (n=3727) Chi-Square 
 n (%) n (%) n (%) n (%) P-value 
      
Age at entry, Mean (SD) 56.1 (8.2) 55.7 (8.2) 57.1 (8.1) 54.3 (7.7) <0.0001
2 
Age group      
40-49 10237 (26.5) 5909 (28.1) 3096 (22.2) 1232 (33.1) <0.0001 
40-59 14669 (37.9) 7852 (37.3) 5263 (37.8) 1553 (41.7)  
60-69 13791 (35.6) 7274 (34.6) 5576 (40.0) 941 (25.3)  
Sex      
Females 21000 (54.3) 12550 (59.7) 6590 (47.3) 1860 (49.9) <0.0001 
Males 17697 (45.7) 8485 (40.3) 7345 (52.7) 1867 (50.1)  
Further Education      
No school certificate 2978 (7.7) 1266 (6.0) 1210 (8.7) 502 (13.5) <0.0001 
School certificate 5997 (15.5) 3059 (14.5) 2281 (16.4) 657 (17.6)  
Completed high school 7051 (18.2) 3873 (18.4) 2418 (17.3) 760 (20.4)  
Trade/certificate/diploma 10821 (27.9) 5502 (26.2) 4292 (30.8) 1027 (27.5)  
University degree 9086 (23.5) 6078 (28.9) 2613 (18.7) 395 (10.6)  
Missing 2764 (7.2) 1257 (5.9) 1121(8.0) 386 (10.4)  
Private Health Insurance      
No 26110 (67.5) 15618 (74.3) 8877 (63.7) 1527 (41.0) <0.0001 
Yes 12588 (32.5) 5346 (25.4) 4995 (35.8) 2180 (58.5)  
Missing 154 (0.4) 71 (0.3) 63(0.6) 20 (0.5)  
Skin colour      
Fair 23534 (60.8) 13014 (61.9) 8322 (59.7) 2198 (58.9) <0.0001 
Medium 12433 (32.1) 6685 (31.8) 4570 (32.8) 1178 (31.6)  
Olive/Dark 2538 (6.6) 1237 (5.9) 977 (7.0) 324 (8.7)  
Missing 192 (0.5) 99 (0.5) 66 (0.5) 27 (0.7)  
Eye colour      
Blue/Grey 15255 (39.4) 8281 (39.4) 5490 (39.4) 1484 (39.8) 0.40 
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Parameter  Smoking status at baseline  
 Total (n=38,697) Never (n= 21,035) Former (n=13,935) Current (n=3727) Chi-Square 
 n (%) n (%) n (%) n (%) P-value 
Green/hazel 14683 (37.9) 8063 (38.3) 5210 (37.4) 1410 (37.8)  
Brown/black 8246 (21.3) 4447 (21.2) 3029 (21.7) 770 (20.7)  
Missing 513 (1.3) 244 (1.2) 206 (1.5) 63 (1.7)  
      
Hair colour      
Dark brown/black 15981 (41.5) 8817 (41.9) 5738 (41.2) 1426 (38.3) <0.0001 
Light brown 14743 (38.3) 7992 (37.9) 5356 (38.4) 1395 (37.4)  
Blonde 5550 (14.4) 2922 (13.9) 1982 (14.2) 646 (17.3)  
Red/auburn 2220 (5.8) 1203 (5.7) 784 (5.6) 233 (6.3)  
Missing 203 (0.5) 101 (0.5) 75 (0.5) 27 (0.7)  
Burning tendency      
No burns 3350 (8.7) 1570 (7.5) 1278 (9.2) 502 (13.5) <0.0001 
Burns a little 16680 (43.1) 8765 (41.7) 6213 (44.6) 1702 (45.7)  
Burns moderately 13021 (33.6) 7353 (34.9) 4588 (32.9) 1080 (28.9)  
Burns badly 5443 (14.1) 3241 (15.4) 1782 (12.8) 420 (11.3)  
Missing 203 (0.5) 106 (0.5) 74 (0.5) 23 (0.6)  
Tanning tendency      
No tan 2489 (6.4) 1464 (6.9) 780 (5.6) 245 (6.6) <0.0001 
Tan lightly 8097 (20.9) 4857 (23.1) 2514 (18.1) 726 (19.5)  
Tan moderately 19252 (49.7) 10463 (49.7) 7093 (50.9) 1696 (45.5)  
Tan deeply 8584 (22.1) 4094 (19.5) 3460 (24.8) 1030 (27.6)  
Missing 275 (0.71) 157 (0.7) 88 (0.6) 30 (0.8)  
Freckles at age 21 years (face)      
None 17884 (46.2) 9337 (44.4) 6778 (48.6) 1769 (47.5) <0.0001 
A few 12177 (31.5) 6847 (32.5) 4219 (30.3) 1111 (29.8)  
Some 6085 (15.7) 3474 (16.5) 2026 (14.5) 585 (15.7)  
Many 2362 (6.1) 1272 (6.1) 850 (6.1) 240 (6.4)  
Missing 189 (0.5) 105 (0.5) 62 (0.4) 22 (0.6)  
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Parameter  Smoking status at baseline  
 Total (n=38,697) Never (n= 21,035) Former (n=13,935) Current (n=3727) Chi-Square 
 n (%) n (%) n (%) n (%) P-value 
Nevus category at age 21      
None 10740 (27.8) 5470 (26.0) 4087 (29.3) 1183 (31.7) <0.0001 
A few 20100 (51.9) 11148 (53.0) 7123 (51.1) 1829 (49.1)  
Some 5677 (14.7) 3227 (15.3) 1922 (13.8) 528 (14.2)  
Many 1158 (2.9) 676 (3.2) 388 (2.8) 94 (2.5)  
Missing 1022 (2.6) 514 (2.4) 515 (2.9) 93 (2.5)  
Sunburns as a child 
Sunburns as a child 
     
Never 7253 (18.7) 4083 (19.4) 2469 (17.7) 701 (18.8) <0.0001 
1-5 16003 (41.4) 8915 (42.4) 5631 (40.4) 1457 (39.1)  
6-10 6228 (16.1) 3355 (15.9) 2301 (16.5) 572 (15.4)  
11+ 5578 (14.4) 2778 (13.2) 2158 (15.5) 642 (17.2)  
Missing 3635 (9.4) 1904 (9.1) 1376 (9.9) 355 (9.5)  
Skin checks by a doctor (past 3 years)      
No 10236 (26.4) 5178 (24.6) 3805 (27.3) 1253 (33.6) <0.0001 
Yes 27616 (71.4) 15440 (73.4) 9824 (70.5) 2352 (63.1)  
Missing 845 (2.2) 417 (1.9) 306 (2.2) 122 (3.3)  
AKs
1
/ skin cancers destructively treated prior to baseline      
None 17252 (44.8) 9130 (43.4) 6122 (43.9) 2000 (53.7) <0.0001 
1-5 10412 (27.1) 5880 (27.9) 3687 (26.5) 845 (22.7)  
6 + 10840 (28.2) 5913 (28.1) 4063 (29.2) 864 (23.2)  
Missing 193 (0.5) 112 (0.5) 63 (0.4) 18 (0.5)  
Family history of melanoma      
No 24132 (62.4) 13181 (62.6) 8796 (63.1) 2155 (57.8) <0.0001 
Yes 8892 (22.9) 5067 (24.1) 2962 (21.3) 863 (23.2)  
Missing 5673 (14.7) 2787 (13.3) 2177 (15.6) 709 (19.0)  
Duration (years) of smoking, Mean (SD) 23.32 (13.2) 36.48 (9.2) 19.78 (11.8) N/A <0.0001 
Intensity of smoking (cigarettes/day), Mean (SD) 19.29 (12.5) 18.71 (9.6) 19.44 (13.2) N/A 0.002 
1
AKs: Actinic Keratosis   
2
P-value for significant difference using Ryan-Einot-Gabriel-Welsch multiple range test 
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After adjusting for potential confounding factors, ever smokers were less likely than never smokers 
to develop invasive melanoma (HR: 0.80; 95% CI 0.62-1.05) [Table 4-9]. We also observed lower 
risks of invasive melanoma among ever smokers in analyses of intensity and time since quitting, but 
not with duration or age at smoking initiation. 
 
When analysed by smoking status, we observed no association between current (HR: 1.01; 95% CI 
0.64-1.61), and former smoking (HR: 0.76; 95% CI 0.57-1.01) with melanoma. The lower risks of 
invasive melanoma among ever smokers were also observed in analyses of smoking intensity and 
time since quitting. There was no association between age at smoking initiation and duration and 
invasive melanoma, but there was a significant inverse trend with increasing smoking intensity (p 
trend = 0.001).  
 
We observed unusual trends among former smokers whereby the inverse association was significant 
among recent quitters and then gradually decreased toward the null. Although this pattern suggests 
a non-linear trend, the test for non-linearity was not statistically significant. The association 
between smoking and melanoma did not differ materially across strata of cumulative sun exposure 
[Table 4-10]. The inverse association among former smokers was similar for women and men.   
 
To further assess the linearity in dose response with incremental change in each continuous 
dimension of smoking, linear terms for smoking duration, intensity and time since quitting were 
modelled simultaneously with an indicator variable for smoking status [Table 4-11]. When duration 
and intensity were included simultaneously in the model, intensity was associated with significantly 
lower risks of melanoma among former smokers (HR: 0.74; 95% CI 0.56-0.98, for every 10 
cigarettes/day). We observed a similar inverse trend among current smokers, although the 
association was not statistically significant (HR 0.81; 95% 0.55-1.51, for every 10 cigarettes/day). 
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Table 4-9. The association between measures of smoking and incidence of invasive melanoma 
 
Parameter    
Minimally 
adjusted   model
1 
  
Fully adjusted model
2 
Cases /Person-  
years 
Total cohort  
 
HR (95% CI) 
Total cohort  
 
HR (95% CI) 
Males  
 
HR (95% CI) 
Females 
 
HR (95% CI) 
Smoking status        
Never smoker
3 
151/73321  1.00  1.00 1.00 1.00 
Ever smoker    96/61347  0.72 (0.55-0.92)  0.80 (0.62-1.05) 0.87 (0.62-1.22) 0.71 (0.46-1.09) 
Ex-smoker    75/48417  0.66 (0.50- 0.88)  0.76 (0.57-1.01) 0.79 (0.55-1.15) 0.71 (0.45-1.13) 
Current smoker   21/12930  0.81 (0.51-1.27)  1.01 (0.64-1.61) 1.26 (0.72-2.20) 0.69 (0.29-1.60) 
p-value    0.01  0.1   0.2                        0.3                          
Age (years) at starting smoking         
Never  151/73321  1.00  1.00 1.00 1.00 
≤16   32/26107  0.53 (0.36-0.78)  0.63 (0.43-0.93) 0.69 (0.44-1.09) 0.50 (0.22-1.12) 
>16   63/34517  0.81 (0.60-1.09)  0.93 (0.69-1.26) 1.03 (0.69-1.53) 0.82 (0.52-1.31) 
p-value
4 
  0.053  0.07 0.1 0.5 
Duration (years) of smoking        
Never  151/73321  1.00  1.00 1.00 1.00 
≤10   23/13243  0.86 (0.56-1.34)  0.91 (0.58-1.42) 0.97 (0.53-1.75) 0.85 (0.42-1.71) 
11-20   27/14102  0.86 (0.57-1.30)  1.01 (0.67-1.52) 1.16 (0.71-1.91) 0.73 (0.34-1.60) 
21-30   15/13698  0.51 (0.30-0.87)  0.61 (0.36-1.05) 0.63 (0.32-1.22) 0.60 (0.24-1.49) 
>30   29/19347  0.58 (0.38-0.86)  0.71 (0.47-1.07) 0.77 (0.47-1.28) 0.61 (0.29-1.27) 
p-trend
4 
  0.049  0.1 0.2 0.4 
Intensity of smoking 
(cigarettes/day) 
       
Never 151/73321  1.00  1.00 1.00 1.00 
≤10   37/18491  0.99 (0.66-1.42)  1.14 (0.79-1.64) 1.08 (0.63-1.83) 1.20 (0.73-1.98) 
11-20   41/24678  0.71 (0.50-1.01)  0.79 (0.56-1.13) 0.96 (0.63-1.47) 0.49 (0.24-1.04) 
>20   16/16825  0.38 (0.22-0.63)  0.47 (0.28-0.79) 0.57 (0.32-1.02) 0.23 (0.05-0.93) 
p-trend
4 
  0.001  0.001 0.054 0.006 
Pack-years of smoking        
Never 151/73321  1.00  1.00 1.00 1.00 
≤10   36/19247  0.94 (0.65-1.35)  1.01 (0.69-1.46) 0.98 (0.58-1.65) 1.04 (0.61-1.78) 
11-20   18/13034  0.63 (0.39-1.03)  0.75 (0.46-1.22) 0.99 (0.57-1.73) 0.34 (0.11-1.07) 
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Parameter    
Minimally 
adjusted   model
1 
  
Fully adjusted model
2 
Cases /Person-  
years 
Total cohort  
 
HR (95% CI) 
Total cohort  
 
HR (95% CI) 
Males  
 
HR (95% CI) 
Females 
 
HR (95% CI) 
21-30   19/9546  0.88 (0.54-1.42)  1.01 (0.62-1.64) 1.03 (0.55-1.91) 1.00 (0.44-2.29) 
>30   20/17428  0.42 (0.26-0.68)  0.54 (0.34-0.86) 0.65 (0.38-1.10) 0.30 (0.09-0.95) 
p-trend
4 
  0.003  0.02 0.1 0.045 
Years since quitting (past 
smokers) 
       
Never  151/73321  1.00  1.00 1.00 1.00 
≤10     8/11892  0.33(0.16-0.67)  0.36 (0.17-0.78) 0.42 (0.17-1.03) 0.29 (0.07-1.17) 
11-20   17/11892  0.68 (0.41-1.13)  0.82 (0.49-1.37) 0.81 (0.41-1.57) 0.86 (0.39-1.88) 
21-30   21/14209  0.66 (0.42-1.05)  0.75 (0.47-1.18) 0.74 (0.41-1.34) 0.76 (0.37-1.58) 
>30   28/10045  1.01 (0.66-1.50)  1.01 (0.67-1.53) 1.34 (0.69-1.86) 0.76 (0.33-1.74) 
p-trend
4 
  0.01  0.044 0.049 0.5 
 
1
Models were adjusted for age and sex 
2
Models were adjusted for age, sex, natural skin colour, tanning tendency, number of moles at age 21, history of skin cancer surgically removed, history of skin cancer 
destructively removed, history of sunburn as a child, cumulative sun exposure and family history of melanoma. 
3‘Never smoker’ was the reference category for all analyses. 
4
p-Trend values do not include reference group (p-value for the exact Cochran-Armitage trend test) 
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Table 4-10. The association between smoking status and incidence of invasive melanoma across strata of cumulative sun exposure 
 
Parameter   
Minimally 
adjusted   model
1 
  
Fully adjusted model
2 
Total cohort  
 
HR (95% CI) 
Total cohort  
 
HR (95% CI) 
Males  
 
HR (95% CI) 
Females 
 
HR (95% CI) 
       
Cumulative sun exposure (Q1 and Q2)
3 
Smoking status 
      
Never smoker
 
 1.00  1.00 1.00 1.00 
Ever smoker   0.81 (0.53-1.24)  0.95 (0.62-1.47) 1.02 (0.52-2.02) 0.90 (0.51-1.61) 
Ex-smoker   0.78 (0.49-1.23)  0.92 (0.57-1.45) 0.93 (0.44-1.95) 0.89 (0.49-1.66) 
Current smoker  0.94 (0.40-2.20)  1.19 (0.51-2.82) 1.65 (0.48-5.61) 0.89 (0.27-2.99) 
p-value   0.6  0.8 0.7 0.9 
 
Cumulative sun exposure (Q3 and Q4)
4 
      
Smoking status       
Never smoker
 
 1.00  1.00 1.00 1.00 
Ever smoker   0.67 (0.46-1.03)  0.76 (0.53-1.11) 0.79 (0.52-1.20) 0.68 (0.28-1.66) 
Ex-smoker   0.63 (0.42-1.01)  0.69 (0.46-1.04) 0.69 (0.44-1.09) 0.75 (0.30-1.87) 
Current smoker  0.85 (0.47-1.55)  1.10 (0.60-2.01) 1.29 (0.67-2.46) 0.43 (0.06-3.37) 
p-value   0.03  0.2 0.3 0.6 
1
Models were adjusted for age and sex 
2
Models were adjusted for age, sex, natural skin colour, tanning tendency, number of moles at age 21, history of skin cancer surgically removed, past history of skin cancer 
destructively removed, history of sunburn as a child, and family history of melanoma. 
3
First and second quartiles  
4
Third and fourth quartiles  
 
  
  
96 
 
Table 4-11. The association between smoking and invasive melanoma: simultaneous modelling of qualitative and quantitative smoking 
measures 
 
Model  Overall Males Females 
   HR
1 
(95% CI)
 
HR
1 
(95% CI) HR
1 
(95% CI) 
     
A Current smoker 1.06 (0.41-2.72) 1.82 (0.62-5.4) 0.26 (0.03-2.09) 
 Intensity of smoking (per 10 cigarettes/day)
2 
0.81 (0.55-1.51) 1.41 (0.88-2.26) 0.40 (0.18-0.90) 
 Duration of smoking (per 10 years)
2 
0.99 (0.61-1.63) 0.78 (0.47-1.32) 1.49 (0.40-5.50) 
     
B Former smoker 0.68 (0.50-0.93) 0.74 (0.50-1.09) 0.47 (0.24-0.94) 
 Intensity of smoking (per 10 cigarettes/day)
2 
0.74 (0.56-0.98) 0.82(0.60-1.10) 0.49 (0.27-0.92) 
 Duration of smoking (per 10 years)
2 
0.88 (0.73-1.06) 0.81 (0.64-1.01) 1.06 (0.75-1.49) 
     
C Former smoker 0.65 (0.47-0.90) 0.72 (0.48-1.08) 0.46 (0.23-0.90) 
 Intensity of smoking (per 10 cigarettes/day)
2 
0.75 (0.56-0.98) 0.80 (0.59-1.09) 0.53 (0.29-0.97) 
 Time since quitting smoking (per 10 years)
2 
1.22 (1.01-1.48) 1.23 (0.99-1.54) 1.15 (0.81-1.65) 
     
D Former smoker 0.68 (0.49-0.93) 0.70 (0.47-1.05) 0.71 (0.43-1.28) 
 Duration of smoking (per 10 years)
2 
0.99 (0.68-1.43) 0.78 (0.49-1.26) 1.40 (0.75-2.56) 
 Time since quitting smoking (per 10 years)
2 
1.29 (0.89-1.85) 1.06 (0.66-1.68) 1.66 (0.90-3.10) 
     
E Former smoker 0.67 (0.49-0.93) 0.73 (0.48-1.08) 0.53 (0.26-1.02) 
 Pack-years of smoking
 
0.90 (0.74-1.11) 0.92 (0.73-1.15) 0.77 (0.52-1.13) 
 Time since quitting smoking (per 10 years)
2 
1.18 (0.91-1.51) 1.18 (0.87-1.59) 1.08 (0.68-1.69) 
     
1
Models were adjusted for age, sex, natural skin colour, tanning tendency, number of moles at age 21, history of skin cancer surgically removed, past history of skin cancer 
destructively removed, history of sunburn as a child, cumulative sun exposure and family history of melanoma. 
2
Continuous measures were centred and estimates of hazard ratio were obtained using separate models that each included an indicator of ever/never smoking 
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Smoking intensity remained significantly inversely associated with melanoma even after including 
time since quitting in the model. Longer time since quitting was associated with a relative risk of 
melanoma that was not significantly different from the null (HR: 1.18; 95% CI: 0.91-1.51, for every 
10 years since quitting). In contrast, we saw no significant associations between smoking duration 
and melanoma risk in any analyses. We did not observe statistically significant non-linear dose 
effects for smoking duration, intensity or time since quitting (p=0.09, 0.06, 0.8 respectively for 
testing for departure from linearity [Figures 4-11 – Figure 4-13]. 
 
We performed further analysis by combining current smokers and recent quitters (≤10 years) which 
increased the number of melanoma cases among current smokers by approximately 40%. This 
analysis made essentially no difference to the observed risk in current smokers; (HR (95%CI):  0.99 
(0.66-1.24), while the inverse association observed in former smokers was somewhat attenuated 
(HR: 95%CI, 0.86 (0.64-1.15). 
 
We conducted sensitivity analyses in which we included as cases those participants who were 
diagnosed with in situ melanomas as well as those diagnosed with invasive melanoma [Table 4-12]. 
These analyses resulted in slightly attenuated associations with ever smoking but the direction of 
association remained unchanged. Finally, we performed two additional sensitivity analyses, firstly 
by ignoring any in situ melanoma diagnoses during follow-up, and secondly by treating a diagnosis 
of in situ melanoma as a time dependent covariate [Table 4-13]. These analyses made essentially no 
difference to the estimates we have reported in [Table 4-9].  
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Figure 4-11. Relation of duration of smoking and its dose-response patterns with risk of 
melanoma 
The solid line represents log hazard, and the dashed line represents its 95% confidence Intervals. 
Figure 4-12. Relation of smoking intensity and its dose-response patterns with risk of 
melanoma 
The solid line represents log hazard, and the dashed line represents its 95% confidence Intervals 
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Figure 4-13. Relation of time since quitting smoking and its dose-response patterns with risk 
of melanoma  
The solid line represents the log hazard, and the dashed line represents its 95% confidence Intervals.  
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Table 4-12. The association between smoking and all melanoma (invasive and in situ) 
 
Parameter Number of 
Cases 
Total cohort  
 
HR
1
 (95% CI) 
Males  
 
HR
1
 (95% CI) 
Females  
 
HR
1
 (95% CI) 
Smoking status     
Never smoker
2 
374 1.00 1.00 1.00 
Ever smoker  267 0.85 (0.73-1.01) 0.91 (0.74-1.12) 0.75 (0.58-0.97) 
Ex-smoker  219 0.86 (0.72-1.02) 0.90 (0.72-1.12) 0.77 (0.58-1.02) 
Current smoker 48 0.84 (0.62-1.12) 0.95 (0.65-1.39) 0.68 (0.41-1.14) 
p-value   0.2 0.7 0.1 
Age (years) at starting smoking      
Never  374 1.00 1.00 1.00 
≤16 97 0.71 (0.56-0.90) 0.69(0.44-1.09) 0.63 (0.41-0.97) 
>16 164 0.95 (0.79-1.15) 1.03 (0.70-1.53) 0.81 (0.60-1.10) 
p-value
3 
 0.02 0.03 0.3 
Duration (years) of smoking     
Never  374 1.00 1.00 1.00 
≤10 56 0.87 (0.65-1.15) 0.92 (0.64-1.34) 0.79 (0.50-1.23) 
11-20 63 0.88 (0.67-1.15) 0.93 (0.66-1.31) 0.77 (0.48-1.24) 
21-30 59 0.91 (0.69-1.21) 0.95 (0.67-1.33) 0.85 (0.53-1.38) 
>30 82 0.77 (0.60-0.99) 0.85 (0.63-1.15) 0.60 (0.38-0.96) 
p-trend
3 
 0.4 0.6 0.5 
Intensity of smoking 
(cigarettes/day) 
    
Never 374 1.00 1.00 1.00 
≤10 75 0.90 (0.70-1.15) 0.97 (0.69-1.36) 0.82 (0.57-1.17) 
11-20 114 0.87 (0.70-1.08) 0.92 (0.71-1.21) 0.77 (0.53-1.12) 
>20 67 0.74 (0.56-0.96) 0.80 (0.59-1.09) 0.58 (0.33-1.02) 
p-trend
3 
 0.1 0.3 0.3 
Pack-years of smoking     
Never 374 1.00 1.00 1.00 
≤10 83 0.91 (0.71-1.15) 0.87 (0.62-1.21) 0.94 (0.67-1.33) 
11-20 52 0.82 (0.61-1.09) 1.05 (0.75-1.48) 0.39 (0.20-0.77) 
21-30 51 1.07 (0.79-1.44) 1.10 (0.76-1.59) 1.06 (0.63-1.77) 
>30 68 0.69 (0.52-0.89) 0.74 (0.54-1.01) 0.56 (0.33-0.97) 
p-trend
3 
 0.08 0.2 0.3 
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Parameter Number of 
Cases 
Total cohort  
 
HR
1
 (95% CI) 
Males  
 
HR
1
 (95% CI) 
Females  
 
HR
1
 (95% CI) 
Years since quitting (past smokers) 
Never  374 1.00 1.00 1.00 
≤10 40 0.73 (0.53-1.02) 0.82 (0.55-1.24) 0.59 (0.32-1.08) 
11-20 51 0.92 (0.68-1.24) 0.99 (0.68-1.44) 0.80 (0.48-1.33) 
21-30 66 0.89 (0.68-1.17) 0.86 (0.61-1.21) 0.93 (0.61-1.42) 
>30 59 0.88 (0.68-1.16) 0.96 (0.69-1.33) 0.59 (0.31-1.09) 
p-trend
3 
 0.5 0.6 0.7 
 
1
Models were adjusted for age, sex, natural skin colour, tanning tendency, number of moles at age 21, history of skin cancer surgically removed, past history of skin cancer 
destructively removed, history of sunburn as a child, cumulative sun exposure and family history of melanoma. 
2‘Never smoker’ was the reference category for all analyses. 
3
p-Trend values do not include reference group (p-value for the exact Cochran-Armitage trend test). 
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Table 4-13. The association between smoking and invasive melanoma –sensitivity analyses 
around the treatment of in situ melanoma arising during follow-up 
 
Parameter Sensitivity Analysis 1:  
Ignore in situ melanoma during 
follow-up 
 
HR
1
 (95% CI) 
Sensitivity Analysis 2: 
treating in situ melanoma as time 
varying covariate 
 
HR
1
 (95% CI) 
Smoking status   
Never smoker
2 
1.00 1.00 
Ever smoker  0.81 (0.62-1.04) 0.81 (0.63-1.05) 
Ex-smoker  0.76 (0.58-1.01) 0.76 (0.58-1.01) 
Current smoker 1.04 (0.66-1.63) 1.04 (0.67-1.64) 
p-value  0.1 0.1 
Age (years) at starting smoking    
Never  1.00 1.00 
≤16 0.61 (0.41-0.91) 0.62 (0.42-0.91) 
>16 0.96 (0.72-1.28) 0.96 (0.72-1.28) 
p-value
3 
0.04 0.04 
Duration (years) of smoking   
Never  1.00 1.00 
≤10 0.97 (0.63-1.49) 0.98 (0.63-1.51) 
11-20 0.98 (0.65-1.47)  0.98 (0.65-1.47) 
21-30 0.59 (0.35-1.02) 0.60 (0.35-1.02) 
>30 0.72 (0.48-1.07) 0.72 (0.48-1.08) 
p-trend
3 
0.1 0.1 
Intensity of smoking (cigarettes/day)   
Never 1.00 1.00 
≤10 1.15 (0.80-1.64) 1.16 (0.81-1.65) 
11-20 0.78 (0.55-1.10) 0.78 (0.55-1.11) 
>20 0.52 (0.32-0.84) 0.52 (0.32-0.85) 
p-trend
3 
0.001 0.001 
Pack-years of smoking   
Never 1.00 1.00 
≤10 1.01 (0.71-1.46) 1.02 (0.71-1.47) 
11-20 0.73 (0.45-1.19) 0.73 (0.45-1.19) 
21-30 1.04 (0.65-1.67) 1.03 (0.42-1.66) 
>30 0.56 (0.35-0.88) 0.56 (0.35-0.88) 
p-trend
3 
0.02 0.02 
Years since quitting (past smokers)   
Never  1.00 1.00 
≤10 0.36 (0.17-0.77) 0.35 (0.16-0.76) 
11-20 0.80 (0.48-1.33) 0.80 (0.48-1.33) 
21-30 0.73 (0.47-1.16) 0.73 (0.46-1.16) 
>30 1.08 (0.72-1.61) 1.08 (0.72-1.62) 
p-trend
3 
0.02 0.02 
1
Models were adjusted for age, sex, natural skin colour, tanning tendency, number of moles at age 21, history 
of skin cancer surgically removed, history of skin cancer destructively removed, history of sunburn as a child, 
cumulative sun exposure and family history of melanoma. 
2‘Never smoker’ was the reference category for all analyses. 
3
p-Trend values do not include reference group (p-value for the exact Cochran-Armitage trend test). 
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DISCUSSION 
We investigated the association between cigarette smoking and incidence of melanoma in a 
prospective cohort study of more than 38,000 participants. We found no evidence that smoking 
increases the risk of melanoma; indeed, our analysis suggests that former smokers may have lower 
risks of melanoma than never smokers, although this assessment is offered cautiously.  Overall, the 
inverse association was apparent among former smokers but not in current smokers, and although 
not always statistically significant, the reductions in risk in former smokers appeared greater with 
longer durations or greater intensity of smoking. Taken together, these headline findings are similar 
to those from previous cohort studies [348, 361, 362] and meta-analyses [263, 265] which have 
mostly reported moderately lower risks of melanoma among smokers. We observed non-significant 
dose response trends; smoking intensity and duration decreased the risk whereas longer time since 
quitting was associated with a relative risk of melanoma that was not significantly different from 
the null. Again, these observations are consistent with previous studies which reported diminished 
risks of invasive melanoma with longer durations of smoking and greater quantity of tobacco 
smoked [263, 361].  
 
We explored whether these findings might be explained by the confounding effects of other factors, 
since in this cohort, smoking was significantly associated with a large number of factors that are 
known to influence a person’s risk of melanoma (including sex, education, private health insurance, 
pigmentation phenotypes, burning and tanning tendency, and history of prior actinic skin damage 
and sun exposure). We therefore adjusted for these factors in our analyses, but risk estimates 
changed little between minimally adjusted and fully adjusted models. Recall bias is unlikely since 
smoking exposures were captured prior to melanoma development and in the 3 years of follow-up, 
smoking status is unlikely to have changed appreciably. Loss to follow-up is also unlikely to 
explain these findings as notifications to the cancer registry are mandatory in Queensland, and 
registration is virtually complete. It has been suggested previously that the inverse associations 
between smoking and melanoma in cohort studies might be explained by competing risks of deaths 
from smoking-related diseases [368]. In a simulation study, it was argued that smokers are at 
increased risk of acquiring various smoking-related diseases, and thus may die at younger ages 
before being diagnosed with age-dependent conditions such as melanoma. This explanation was 
certainly possible in our dataset, as we observed a substantially higher cumulative mortality among 
current smokers compared with never smokers (2.6% vs 0.7% respectively). We therefore 
conducted a competing risks analysis to account for this effect but observed that the inverse 
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relationship between smoking and melanoma was essentially unchanged.  However, in spite of very 
high repeatability of smoking measures in this cohort [321], we cannot completely exclude the 
possibility of residual confounding due to measurement error. For example, our repeatability study 
showed a moderate-to-high agreement for measures of phenotypic characteristics whereas measures 
of sun exposure had lower levels of agreement.  
 
The key question is whether the observed inverse association reflects a “protective effect” of 
smoking on development of melanoma, or whether there are alternative non-causal explanations. It 
is likely that never smokers have more medical surveillance and earlier detection of disease 
compared with smokers as a consequence of a generally healthier lifestyle [359]. In our dataset, a 
greater proportion of never smokers than ever smokers self-reported that they had undergone a skin 
screening examination by a doctor in the 3 years prior to enrolment (75% vs 66% respectively). 
Thus, it is possible that increased opportunities for melanoma detection contributed to a higher 
incidence of melanoma amongst never smokers, thereby creating a spurious inverse association 
with smoking status [369]. We have previously found evidence for such an effect for basal cell 
carcinomas in this cohort, but not for squamous cell carcinomas [359]. Longer follow-up of the 
cohort would resolve this question, since invasive melanomas would eventually come to clinical 
attention, even among people with low health awareness.  
 
If confounding and bias do not fully explain the inverse associations, then potential biological 
mechanisms ought to be considered for completeness. Nicotine, one of the constituents of tobacco 
smoke, has anti-inflammatory properties [370, 371] and nicotine administration via a transdermal 
delivery system suppresses the cutaneous responses to known inflammatory stimuli such as UV-B 
[372]. Moreover, a recent Mendelian randomisation study tested whether smoking-related genetic 
variants were associated with melanoma risk and found inverse associations with variants located 
on chromosome 15q25.1 [373]. While this intriguing finding is outwardly supportive of the inverse 
associations we observed, that study suffered from limited sample size and multiple testing, and so 
cautious interpretation is required. Despite these speculations, the discordant associations we 
observed for current and former smoking run counter to any biological mechanism of which we can 
conceive and suggest that the observed associations are explained by other factors. 
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Our study has some limitations. Follow-up duration was short, and the number of melanoma cases 
was limited, so some analyses were constrained by sample size, particularly in current smokers who 
represented a small proportion of the overall study population. For example, we could not stratify 
our analysis by history of skin checks or melanoma thickness. While QSkin shares several design 
features with previous studies, such as large sample size and complete follow-up through data 
linkage, the cohort is unique in having been purpose-designed to investigate skin cancer and having 
sampled participants from the general population. At baseline, we collected comprehensive data on 
key phenotypic and sun exposure variables, allowing greater control of potential confounding than 
earlier prospective investigations. Finally, we used a variety of statistical techniques to explore in 
more detail possibly complex associations between smoking and melanoma (i.e. modelling 
simultaneously several dimensions of smoking) and excluding possible bias from competing risks 
of death. These new data therefore extend the insights gained from previous studies, and resolve 
some (but not all) of the uncertainties in this association. 
 
In summary, we found no evidence that cigarette-smoking increases the risk of cutaneous 
melanoma. The inconsistent findings relating to current and former smokers, and the mixed 
evidence regarding dose-response relationships, make the interpretation of these results difficult and 
argues against biological effects. We infer that the observed lower risk of melanoma associated with 
smoking is probably due to some residual confounding as well as some surveillance bias among 
never-smokers. However, a possible biological effect cannot be completely ruled out. Even if 
melanoma risks were confirmed to be lower among smokers however, there would be no 
justification in advocating smoking on “preventive” grounds given the well-documented adverse 
health effects.  
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5 Body mass index and risk of cutaneous melanoma 
5.1 Introduction  
This chapter discusses the association between obesity (estimated by BMI) and risk of developing 
first invasive melanoma using three separate epidemiological analytical methods. We analysed new 
data from a large prospective cohort study, summarised evidence from prospective observational 
studies and conducted Mendelian randomisation analyses.  
 
Dusingize JC, Olsen CM, An J, Pandeya N, Law MH, Thompson BS, Goldstein AM, Iles MM, 
Webb PM, Neale RE, Ong JS, MacGregor S, Whiteman DC. Body mass index and risk of 
cutaneous melanoma: Evidence from Observational and Mendelian randomisation analyses.  
 
5.2 Contribution of Candidate 
My contribution to this manuscript included the conception and design of the study under guidance 
of my supervisors. I conducted the systematic search of the studies included in the meta-analysis 
and was responsible for the qualitative assessment of the eligible studies. I developed the data 
analysis plan and performed all statistical analyses including the dose-response meta-analyses and 
Mendelian randomisation analyses with the help from JSO, NP and CMO. I wrote the first draft of 
the manuscript and was responsible for incorporating all comments and suggestions from all co-
authors.  I participated in the peer review process by preparing the final draft of the manuscript and 
submitted it to the journal for publication. 
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5.3 Manuscript: Body mass index and risk of cutaneous melanoma: Evidence from 
Observational and Mendelian randomisation analyses 
ABSTRACT  
Epidemiological studies report inconsistent associations between obesity and cutaneous melanoma, 
with some studies suggesting increased risks among obese men but not women. We conducted three 
separate analyses to test whether obesity (as determined by body mass index (BMI) is related to 
melanoma. We first evaluated the association between BMI and melanoma using data from a 
population-based prospective study of skin cancer consisting of 37,523 Australian men and women 
(QSkin). Subsequently, we summarised findings from 14 prospective cohort studies (including 
QSkin) with nearly 2.5 million participants and over 17,000 cases. Finally, we used summary data 
from recent GWAS meta-analyses of BMI and melanoma to perform Mendelian randomisation 
(MR) analyses. In the QSkin cohort, the hazard ratio (HR) per 5 kg/m
2
 increase in BMI was 1.08; 
95% CI: 0.96-1.22. The pooled relative risk of melanoma was 1.00; 95% CI: 0.98-1.02 per 5 kg/m
2
 
increase in BMI in the meta-analysis of prospective observational studies. In both analyses, we 
found no difference between men and women. In MR analysis, the odds ratio for risk of melanoma 
per 1SD increase in genetically predicted BMI (1 SD=4.6 kg/m
2
) was 1.00; 95% CI: 0.91-1.11. 
Three separate analyses using a combination of approaches, found little evidence that obesity alter 
risk of cutaneous melanoma.  
 
INTRODUCTION  
Obesity is a complex phenotype with many physiological and pathological sequelae. Increasingly, 
obesity is recognised as a risk factor for cancer at a number of different sites where it is 
hypothesised to act through hormonal and inflammatory pathways [131, 374]. With regards to 
cutaneous melanoma (hereafter referred to as melanoma), findings from two meta-analyses that 
synthesized results from prospective [observational] cohort and case-control studies consistently 
reported associations between obesity, as measured by BMI, and melanoma among men but not 
women [129, 293]. It remains unclear whether these associations represent a true causal relationship 
or are explained by bias or confounding by other factors. For example, many epidemiological 
studies rely on self-reported weight and height measurements which are subject to sex-specific 
misclassification [294, 295].  Obesity may also be associated with other unknown or unmeasured 
lifestyle factors, and the possibility of residual confounding by such factors remains as a limitation 
of all observational studies.  
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One approach to circumvent threats to validity found in conventional observational studies is to 
conduct instrumental variable analyses using genetic variants as proxy markers for modifiable risk 
factors, a technique commonly known as Mendelian randomisation (MR) [335]. MR uses genetic 
variants associated with a modifiable exposure or biological intermediate to estimate effects on the 
outcome [336]. Because a person's genotype is randomly assigned at conception, according to 
Mendel’s law of independent assortment, genetic variants that are associated with BMI are less 
likely to be confounded by other traits, with reverse causality ruled out because disease status 
cannot alter germline genotype [334]. The MR approach is analogous to a “natural” randomised 
controlled trial in which the distribution of known and unknown confounders is randomly 
distributed across different treatment arms.  
 
The overall aim of this study was to investigate the association between BMI and melanoma risk 
using new data from QSkin [320], a large Australian population-based prospective cohort study 
purpose-designed to investigate skin cancer outcomes, and to summarise evidence from previous 
prospective observational studies by updating the most recent meta-analysis [293]. Furthermore, we 
sought to evaluate whether findings from observational studies were compatible with estimates 
obtained through MR using summary data from a newly published BMI genome-wide association 
study (GWAS) meta-analysis [303] and from a large melanoma GWAS meta-analysis [375].  
 
METHODS 
The QSkin sun and health study 
The QSkin Sun and Health Study is a population-based cohort consisting of 43,794 men and women 
aged between 40-69 years who were randomly sampled from the electoral roll (voter registration in 
mandatory) in 2010-2011. Full details of the study participants’ recruitment process and methods 
have been described elsewhere [320]. We restricted our analysis to participants of European descent 
with no prior diagnosis of in situ or invasive melanoma, leaving 37,523 for analysis. 
 
Exposure measurement 
Eligible participants were invited to complete a self-reported questionnaire which captured 
information on demographic characteristics, general medical history and skin cancer risk factors. 
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Participants also self-reported anthropometric information including weight and height 
measurements with high reproducibility (weighted kappa, 95% CI: 0.99, 0.99-0.99 for height and 
0.98, 0.97-0.99 for current weight) [321]. BMI was calculated as weight in kilograms divided by 
height in meters squared. In all analyses we used 18.5 ≤ BMI < 25 as reference group and defined 
participants with a BMI of 30 or more as obese in accordance to the World Health Organization’s 
criteria [376].  
 
Follow up 
Melanoma cases were ascertained through record linkage to Queensland Cancer registry from date 
of enrolment (2010-2011) through 30 June 2014.  Deaths that occurred in the cohort during follow-
up were identified through linkage with the National Death Index.  
 
Statistical analysis  
We estimated the average effect of a 5 kg/m² increase in BMI on melanoma risk using the Fine-
Gray model, accounting for death that occurred during follow-up as competing risk event. 
Participants were followed from the date of consent up until the first histologically confirmed 
invasive melanoma, or date of death or the end of follow up (June 30, 2014), whichever occurred 
first.  
 
 Initially, we performed analyses adjusted for age at BMI record and sex only, and then examined 
the estimates from fully adjusted models, with BMI as a continuous linear term to estimate the 
average effect of a 5 kg/m² increase in BMI on melanoma risk.  We selected potential confounders 
based on directed acyclic graphs (DAGs). Our final multivariable models were adjusted for age, 
sex, smoking, natural skin colour, tanning tendency, number of moles at age 21, history of excised 
skin cancers, history of destructive skin cancer treatments, family history of melanoma, history of 
sunburn as a child and cumulative lifetime sun exposure.  
 
We used multiple imputations (20 imputations) to account for potential bias due to the large number 
of missing values for BMI and other covariates included in the multivariable model (~5000 missing 
observations). However, the imputation model made negligible difference; hence estimates from 
complete case analysis were presented. We assessed for possible nonlinear associations using 
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generalised additive models (GAMs) with restricted cubic splines fixed at 3 degrees of freedom.  
These analyses were conducted using SAS 9.4 software (SAS Institute, Cary, NC) and R for non-
linear models.  
 
Meta-analysis of prospective studies 
Search strategy and study selection 
We identified published prospective observational studies reporting on the association between 
BMI and risk of invasive cutaneous melanoma among men and women of European ancestry up to 
December 2017. Firstly, we identified and retrieved prospective cohort studies reported by 
Sergentanis and colleagues [293] on the association between BMI and melanoma risk. The search 
strategies employed by Sergentanis et al. retrieved all scientific studies published through 31
st
 
October 2011. Secondly, we replicated the search strategies employed by Sergentanis et al. to 
retrieve studies published from January 2010 through to December 2017.   
 
Our literature search was limited to prospective studies and no restriction on participants’ sex or 
language was used. When studies reported on overlapping study populations, the largest was 
eligible for inclusion in meta-analysis. To be consistent with the Mendelian randomisation analysis, 
we excluded studies that included participants of non-European descent. In addition, studies that did 
not report risk estimates for at least 3 categories of BMI were excluded from the dose-response 
meta-analysis. Finally, in addition to published observational studies, we included the new data 
from the QSkin cohort. 
 
Meta-analysis  
We performed a dose-response meta-analysis using the natural logarithm of risk ratios per 5 kg/m
2
 
of BMI for studies that reported risk estimates per unit of BMI. However, in most studies, risk 
estimates were reported for several categories of BMI with one class serving as reference group. To 
convert risk ratios per BMI category to risk ratios per unit of BMI, we applied the methods 
proposed by  Greenland and Longnecker [377] and Orsini et al [378] which estimate study-specific 
slopes from the natural logarithm of risk estimates across categories of BMI assuming a linear 
relationship. The method requires that the distribution of participants or person-years and risk 
estimates and its corresponding standard errors for at least three categories of BMI are reported. For 
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studies that did not report the distribution of cases and total people at risk or person-years within 
each stratum of BMI [132, 379] we used the variance-weighted least-squares regression models 
[380] to estimate the slopes.  
 
For each study, we assigned a single score (dose) to each category of BMI corresponding to the 
mean or median where this information was available. If mean or median were not reported, we 
used the midpoint of upper and lower boundaries for close-ended categories. For open ended 
categories, the score was assigned following the algorithms suggested by Il’yasova et al [381] 
assuming a normal distribution of BMI. The natural logarithm of relative risk per unit of BMI was 
derived using the publicly available  SAS macro (%metadose)  for meta-analysis of linear 
relationship [378]. Moreover, we assessed for nonlinear dose-response both graphically and also 
through formal statistical tests using flexible restricted cubic splines.  
 
We pooled risk estimates for each 5 kg/m
2
 increase in BMI by use of random effect model [329].  
We used the Cochran’s Q statistic to test for statistical heterogeneity [330], and I2 statistic to 
quantify heterogeneity across studies [331] . To account for potential biases arising from possible 
differences in sunlight exposure, we performed sensitivity analysis restricted to studies that reported 
estimates adjusted for the potential confounding effect for at least one measure of sun exposure 
such as ultraviolet radiation exposure level, hours per week spent outdoors, history of sunburn as a 
child or cumulative lifetime sun exposure. Furthermore, we performed a second sensitivity analysis 
restricted to studies that reported risk estimates from measured BMI as opposed to self-reported.  
Begg’s and Egger’s approaches were used to assess for potential publication biases [382, 383]. The 
meta-analysis was conducted using Stata 15.1.   
 
Mendelian randomisation   
Mendelian randomisation (MR) is a technique that uses genetic variants as instrumental variables 
(IVs) to estimate effects between an exposure and outcome [332]. As a result of growing 
availability of summary data from the genome-wide association studies (GWAS), there is 
increasing number of genetic variants for a wide range of outcomes and exposures allowing valid 
instrument to be identified. To be used as a valid BMI IV, a genetic variant must satisfy 3 
fundamental MR assumptions: 1) The instrument must be associated with measured BMI, 2) the 
BMI associated SNPs must not be associated with confounding factors of measured BMI and 
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melanoma, and 3) BMI associated SNPs must be associated with melanoma only via their 
association with measured BMI (exclusion restriction assumption) [336]. In contrast to traditional 
2-stage least squares MR whereby individual level genotype and phenotype data are obtained from 
the same sample, we used a two-sample MR strategy in which SNP exposure and SNP outcome 
from non-overlapping samples [384]. The two-sample MR approach leverages higher statistical 
power by allowing inference of causality using BMI genetic predictors to infer the relationship of 
BMI on a separate outcome sample of which information on BMI might had not been available in 
those samples. 
 
Instrumental variables  
Genetic summary data were obtained from the largest 2018 GWAS meta-analysis of BMI from the 
Genetic Investigation of Anthropometric Traits (GIANT) consortium [303].  
 
Here we used genome-wide SNPs identified from the latest BMI GWAS meta-analysis combining 
data from the 2015 BMI GWAS meta-analysis consisting of ~250,000 participants, and the new 
GWAS of BMI in ~450,000 participants in the UK Biobank (UKB), totalling up to ~700,000 
participants of European descendent. 
 
Simultaneously, we performed a GWAS to obtain genetic instruments for BMI among cancer-free 
white-British participants within UK Biobank only. First, we used a similar definition outlined 
previously [385] to identify UKBB participants with White-British ancestry. Measurement of BMI 
for UKB participants were recorded under data-field ID: 21001, where BMI is defined as the weight 
(in kilograms) divided by the square of standing height (in meter-squared). For UKB individuals 
reporting BMI at multiple instances/visits, the average was used. Next, we removed any individual 
previously diagnosed with cancer in the BMI GWAS to ensure that our calibration of instruments 
was not affected by reverse causality. The UKB BMI GWAS was performed using BOLT-LMM 
v2a, a linear mixed model framework put in place to account for genetic relatedness among the 
cohort. 
 
Measurement of BMI for UK Biobank (UKBB) participants were recorded under data-field ID: XX, 
where BMI is defined as the weight (in kilograms) divided by the square of standing height (in 
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meters
2
). For individuals reporting BMI at multiple instances/visits, the average was used. To 
ensure that our calibration of instruments is not affected by reverse causality, we removed any 
person with previously diagnosed with cancer in the BMI GWAS. The UKB BMI GWAS was 
performed using BOLT-LMM v2a, a linear mixed model framework put in place to account for 
genetic relatedness among the cohort. Summary statistics generated from the GWAS were then used 
for meta-analysis with the existing GIANT BMI GWAS by Locke et al. (2015). The new GWAS 
meta-analysis combined data from the 2015 BMI GWAS meta-analysis [21] consisting of ~250,000 
participants, and the new GWAS of BMI in ~450,000 participants in the UK Biobank (UKB) as 
described earlier, totalling up to ~700,000 participants of European descendent. We extracted data 
on major and minor alleles for each SNP together with their frequencies, beta coefficients, p-values 
and standard errors.   
 
The large number of SNPs obtained were then clumped to obtain a set of independent variants 
associated with BMI at the genome-wide significance level (p-value < 5 × 10-8). Independent SNPs 
were those in linkage disequilibrium (r
2
 < 0.001) or within 10,000 kb physical distance based on a 
reference dataset (1000 Genomes Project; http://www.internationalgenome.org/).  
 
Association of BMI genetic variants with cutaneous melanoma 
 GWAS summary statistics on melanoma were obtained from the most recent meta-analysis of 
GWAS on melanoma which included 12,874 cases and 23,203 controls from 11 independent 
GWAS in people of European ancestry [375]. For each identified BMI SNP instrument, we 
extracted per allele log OR of melanoma together with its SE and allele frequency from the 
melanoma GWAS meta-analysis. Nineteen BMI SNPs had palindromic strands which could not be 
inferred with allele frequency information (MAF>0.3) and hence were excluded from our analysis. 
 
Two-sample Mendelian randomisation methods 
The association between BMI and melanoma was performed using the Wald-type ratio estimator 
[337]. The 95% confidence intervals (95% CIs) were calculated from the SE of each Wald ratio. 
Individual Wald ratios were combined across all instruments using the fixed-effect inverse 
variance-weighted method (IVW) outlined in Burgess et al [337]. This method assumes that all 
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variants are valid IVs and satisfy IV assumptions. We tested for heterogeneity in Wald ratios using 
Cochran's Q statistic [386].  
 
As the IVW method assumes no horizontal pleiotropy for all SNPs (the effect of genetic variants on 
the outcome operates entirely via exposure) we carried out sensitivity analyses using MR-Egger 
regression. MR-Egger regression is similar to IVW except that the intercept is not constrained to 
pass through the origin [387], with non-zero intercept suggesting possibility of directional 
pleiotropy. In addition to the MR-Egger method, the pleiotropic effect was evaluated using the 
weighted median estimator [388]. This method offers the advantage of estimating the effect even if 
half of the variants are invalid instruments.  
 
Finally, because deriving instruments from datasets which include melanoma cases can conceivably 
induce bias in the causal odds ratios, we performed analysis restricted to 390,628 cancer-free white-
British participants with BMI data in UKBB only. Moreover, a separate analysis restricted to 79 
common genetic variants that were associated with BMI at  the genome-wide significance level  in 
the GIANT consortium in studies of up to 339 224 people from European ancestry [389] was 
conducted. R version 3.3.4 and MR-base [390] were used for this analysis. 
 
RESULTS 
Association between BMI and melanoma in the QSkin Study 
During an average follow-up of 3.5 years (minimum 2.4 years, maximum 3.6 years), 249 incident 
melanoma cases were identified in the QSkin cohort. For the total cohort, the mean age at baseline 
was 56 years; 54% were females. The mean BMI was 27.6 kg/m
2
; 39% of participants were 
overweight and 27% were obese [Table 5-1]. In multivariable-adjusted models, we found no 
association between higher BMI and risk of melanoma for both continuous and categorical 
measures of BMI. The hazard ratio (HR) per 5 kg/m
2
 increase in BMI was 1.08; 95% CI: 0.96-1.22 
[Table 5-2] and this association did not differ between men and women (p interaction = 0.3). When 
we examined the association across categories of BMI, we saw inconsistent associations that varied 
in magnitude and direction, but all were statistically non-significant. We found no evidence of non-
linear dose-response relationships between BMI and melanoma in either sex [Figure 5-1] and 
[Figure 5-2].  
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Table 5-1. Baseline characteristics of QSkin study participants by BMI categories (n=37,523). 
 
Parameter  Total 
(n=37,523)
1 
N (%)
 
Normal weight 
(n=12,774) 
N (%) 
Overweight 
(n=14687) 
N (%) 
Obese 
(n=10,062) 
N (%) 
 
Age at entry (years), Mean (SD) 55.9 (8.1) 55.1 (8.3) 56.3 (8.1) 56.6 (7.9) 
BMI (kg/m
2
), Mean (SD) 27.6 (5.4) 22.5 (1.8) 27.3 (1.4) 34.4 (4.7) 
Age group     
40-49 10051 (26.8) 3946 (30.9) 3731 (25.4) 2374 (23.6) 
40-59 14263 (38.0) 4786 (37.5) 5553 (37.8) 3924 (39.0) 
60-69 13209 (35.2) 4042 (31.6) 5403 (36.8) 3764 (37.4) 
Sex     
Females 20185 (53.8) 8483 (66.4) 6321 (43.0) 5381 (53.5) 
Males 17338 (46.2) 4291 (33.6) 8366 (57.0) 4681 (46.5) 
Smoking     
Current  3503 (9.3) 1423 (11.1) 1252 (8.5) 828 (8.2) 
Former  13534 (36.1) 3886 (30.4) 5562 (37.9) 4086 (40.6) 
Never  20348 (54.2) 7422 (58.1) 7819 (53.2) 5107 (50.8) 
Missing 138 (0.4) 43 (0.3) 54 (0.4) 41 (0.4) 
Further Education     
No school certificate 2798 (7.5) 748 (5.9) 984 (6.7) 1066 (10.6) 
School certificate 5738 (15.3) 1797 (14.1) 2200 (15.0) 1741 (17.3) 
Completed high school 6819 (18.2) 2268 (17.8) 2588 (17.6) 1963 (19.5) 
Trade/certificate/diploma 10589 (28.2) 3401 (26.6) 4353 (29.6) 2835 (28.2) 
University degree 8923 (23.8) 3712 (29.1) 3461 (23.6) 1750 (17.4) 
Missing 2656 (7.1) 848 (6.6) 1101 (7.5) 707 (7.0) 
Burning tendency     
No burns 3228 (8.6) 1065 (8.3) 1242 (8.5) 921 (9.2) 
Burns a little 16186 (43.1) 5449 (42.7) 6421 (43.7) 4316 (42.9) 
Burns moderately 12664 (33.7) 4378 (34.3) 5040 (34.3) 3246 (32.3) 
Burns badly 5258 (14.0) 1814 (14.2) 1922 (13.1) 1522 (15.1) 
Missing 187 (0.5) 68 (0.5) 62 (0.4) 57 (0.6) 
Freckles on face as teenager     
None 17355 (46.3) 5594 (43.8) 6962 (47.4) 4799 (47.7) 
A few 11832 (31.5) 4148 (32.5) 4662 (31.7) 3022 (30.0) 
Some 5866 (15.6) 2178 (17.1) 2157 (14.7) 1531 (15.2) 
Many 2288 (6.1) 786 (6.2) 843 (5.7) 659 (6.5) 
Missing 182 (0.5) 68 (0.5) 63 (0.4) 51 (0.5) 
Moles on skin as a teenager     
None 10346 (27.6) 3154 (24.7) 4203 (28.6) 2989 (29.7) 
A few 19570 (52.2) 6966 (54.5) 7564 (51.5) 5040 (50.1) 
Some 5513 (14.7) 1928 (15.1) 2124 (14.5) 1461 (14.5) 
Many 1126 (3.0) 435 (3.4) 428 (2.9) 263 (2.6) 
Missing 968 (2.6) 291 (2.3) 368 (2.5) 309 (3.1) 
Sunburns as a child     
Never 7000 (18.7) 2539 (19.9) 2639 (18.0) 1822 (18.1) 
1-5 15538 (41.4) 5427 (42.5) 6133 (41.8) 3978 (39.5) 
6-10 6058 (16.1) 2025 (15.9) 2392 (16.3) 1641 (16.3) 
11+ 5458 (14.5) 1661 (13.0) 2168 (14.8) 1629 (16.2) 
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Parameter  Total 
(n=37,523)
1 
N (%)
 
Normal weight 
(n=12,774) 
N (%) 
Overweight 
(n=14687) 
N (%) 
Obese 
(n=10,062) 
N (%) 
 
Missing 3469 (9.2) 1122 (8.8) 1355 (9.2) 992 (9.9) 
History of skin cancers surgically 
treated 
    
No 22769 (60.7) 7953 (62.3) 8782 (59.8) 6034 (60.0) 
Yes 14499 (38.6) 4747 (37.2) 5810 (39.6) 3942 (39.2) 
Missing  255 (0.7) 74 (0.6) 95 (0.6) 86 (0.9) 
AKs/skin cancers treated destructively     
None 16710 (44.5) 5742 (45.0) 6327 (43.1) 4641 (46.1) 
1-5 10106 (26.9) 3651 (28.6) 3879 (26.4) 2576 (25.6) 
6-10 10540 (28.1) 3324 (26.0) 4420 (30.1) 2796 (27.8) 
Missing 167 (0.4) 57 (0.4) 61 (0.4) 49 (0.5) 
Family history of melanoma     
No 23444 (62.4) 8219 (64.3) 9288 (63.2) 5937 (59.0) 
Yes 8634 (23.1) 2965 (23.2) 3296 (22.4) 2373 (23.6) 
Missing 5445 (14.5) 1590 (12.5) 2103 (14.3) 1752 (17.4) 
Abbreviations: AK, actinic keratoses; SD, standard deviation. 
1
Numbers may not sum to total because of missing data  
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Table 5-2. Hazard ratios (HRs) and 95% confidence intervals (CIs) of cutaneous melanoma 
according to body mass index in the QSkin cohort study 
 
 
1
Adjusted for age and sex or age 
2
Adjusted for age, sex, smoking, natural skin colour, tanning tendency, moles on skin as teenager, history of excised 
skin cancers, past history of destructive skin cancer treatments, family history of melanoma, history of sunburn as a 
child and cumulative lifetime sun exposure. 
 
 
  
Parameter Cases/ Person-Years 
Total cohort 
N= 37,523 
Males 
N= 17,338 
Females 
N= 20,185 
Minimally adjusted model
1     
Continuous (per 5kg/m
2
) 249/ 131246 1.01 (0.89-1.13) 1.04 (0.89-1.21) 0.98 (0.83-1.16) 
BMI < 18.5 4/1260 2.23 (0.81-6.09) 2.29 (0.31-16.64) 2.15 (0.67-6.94) 
18.5 ≤ BMI < 25 64/ 43442 1.00 1.00 1.00 
25.0 ≤ BMI <30 112/ 51393 1.25 (0.93-1.71) 1.42 (0.92-2.18) 1.09 (0.69-1.71) 
BMI ≥30 69/ 35151 1.16 (0.83-1.63) 1.14 (0.69-1.87) 1.23 (0.77-1.95) 
Fully adjusted model
2     
Continuous (per 5kg/m
2
) 249/ 131246 1.08 (0.92-1.26) 1.09 (0.92-1.28) 1.07 (0.89-1.29) 
BMI < 18.5 4/1260 2.04 (0.49-8.47) 3.78 (0.49-28.9) 1.45 (0.19-10.61) 
18.5 ≤ BMI < 25 64/ 43442 1.00 1.00 1.00 
25.0 ≤ BMI <30 112/ 51393 1.32 (0.91-1.91) 1.43 (0.88-2.32) 1.09 (0.58-2.04) 
BMI ≥30 69/ 35151 1.31 (0.87-2.06) 1.21 (0.68-2.18) 1.51 (0.79-2.92) 
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Figure 5-1. Nonlinear relation of BMI and risk of melanoma for men 
The solid line represents log hazard, and the dashed line represents its 95% confidence Intervals 
 
 
 
Figure 5-2. Nonlinear relation of BMI and risk of melanoma for women 
The solid line represents log hazard, and the dashed line represents its 95% confidence Intervals 
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Dose response meta-analysis of the association between BMI and melanoma risk  
We identified 19 previous prospective studies investigating the relationship between BMI and 
melanoma. [Figure 5-3]. Six studies were excluded because they reported risk estimates for fewer 
than 3 categories of BMI [391-393], reported estimates including participants of non-European 
descent [394], or reported on overlapping study populations [361, 395]. With the addition of the 
new estimates from the QSkin study [Table 5-2], a total of 14 studies (11 in men and 13 in women) 
involving 17,546 incident melanoma cases in a total population of 2,474,894 participants of 
European ancestry were included in the meta-analysis.  
 
Figure 5-3. PRISMA flow chart for studies included in the meta-analysis of BMI and 
melanoma 
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All studies were published between 2003 and 2017 with a follow-up duration ranging from 3.5 to 
43 years [Table 5-3]. The results of the dose-response meta-analyses for men and women are 
presented in [Figure 5-4]. For all people (i.e. men and women combined), the overall association 
between BMI and melanoma was null; the summary RR per 5 kg/m
2
 increase in BMI was 1.00; 
95% CI: 0.98-1.02. There was no evidence of a non-linear dose-response relationship between BMI 
and melanoma in men (p=0.4) while a weak non-linear association was found in women (p=0.06) 
[Figure 5-5] and [Figure 5-6].  We observed strong evidence of heterogeneity across studies 
(Pheterogeneity < .001, I2 = 70% in women and Pheterogeneity =0.002, I2 = 64% in men).  
 
To examine potential sources of between-study heterogeneity, we performed subgroup analyses 
restricted to (i) studies that had measured BMI (as opposed to self-reported), and (ii) studies that 
reported estimates adjusted for sunlight exposure. These analyses did not produce results that were 
materially different from those obtained from the overall analyses [Figure 5-7 and Figure 5-8]. 
Excluding one study that reported estimates combining both in situ and invasive melanoma [34] did 
not change the pooled estimates. Overall, the Egger’s tests and graphical inspection of funnel plots 
showed no evidence of substantial influence of publication bias.  
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  Table 5-3. Characteristics of prospective cohort studies included in the meta-analysis of BMI and melanoma 
 
Author, year of 
publication 
Country Cohort name Cohort size Gender  Study 
period 
Exposure 
assessment  
Melanoma 
ascertainment 
Number 
of events 
Adjustment factors 
Freedman, 
2003 
USA US Radiologic 
Technologist Study 
68,588 F/M 1994–1998 Self-
reported 
Self-reported 
(66% validated 
by review of 
pathology 
reports)  
159 F; 
48 M 
Sex, smoking, alcohol, hair, 
eye, and skin colour, 
childhood and adult sunlight 
exposure, history of 
keratinocytes carcinoma and 
family history of melanoma 
Rapp, 2005 Austria Vorarlberg Health 
Monitoring and 
Promotion Program 
145,931 F/M 1985–2002 Measured  Cancer 
registry  
130 F; 
122 M 
Age smoking status, 
occupational group 
Lukanova, 
2006 
Sweden Northern Sweden 
Health and Disease 
Cohort (NSHDC) 
68,786 F/M 1985–2003 Measured  Swedish 
Cancer 
Registry 
48 F; 
44 M 
Age, calendar year, smoking 
Samanic, 
2006 
 
Sweden Swedish Foundation 
for Occupational 
Safety and Health of 
the Construction 
Industry 
362,552 M 1971–1999 Measured  Swedish 
Cancer 
Registry 
1083 Age, smoking, calendar year  
Reeves, 
2007 
UK Million Women 
Study 
1,222,630 F 1996–2005 Self-
reported  
Cancer 
registry  
1635 Age, socio-economic status, 
alcohol. Smoking, 
reproductive factors, 
geographical region, 
physical activity, years since 
menopause and hormone 
replacement therapy 
Andreotti, 
2010 
USA Agricultural Health 
Study (AHS) 
67,947 F/M 1993-2005 Self-
reported 
Cancer 
registry 
79F; 
125M 
Age, state of residence, 
race, smoking status, 
education, alcohol, 
hypertension, diabetes, 
family history of cancer, 
fruits, meat and vegetable 
intake, vitamin supplements, 
leisure time exercises and 
menopausal status for 
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Author, year of 
publication 
Country Cohort name Cohort size Gender  Study 
period 
Exposure 
assessment  
Melanoma 
ascertainment 
Number 
of events 
Adjustment factors 
women 
Pothiawala, 
2012 
USA Nurses’ Health Study 
and (NHS) Health 
Professionals Follow-
up Study (HPFS) 
143,129 F/M 1976-2006 Self-
reported 
Review of 
medical 
records 
NA
1 
Age, childhood or 
adolescent tendency to burn, 
natural hair colour, family 
history of melanoma, 
number of nevi, location of 
birth and location residence 
at 15 and 30 years of 
age, UV exposure level, 
hours per week spent 
outdoors and physical 
activity 
Tang et al, 
2013 
USA Women’s Health 
Initiative (WHI) 
61,657 F NA
1 
Self-
reported  
Review of 
medical 
records 
386 Age, skin type, childhood 
and baseline sun exposure, 
smoking status, education, 
time walking outdoors per 
week and history of skin or 
other cancer and sunscreen 
use  
Kvaskoff et al, 
2014 
France Etude Epidemiologique 
aupres de femmes de 
l’Education 
Nationale(E3N) 
92,050 F 1990–2008 
 
Self-
reported 
Review of 
pathology 
reports 
589 
(19.5%) 
in situ 
age, hair colour, skin 
complexion, number of 
naevi, number of freckles, 
skin sensitivity to sun 
exposure, physical activity, 
and mean ultraviolet 
radiation dose 
in counties of birth and of 
residence at baseline 
Bhaskaran et al, 
 2014 
UK Clinical Practice 
Research Datalink 
(CPRD) 
5·24 million F/M 1987-2012 Measured  Review of 
medical 
records 
8505 Age, sex, smoking status, 
alcohol use, history of 
diabetes, socio-economic 
status  
Præstegaard et al, 
2015 
Denmark  Danish Diet, Cancer, 
and Health Cohort 
57,053 F/M 1993-2010 Measured  Danish Cancer 
Registry 
357 Skin reaction to the sun, 
numbers of freckles, number 
of moles on the arms, vital 
status and migration  
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Author, year of 
publication 
Country Cohort name Cohort size Gender  Study 
period 
Exposure 
assessment  
Melanoma 
ascertainment 
Number 
of events 
Adjustment factors 
Lahmann et al, 
2016 
Australia  The Nambour Skin 
Cancer Prevention Trial 
1,621 F/M 1992-2007 Measured  Queensland 
Cancer 
Registry 
28 Age, history of BCC or 
cSCC, clinical elastosis of 
the neck, freckling of the 
back, smoking status, 
recreational sun exposure, 
occupational 
sun exposure and sunburns 
Stenehjem et al, 
2017 
Norway Janus Cohort 291,602 F/M 1972-2014 Measured  Cancer 
Registry 
of Norway 
3000 Age, BMI, height, ambient 
UVR of residence, average 
intensity of 
sunburns, occupation, 
physical activity, education, 
smoking 
status, average intensity of 
solarium sessions and 
average 
intensity of sunbathing 
vacations 
QSkin cohort, 
2018 
(Unpublished) 
Australia  QSkin Sun and Health 
Study  
38,697 F/M 2010-2014 Self-
reported  
Queensland 
Cancer 
Registry 
247 age, sex, natural skin colour, 
tanning tendency, number of 
moles at age 21, history of 
excised skin cancers, history 
of destructive skin cancer 
treatments, family history of 
melanoma, history of 
sunburn as a child and 
cumulative lifetime sun 
exposure 
1
Information not reported 
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Figure 5-4. Meta-analysis of the association between BMI and melanoma in women and men 
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Figure 5-5. BMI effect on melanoma for men 
The solid lines represent Relative Risks, and the dotted lines represent their 95% confidence limits. 
 
 
       
Figure 5-6. BMI effect on melanoma for women 
 
The solid lines represent Relative Risks, and the dotted lines represent their 95% confidence limits. 
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Figure 5-7. Meta-analysis of the association between BMI and melanoma (women and men) in 
studies adjusted for sun-exposure 
 
 
Figure 5-8. Meta-analysis of the association between BMI and melanoma (women and men) in 
studies with measured weight and height 
NA: Sex-specific events not reported 
 
  
  
127 
 
Mendelian randomisation analyses of the association between BMI and melanoma risk 
Our primary analysis used a total of 730 genetic variants as instruments from UKBB and the 
GIANT consortia. These variants explained approximately 8% of the BMI variance. We estimated 
the overall odds ratio of developing melanoma per one SD increase in BMI (1 SD=4.6 kg/m
2
). 
Based on the combined estimate derived from 730 genetic variants for BMI, we found no evidence 
of an association between higher genetically predicted BMI and melanoma (OR per 1SD increase in 
BMI 1.00, 95% CI: 0.91-1.11) [Table 5-4].  
 
We performed sensitivity analyses to check whether the null association we observed might have 
arisen through violations of the MR assumptions. We found no evidence that our risk estimates 
were influenced by directional pleiotropy as our MR-Egger intercept were close to null (MR-Egger 
intercept: 0.0001, p-value=0.97, [Table 5-5] .Graphical assessment of bias in the MR funnel plots 
suggested that the dispersion of individual estimates was symmetrically distributed [Figure 5-9], 
indicating that our estimates were not driven by individual outliers. Taken together, our MR 
sensitivity analyses suggest that the null findings were very unlikely to be due to violation of the 
MR assumptions.  
 
Finally, we performed further sensitivity analyses to evaluate whether our inferences were 
influenced by the choice of instruments. We first used the 79 BMI-associated variants identified by 
the GIANT consortium, and then repeated the same analysis using the 495 variants identified from 
UKBB. The results were similar regardless of the source of instruments [Table 5-4]. 
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Table 5-4. Association between increased BMI (per 4.6 units) and risk of melanoma using two-sample Mendelian randomisation (MR) 
 
Instruments from  Number of 
SNPs 
Total variance 
explained* 
MR method Odds ratio 95% CI P-Value 
UK Biobank + GIANT 730 7.8% IVW 1.00 0.91-1.11 0.99 
MR-Egger 1.02 0.70-1.39 0.97 
Weighted Median  1.01 0.85-1.16 0.92 
GIANT only 79 2.7% IVW 1.01 0.86-1.19 0.91 
MR-Egger 1.18 0.79-1.58 0.41 
Weighted Median  0.97 0.73-1.22 0.83 
UK Biobank only 495 7% 
 
IVW 1.02 0.91-1.14 0.76 
MR-Egger 1.19 0.85-1.66 0.31 
Weighted Median  1.02 0.86-1.22 0.82 
IVW: inverse variance weighted 
SNP: single-nucleotide polymorphism 
CI: confidence interval  
GIANT: Genetic Investigation of ANthropometric Traits 
*Total variance explained by instrument is computed based on the genetic influence of the BMI SNPs (instruments) on measured  
BMI from the white-British participants from the UK Biobank cohort. 
 
 
Table 5-5. Estimates of Egger intercept to evaluate evidence for directional pleiotropy in MR association 
 
Outcome Egger intercept SE of Egger intercept P-value 
UKBB + GIANT 0.0001 0.002 0.9 
UKBB only -0.002 0.02 0.3 
GIANT only -0.005 0.005 0.4 
Here, p-value refers to the p-value of the estimated Egger intercept being null. A significant p-value (P<0.05)  
would present evidence that the MR causal estimates derived via the inverse-variance weighted model were biased by directional pleiotropy. 
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Legend: Funnel plot of MR estimate based on individual variants plotted against the inverse of their standard error. 
 
 
DISCUSSION  
We have comprehensively evaluated the relationship between BMI and melanoma using several 
approaches. We first evaluated the association between BMI and melanoma using data from a large 
population-based prospective study of skin cancer and found no association between higher BMI 
and melanoma risk overall, or in either sex. We then performed an up-to-date meta-analysis, 
including 14 independent prospective cohorts with nearly 2.5 million participants and over 17,000 
melanoma cases, and found no association between BMI and melanoma overall. Sex-specific 
analyses found no association between BMI and melanoma in men, but there was weak evidence of 
a non-linear relationship among women. Finally, using MR, we found no evidence that genetically 
predicted BMI was associated with the risk of melanoma. Collectively, our data provide no 
evidence that obesity is a risk factor for cutaneous melanoma.  
 
Investigating a possible causal association between obesity and melanoma is relevant given the 
heterogeneity observed across previous studies, the substantial increase in obesity prevalence 
Figure 5-9. Funnel plot assessing symmetry of the distribution of 
individual variant estimates around the point estimate for BMI and 
melanoma association 
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worldwide [396] and the rapid increases in melanoma incidence observed in many populations 
[104]. Several observational studies had previously investigated the association between BMI and 
melanoma risk, but to our knowledge, this is the first analysis to use Mendelian randomisation 
techniques to examine the role of BMI in melanoma development. Our findings suggest that the 
increased risk of melanoma among overweight and obese people reported in previous 
epidemiological studies, particularly among men [129, 293, 309, 397], may be due to ascertainment 
biases, misclassification or residual confounding inherent to observational studies.  
 
Our findings also negate some earlier experimental studies suggesting that an association between 
BMI and melanoma might be plausible. For example, there were reports that obese mice exposed to 
UVB radiation had higher levels of proinflammatory cytokines in their skin than their non-obese 
counterparts [398]. These findings gave some credence to a possible link between obesity and skin 
cancer, on the basis that inflammatory responses in the skin might increase the risk of neoplasia 
[399, 400]. Our data indicate that even if obesity modifies cutaneous responses to sunlight in some 
animal models, the effects do not translate into measurable changes in melanoma risk in humans.  
 
Our study has some limitations. We employed BMI as a measure of adiposity, an imperfect measure 
for which the concordance with total body fat is known to vary with sex, age, and ethnicity [401, 
402]. For example, women have, on average, a greater amount of total body fat than men of 
equivalent BMI, and older adults tend to have more body fat than younger adults of equivalent BMI 
because of decrease in stature, reduction in lean body mass and accumulation of fat tissue. A 
limitation of our meta-analysis was the significant heterogeneity in effect detected across studies, 
which persisted even after controlling for possible explanatory factors such as self-report versus 
measured BMI, or extent of confounder control. For MR analyses, our genetic instruments for BMI 
do not distinguish BMI attained through different mechanisms (muscle mass, central adiposity, 
body fat), limiting our ability to generalise these findings to studies that evaluate specific 
mechanisms of changing BMI; although in the presence of a null finding, the effect of variants from 
different BMI mechanisms on melanoma will have to cancel-out each other, which is extremely 
unlikely.  Unfortunately, we were unable to examine sex-specific associations between BMI and 
melanoma using MR techniques as the summary melanoma GWAS data did not record sex. 
However, the observational data provide little evidence that BMI appreciable affects melanoma risk 
in either sex. Finally, MR analysis assumes that the instruments affect the outcome only through the 
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exposure of interest; this cannot be proven formally in MR setting, although we tested for possible 
violations and found no evidence to indicate a concern. 
Our report also has several notable strengths.  Population stratification is unlikely to affect our MR 
estimates, given the studies were restricted to populations of European descent. Two-sample MR 
has methodological advantages by giving greater power than traditional 2-stage least square models, 
which strengthens and increases the precision of the MR estimates. Our instruments in total 
explained ~8% of phenotypic variation in our exposure, which is substantially higher than 
instruments used in previous BMI MR Studies (~1-1.5%) [403-406]. This led to fairly narrow 
confidence intervals for our MR estimate. Although employing a large number of genetic variants 
increases the likelihood of including invalid instruments, or pleiotropic variants, the sensitivity 
analysis using a weighted median estimator which can still provide valid estimates even if 50% of 
the variants are invalid [337], yielded estimates closer to that obtained from MR-IVW.  
 
In summary, and based on several complementary strands of observational data, we found no 
consistent evidence that higher BMI is a risk factor for melanoma, although we cannot conclusively 
rule out a possible non-linear effect in women based on observational studies.  In the future, we 
anticipate that sex-specific summary data from melanoma GWAS studies will be available to 
resolve this as yet unanswered question.  
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6 Adult height and risk of cutaneous melanoma 
6.1 Introduction  
This chapter discusses the association between adult height and risk of developing first invasive 
melanoma using two separate epidemiological analytical methods. We first conducted two-sample 
Mendelian randomisation analyses using summary data from the most recent GWAS meta-analyses 
of height and melanoma.   Subsequently, we performed a prospective observational study of height 
and melanoma using data from a population-based cohort study of skin cancer in Queensland, 
Australia. 
 
Dusingize JC, Olsen CM, An J, Pandeya N, Law MH, Thompson BS, Goldstein AM, Iles MM, 
Webb PM, Neale RE, Ong JS, MacGregor S, Whiteman DC. Adult height and risk of cutaneous 
melanoma: findings from the QSkin Sun and Health cohort study and Mendelian randomisation.  
 
6.2 Contribution of Candidate 
I participated in the conception and design of the research question with the help of my supervisors.  
CMO and NP assisted in data cleaning and linkage between the QSkin and to the cancer registry. I 
performed all statistical analyses and was responsible for the interpretation of the results in 
consultation with the study team. I was responsible for writing and editing the manuscript taking 
into account the comments and suggestions of all co-authors. 
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6.3 Manuscript: Adult height and risk of cutaneous melanoma: findings from the QSkin 
Sun and Health cohort study and Mendelian randomisation  
 
ABSTRACT  
Background: Most previous epidemiological studies of melanoma have reported increased risks 
among taller people.  It remains unclear however, whether the association reflects causality or 
whether it is due to residual confounding by environmental and lifestyle risk factors. We evaluated 
these associations using two different analytical approaches.  
Methods: We first conducted two-sample Mendelian randomisation analyses using summary data 
from the most recent GWAS meta-analyses of height [GIANT consortium n=700 000] and 
melanoma [international GWAS consortium n= 12 874 cases and 23 203 controls], respectively.   
Subsequently, we performed a prospective observational study of height and melanoma using data 
from a population-based cohort study of skin cancer in Queensland, Australia (QSkin, n=38,065).   
Results: Using Mendelian randomisation techniques, we found that genetically-predicted height 
was significantly associated with an increased melanoma risk in the international GWAS 
consortium dataset [OR: 1.06, 95% CI: 1.02-1.12, per 1SD (9.27 cm) increase in height]. In the 
QSkin cohort, we observed nonlinear associations between height and melanoma risk overall (P-
nonlinearity=0.06). When stratified by sex, we found a significant non-linear association between 
increasing height and melanoma for men (P-nonlinearity < 0.001) but not for women.  
Conclusions: The genetic data from international studies suggest robust associations between 
height and melanoma, whereas the observational data from Queensland revealed complex and sex-
specific associations. In part, these apparently discordant findings may reflect differing proportions 
of environmental versus genetic contributions to melanoma risk, depending on the setting.  
 
INTRODUCTION 
Adult height has been positively associated with several common cancers in humans including 
breast, and ovary [138]. Height is determined by both genetic and environmental factors [407]. For 
example, a study including more than 30 000 twin pairs reported that the heritability of human 
height is approximately 80% [408].  However, modifiable early-life and pre-pubertal factors such as 
childhood illness and diet also play an important role [310, 311]. Diverse mechanisms have been 
postulated to explain the association between height and cancer risk, including 1) height is a proxy 
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for the total number of cells in the body, which increases the chances of stochastic malignant 
transformation [139]; 2) height acts as surrogate marker for childhood nutritional status and caloric 
intake, and greater caloric intake may promote carcinogenesis [317, 409] (and conversely, 
restricting caloric intake inhibits the development of various tumours  [318, 410]); and 3) the level 
of insulin-like growth factor 1 (IGF-1), the  major determinant of long-term growth in children 
[411], has been reported to stimulate angiogenesis and contribute to cancer cell growth [412, 413].   
 
Most previous observational studies of melanoma have reported increased risks among taller people 
[138, 306-309]. For example, the UK Million Women Study reported a 30% increase in melanoma 
risk per 10cm increase in height [138]. A large Norwegian cohort observed a 50% increased 
melanoma risk for men and women in the fifth quintile of height versus the first quintile [309].  
However, most observational studies have relied on self-reported height with known 
misclassification [295, 414], and suffer from residual confounding and lack of information 
regarding environmental and lifestyle risk factors in childhood and adolescence. Therefore, it 
remains unclear whether the reported associations between height and melanoma risk operate 
through underlying biological pathways or whether height serves as a surrogate measure of lifestyle 
and environmental factors that influence melanoma risk.  
 
One way to overcome some of the limitations inherent to observational studies is to perform 
instrumental variable analysis, using a technique known as Mendelian randomisation (MR) [335]. 
Mendelian randomisation uses genetic variants as instrumental variables to estimate the association 
between an exposure and an outcome [336]. Because genetic variants associated with adult height 
are randomly assigned from parents to offspring at conception, Mendelian randomisation studies are 
analogous to the random assignment of exposure in a randomised controlled trial, assuming various 
conditions are met. Our study is partially motivated by a previous Mendelian randomisation 
investigation evaluating the relationship between height and cancer outcomes, in which we found 
that height is associated with increased risk of melanoma among white Britons [385]. However, it is 
unclear whether these findings are generalizable to other susceptible populations. 
 
In this report, we first conducted Mendelian randomisation analyses using GWAS summary 
statistics from the Genetic Investigation of ANthropometric Traits (GIANT) consortium [303] and 
consortium data from the melanoma GWAS meta-analysis [375]. Secondly, we evaluated 
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observational evidence for the association between height and risk of melanoma in a high UV 
environment in Queensland, Australia using data from the QSkin Sun and Health cohort study 
[320].  
 
METHODS 
Mendelian randomisation analyses  
The single nucleotide polymorphisms (SNPs) for height were identified from the 2018 height 
GWAS meta-analysis from the GIANT consortium which included more than 700,000 participants 
of European descendant [303]. To obtain a set of independent instrumental variables, all SNPs 
identified from the GIANT consortium were clumped using the following criteria: p-value < 5 × 10-
8, within 10,000 physical distances and in linkage disequilibrium (r
2
 < 0.001). For each independent 
SNP for height, we extracted the beta coefficients and standard errors, allele frequencies and p-
values.  
 
We obtained GWAS summary statistics for melanoma from the largest melanoma GWAS meta-
analysis consisting of 12,874 cases and 23,203 controls of European descent. Details regarding 
GWAS quality control and study samples have been published previously [375]. For each candidate 
SNP for height, the following information was extracted:  per allele log OR of melanoma, SE of log 
OR, allele frequencies and p-value.    
 
Two-sample Mendelian randomisation methods 
In this analysis, we used a two-sample Mendelian randomisation approach in which summary 
statistics for SNP-exposure and SNP-outcome associations were estimated separately [384]. To 
estimate the log OR of melanoma per 1 SD increase in height (1SD=~9.27cm) and its 
corresponding 95% CI, we used the Wald-type estimator [337]. We then combined these estimates 
across all SNPs using an inverse variance weighted method (IVW) [337].  
Using MR-Egger regression and weighted median methods, we performed sensitivity analyses to 
assess whether our estimates were biased by directional pleiotropy or the presence of invalid SNPs.  
In contrast to the IVW method which assumes no pleiotropy, MR-Egger regression can be used to 
detect bias due to directional pleiotropy and give unbiased causal estimates [387].  Moreover, given 
the large number of SNPs obtained from the recent GWAS, it is possible that some of them might 
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be invalid instruments for height. Therefore, we employed the weighted median methods which can 
still yield reliable estimates even if some of the variants are invalid IVs [388].  
 
We performed additional sensitivity analysis restricted to 390,628 cancer-free white British 
participants with height data in UKBB only. For this analysis we used 1,810 independent genetic 
variants that were associated with height at genome-wide significance as previously described 
[385].   Lastly, we conducted a separate analysis using 360 genetic variants identified in an earlier 
published study of 339,224 participants of European descent in the GIANT consortium only [415]. 
The variants in UKKB and GIANT explained 17% and 13% of the variation in height respectively. 
We used R software (TwoSampleMR package) for Mendelian randomisation analyses [416].   
 
The QSkin Sun and Health Study 
The QSkin Sun and Health Study (QSkin) is large prospective cohort study designed to investigate 
skin cancer outcomes.  At study entry (2010-2011), adult men and women aged between 40-69 
years were randomly sampled from the Queensland population through the Australian national 
electoral roll. Full details regarding participant recruitment have been described elsewhere [320]. 
Because of the low risk of melanoma among participants of non-European ancestry, we restricted 
our analysis to white participants with no history of in situ or invasive melanoma prior to enrolment 
(n=38,065). This study was approved by the Human Research Ethics Committee of the QIMR 
Berghofer Medical Research Institute. Each participant provided written informed consent to take 
part.  
 
At enrolment, participants were invited to complete a self-reported questionnaire asking, among 
other things, about demographic items, phenotypic characteristics (e.g. number of moles on skin 
and freckles on face as a teenager), history of sun exposure and sun protection behaviour and 
lifestyle factors. Participants were asked “How tall are you?” and given the opportunity to respond 
in metric or imperial units; repeatability of this measure was very high [321].  
Information on incident melanoma was obtained through record linkage to the Queensland Cancer 
Registry from enrolment up to 31 December 2014. Melanoma registration in Australia is mandatory 
and virtually complete. Deaths that occurred in the cohort during follow-up were identified through 
linkage to the National Death Index.   
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Statistical analysis 
We used Fine-Gray models to estimate the overall and gender-specific sub-distribution hazard ratios 
and corresponding 95% confidence intervals (CI) for the association between height at enrolment 
and melanoma, accounting for death as a competing event [327]. Person-time was calculated for 
each participant from baseline up until diagnosis of the first histologically confirmed invasive 
melanoma (C43), death or end of follow-up, whichever occurred first.  
 
In preliminary analyses, height was modelled as continuous linear term expressed per 10 cm 
increment. We also modelled height as a nonlinear term using generalised additive models (GAMs) 
with smoothed functions. Lastly, we categorised height into five categories (specific for each sex) 
and used the middle category as the reference. We performed minimally adjusted analyses 
controlling for age and sex. We then adjusted for other potential confounders. The selection of 
potential confounding factors was based on the pairwise associations in our data, supplemented by 
literature review and consideration of likely mediators. Our final multivariate models were adjusted 
for age, sex, education status, smoking, history of sunburn as a teenager, and cumulative lifetime 
sun exposure. To reduce potential bias arising as result of missing observations for some covariates, 
missing values were recoded as a separate category and included as an indicator variable in the 
multivariable models. However, we also conducted a sensitivity analysis using a complete-case 
analysis which excluded participants who had missing values for any of the covariates.  
 
RESULTS 
Height-related SNPs and melanoma risk  
We used a total of 3,163 genetic variants, explaining ~ 19% of variance in height in this analysis. 
Using the IVW method to pool estimates from individual variants, genetically-predicted height was 
associated with increased melanoma risk (OR 1.06, 95% CI: 1.02-1.12, per 1SD (9.27 cm)) increase 
in height [Table 6-1]. We performed sensitivity analyses firstly using data from the UKBB, and 
secondly using a restricted list of 360 height-associated variants from the earlier GIANT consortium 
analysis [415], but our findings were essentially unchanged regardless of the source of instruments 
[Table 6-1].  
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Table 6-1. Association between increased height (per 9.27 cm) and risk of melanoma using 
two-sample Mendelian randomisation (MR) 
 
Instruments from  
Number of SNPs 
 
Total variance explained Odds ratio 95% CI P-Value 
UKBB + GIANT
1 
3163 
 
 
19% 1.06 1.02-1.12 0.007 
GIANT only
2 
360 13% 1.08 1.01-1.16 0.03 
UKBB only
3 
1810 17% 1.07 1.01-1.13 0.01 
 
SNP: single-nucleotide polymorphism 
CI: confidence interval  
UKBB= UK Bio-bank  
GIANT: Genetic Investigation of ANthropometric Traits 
1
UKBB + GIANT: Genetic variants obtained from the 2018 BMI GWAS meta-analysis in GIANT consortium  
2
GIANT only: Genetic variants obtained from the 2015 BMI GWAS meta-analysis in GIANT consortium  
3
UKBB only:  Genetic variants obtained from the UKBB only 
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Additional sensitivity analysis using MR-Egger regression showed that the intercept was not 
statistically different from null (intercept=-0.001, p-value=0.6), indicating that our estimates were 
not affected by pleotropic SNPs [Table 6-2]. Visual assessment of directional pleiotropy using a 
funnel plot indicated that individual variants were symmetrically distributed around the point 
estimate [Figure 6-1].  
Table 6-2. Estimates of Egger intercept to evaluate evidence for directional pleiotropy in MR 
association 
 
Outcome Egger intercept SE of Egger intercept P-value 
UKBB + GIANT 0.001 0.0008 0.6 
UKBB only 0.003 0.001 0.5 
GIANT only 0.004 0.003 0.2 
Here, p-value refers to the p-value of the estimated Egger intercept being null.  
A significant p-value (P<0.05) would present evidence that the MR causal estimates derived via the inverse-variance 
weighted model were biased by directional pleiotropy. 
 
 
 
Figure 6-1. Funnel plot assessing symmetry of the distribution of individual variant estimates 
around the point estimate for height and melanoma association  
 
Legend: Funnel plot of MR estimate based on individual variants plotted against the inverse of their standard error. 
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Height and melanoma risk in QSkin cohort 
In the QSkin cohort, the mean heights for men and women were 177 cm and 164 cm, respectively. 
Overall, the mean age at baseline was 56 years; and 54% of participants were females. Compared to 
participants in the lowest category of height (height < 170 cm for men or height < 155 cm for 
women), participants in the highest category of height (height >= 185 cm for men or height >= 170 
cm for women) were younger (36% vs. 20%), more likely to hold a university degree (30% vs. 
18%) and less likely to be obese (22% vs. 37%)  
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        Table 6-3. Baseline characteristics of QSkin study participants by categories of height 
 
  Height categories
1
   
 Overall (n=38065) 
Category 1 
(n=3968)  
Category 2 
(n=6269) 
Category 3 
(n=10912) 
Category 4  
(n=9732) 
Category 5  
(n=7184) 
Parameter  N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
Age (in years) at entry (Mean, SD) 56.0 (8.2) 57.7 (7.9) 57.1 (8.0) 56.5 (8.1) 55.5 (8.2) 54.0 (8.2) 
Height (in cm) for women, (Mean, SD) 163.9 (6.9) 152.3 (2.8) 157.1 (0.9) 161.8 (1.4) 166.5 (1.4) 173.4 (3.6) 
Height (in cm) for men, (Mean, SD) 177.4 (6.9) 164.9 (3.8) 171.8 (1.4) 176.8 (1.4) 181.4 (1.4) 188.2 (3.4) 
Age group (years)        
40-49 10281 (26.5) 773 (19.5) 1363 (21.7) 2649 (24.3) 2803 (28.8) 2554 (35.6) 
40-59 14731 (37.9) 1482 (37.3) 2382 (38.0) 4185 (38.4) 3705 (38.1) 2701 (37.6) 
60-69 13842 (35.6) 1713 (43.2) 2524 (40.3) 4078 (37.4) 3224 (33.1) 1929 (26.9) 
Sex       
Females 21076 (54.2) 2020 (50.9) 3068 (48.9) 5629 (51.6) 5280 (54.3) 4536 (63.1) 
Males 17778 (45.8) 1948 (49.1) 3201 (51.1) 5283 (48.4) 4452 (45.7) 2648 (36.9) 
Further Education       
No school certificate 2994 (8.3) 466 (12.7) 575 (9.9) 827 (8.2) 602 (6.7) 406 (6.0) 
School certificate 6017 (16.7) 720 (19.7) 1028 (17.8) 1747 (17.2) 1398 (15.5) 953 (14.1) 
Completed high school 7085 (19.6) 725 (19.8) 1098 (19.0) 1991 (19.6) 1787 (19.8) 1328 (19.7) 
Trade/certificate/diploma 10868 (30.1) 1090 (29.8) 1810 (31.3) 2998 (29.6) 2775 (30.7) 2040 (30.3) 
University degree 9103 (25.2) 659 (18.0) 1272 (22.0) 2575 (25.4) 2480 (27.4) 2008 (29.8) 
Missing 2787  308  486  774  690  449  
Smoking status       
Current  3703 (9.6) 412 (10.4) 621 (9.9) 1025 (9.4) 892 (9.2) 665 (9.3) 
Former 13959 (36.1) 1378 (34.8) 2319 (37.1) 3892 (35.8) 3544 (36.6) 2564 (35.8) 
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  Height categories
1
   
 Overall (n=38065) 
Category 1 
(n=3968)  
Category 2 
(n=6269) 
Category 3 
(n=10912) 
Category 4  
(n=9732) 
Category 5  
(n=7184) 
Parameter  N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
Never  21035 (54.4) 2168 (54.8) 3307 (52.9) 5957 (54.8) 5249 (54.2) 3930 (54.9) 
Missing 157  10  22  38  47  25  
Body Mass Index       
BMI < 25 kg/m
2 
12774 (34.0) 993 (25.5) 1827 (29.6) 3612 (33.6) 3433 (35.7) 2909 (41.1) 
25.0 ≤ BMI <30 kg/m2 14687 (39.1) 1450 (37.2) 2487 (40.3) 4292 (39.9) 3814 (39.6) 2644 (37.3) 
BMI ≥30 kg/m2 10062 (26.8) 1454 (37.3) 1858 (30.1) 2848 (26.5) 2375 (24.7) 1527 (21.6) 
Missing  1331  71  97  160  110  104  
Skin colour        
Fair 23625 (61.1) 2372 (60.1) 3758 (60.3) 6600 (60.8) 6024 (62.1) 4429 (61.9) 
Medium 12484 (32.3) 1250 (31.7) 2015 (32.3) 3544 (32.7) 3118 (32.2) 2284 (31.9) 
Olive/Dark 2552 (6.6) 324 (8.2) 461 (7.4) 704 (6.5) 555 (5.7) 442 (6.2) 
Missing 193  22  35  64  35  29  
Hair colour        
Dark brown/black 16047 (41.5) 1672 (42.3) 2579 (41.4) 4558 (42.0) 4010 (41.5) 2895 (40.5) 
Light brown 14797 (38.3) 1518 (38.4) 2477 (39.7) 4169 (38.4) 3643 (37.7) 2707 (37.9) 
Blonde 5574 (14.4) 533 (13.5) 838 (13.4) 1517 (14.0) 1468 (15.2) 1098 (15.4) 
Red/auburn 2230 (5.8) 227 (5.7) 342 (5.5) 617 (5.7) 553 (5.7) 448 (6.3) 
Missing 206  18  33  51  58  36  
Eye colour       
Blue/grey 15324 (40.0) 1529 (39.1) 2493 (40.3) 4242 (39.4) 3915 (40.8) 2840 (40.0) 
Green/hazel 14741 (38.5) 1440 (36.8) 2361 (38.2) 4147 (38.5) 3694 (38.5) 2806 (39.5) 
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  Height categories
1
   
 Overall (n=38065) 
Category 1 
(n=3968)  
Category 2 
(n=6269) 
Category 3 
(n=10912) 
Category 4  
(n=9732) 
Category 5  
(n=7184) 
Parameter  N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
Brown/black 8272 (21.6) 943 (24.1) 1329 (21.5) 2383 (22.1) 1991 (20.7) 1457 (20.5) 
Missing 517  56  86  140  132  81  
Burning tendency       
Never burn 3370 (8.7) 406 (10.3) 580 (9.3) 958 (8.8) 794 (8.2) 568 (7.9) 
Burns a little 16744 (43.3) 1727 (43.8) 2827 (45.4) 4704 (43.3) 4166 (43.0) 2974 (41.5) 
Burns moderately 13069 (33.8) 1267 (32.2) 2020 (32.4) 3683 (33.9) 3350 (34.6) 2489 (34.8) 
Burns badly 5468 (14.1) 540 (13.7) 803 (12.9) 1520 (14.0) 1368 (14.1) 1128 (15.8) 
Missing 203  28  39  47  54  25  
Tanning tendency       
No tan 2498 (6.5) 282 (7.2) 370 (6.0) 686 (6.3) 640 (6.6) 457 (6.4) 
Tan lightly 8131 (21.1) 859 (21.8) 1287 (20.7) 2312 (21.3) 2013 (20.8) 1490 (20.9) 
Tan moderately 19325 (50.1) 1928 (48.9) 3154 (50.7) 5446 (50.3) 4858 (50.2) 3554 (49.8) 
Tan deeply 8624 (22.4) 870 (22.1) 1406 (22.6) 2392 (22.1) 2165 (22.4) 1634 (22.9) 
Missing 276  29  52  76  56  49  
Freckles on face as teenager       
None 17964 (46.5) 1925 (48.8) 3146 (50.4) 5074 (46.7) 4374 (45.2) 3094 (43.3) 
A few 12222 (31.6) 1148 (29.1) 1849 (29.6) 3534 (32.6) 3131 (32.3) 2317 (32.4) 
Some 6108 (15.8) 628 (15.9) 901 (14.4) 1641 (15.1) 1574 (16.3) 1218 (17.0) 
Many 2369 (6.1) 245 (6.2) 348 (5.6) 608 (5.6) 606 (6.3) 519 (7.3) 
Missing 191  22  25  55  47  36  
Moles on skin at age 21 years       
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  Height categories
1
   
 Overall (n=38065) 
Category 1 
(n=3968)  
Category 2 
(n=6269) 
Category 3 
(n=10912) 
Category 4  
(n=9732) 
Category 5  
(n=7184) 
Parameter  N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
N (%)
2 
None 10788 (28.5) 1340 (34.8) 1887 (31.0) 2991 (28.2) 2603 (27.4) 1714 (24.4) 
A few 20183 (53.4) 1887 (49.1) 3206 (52.7) 5742 (54.1) 5141 (54.1) 3841 (54.7) 
Some 5695 (15.1) 529 (13.8) 847 (13.9) 1540 (14.5) 1452 (15.3) 1215 (17.3) 
Many 1162 (3.1) 91 (2.4) 145 (2.4) 335 (3.2) 314 (3.3) 256 (3.6) 
Missing 1026  121  184  304  222  158  
Sunburns as a teenager       
Never 1646 (4.4) 212 (5.6) 300 (5.0) 457 (4.3) 384 (4.0) 251 (3.6) 
1-5 16362 (43.6) 1740 (45.8) 2709 (44.9) 4616 (43.8) 4053 (42.7) 2906 (41.5) 
6-10 9397 (25.0) 890 (23.5) 1522 (25.2) 2628 (25.0) 2352 (24.8) 1830 (26.2) 
11+ 10143 (27.0) 953 (25.1) 1501 (24.9) 2830 (26.9) 2697 (28.4) 2008 (28.7) 
Missing 1306  173  237  381  246  189  
History skin cancers surgically 
treated 
      
No 23536 (61.0) 2397 (60.9) 3804 (61.2) 6562 (60.5) 5866 (60.6) 4455 (62.4) 
Yes 15029 (39.0) 1539 (39.1) 2410 (38.8) 4279 (39.5) 3806 (39.4) 2681 (37.6) 
Missing  289  32  55  71  60  48  
AKs/skin cancers destructively 
treated 
      
None 17311 (44.8) 1807 (45.8) 2808 (45.1) 4719 (43.4) 4303 (44.4) 3344 (46.7) 
1-5 10463 (27.1) 1032 (26.2) 1668 (26.8) 2991 (27.5) 2639 (27.2) 1913 (26.7) 
6-10 10886 (28.2) 1106 (28.0) 1756 (28.2) 3154 (29.0) 2750 (28.4) 1898 (26.5) 
Missing 194  23  37  48  40  29  
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1
Definition of height categories:  
Category 1: height < 170 for men or height < 155 for women  
Category 2: 170 <= height <175 for men or 155 <= height <160 for women 
Category 3: 175<= height <180 for men or 160<= height <165 for women 
Category 4: 180 <= height<185 for men or 165 <= height <170 for women 
Category 5: height >= 185 for men or height >= 170 for women 
2
Percentages in each category do not include the missing values 
3
AK: actinic keratosis  
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During an average follow-up of 3.5 years, 251 incident melanoma cases were identified in the 
eligible QSkin cohort. After adjusting for potential confounding factors, we found a non-significant 
linear association between increasing height (per 10 cm) and melanoma risk in men but not in 
women [Table 6-4]. In formal testing, we found some evidence of non-linear associations (P-
nonlinearity=0.06). When stratified by sex, we found a highly significant non-linear association for 
men (P-nonlinearity <0.001) [Figure 6-2] but not for women (P-nonlinearity=0.4) [Figure 6-3]. To 
quantify the magnitude of the association in each sex, we categorised height into 5 groups based on 
the distribution of height in our data, with the middle category containing the mean value (men: 
175-179 cm; women 160-164 cm) serving as the reference. Compared to men in the middle 
category, those in the shortest (< 170 cm) and tallest categories (185+ cm) had significantly 
increased risks (HR: 2.55, 95% CI: 1.47-4.30 and HR: 2.13, 95% CI: 1.23-3.70 respectively) [Table 
6-4]. We did not observe any significant associations among women. Additional sensitivity analyses 
in which participants diagnosed with in situ melanomas and those diagnosed with invasive 
melanoma were included as cases resulted in slightly attenuated risk estimates, but the direction of 
association was unchanged [Table 6-5].  
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Table 6-4. Hazard ratios (HR) and 95% CIs for the association between height and melanoma risk 
 
 Total cohort  Males Females  
Parameter Cases HR 95% CI Cases HR 95% CI Cases HR 95% CI 
Minimally adjusted model
1 
         
Continuous
2
  (per 10cm) 251 1.03 0.85 1.24 144 1.08 0.82 1.42 107 0.97 0.76 1.23 
Height category 1 37 1.53 1.02 2.30 26 2.40 1.40 4.09 11 0.83 0.42 1.64 
Height category 2 32 0.85 0.55 1.29 21 1.19 0.67 2.09 11 0.56 0.29 1.12 
Height category 3 63 1.00 ref ref 28 1.00 ref ref 35 1.00 ref ref 
Height category 4 73 1.37 0.97 1.92 43 1.92 1.19 3.10 30 0.94 0.57 1.53 
Height category 5 46 1.30 0.88 1.94 26 2.14 1.24 3.71 20 0.76 0.43 1.33 
 
Fully adjusted model
3 
            
Continuous
2
  (per 10cm) 251 1.02 0.84 1.23 144 1.06 0.81 1.41 107 0.96 0.75 1.24 
Height category 1 37 1.59 1.06 2.39 26 2.52 1.47 4.30 11 0.87 0.44 1.73 
Height category 2 32 0.88 0.57 1.34 21 1.25 0.71 2.21 11 0.58 0.29 1.14 
Height category 3 63 1.00 ref ref 28 1.00 ref ref 35 1.00 ref ref 
Height category 4 73 1.37 0.97 1.92 43 1.92 1.19 3.09 30 0.92 0.56 1.51 
Height category 5 46 1.28 0.86 1.91 26 2.13 1.23 3.70 20 0.75 0.42 1.32 
1
Model adjusted for age or age and sex for total cohort 
2
Height modelled as a linear term per 10cm increase  
3
Model adjusted for age, sex, education status, smoking, history of sunburn as a teenager, and cumulative lifetime sun exposure 
 
Definition of height (cm) categories in men 
Category 1: height < 170  
Category 2: 170 <= height <175  
Category 3: 175<= height <180   
Category 4: 180 <= height<185 
Category 5: height >= 185 
 
Definition of height (cm) categories in women 
Category 1: height < 155 
Category 2: 155 <= height <160 
Category 3: 160<= height <165 
Category 4: 165 <= height <170 
Category 5: height >= 170
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Figure 6-2. Nonlinear relation of height and risk of melanoma for men 
 
The solid line represents log hazard, and the dashed line represents its 95% confidence limits. 
 Adjusted for age, sex, education status, smoking, history of sunburn as a teenager, and cumulative lifetime sun 
exposure. 
 
 
Figure 6-3. Nonlinear relation of height and risk of melanoma for women 
 
The solid line represents log hazard, and the dashed line represents its 95% confidence limits. 
 Adjusted for age, sex, education status, smoking, history of sunburn as a teenager, and cumulative lifetime sun 
exposure. 
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Table 6-5. Hazard ratios (HR) and 95% CIs for the associations of height with melanoma (in situ + invasive) risk 
 
 Total cohort  Males Females  
Parameter Cases HR 95% CI Cases HR 95% CI Cases HR 95% CI 
Minimally adjusted model
1 
         
Continuous
2
  (per 10cm) 634 1.13 1.01 1.27 371 1.17 0.99 1.37 263 1.08 0.92 1.27 
Height category 1 71 1.02 0.78 1.35 48 1.17 0.83 1.64 23 0.81 0.51 1.30 
Height category 2 86 0.79 0.61 1.02 54 0.80 0.58 1.12 32 0.76 0.50 1.15 
Height category 3 182 1.00   106 1.00   76 1.00   
Height category 4 169 1.09 0.88 1.35 94 1.10 0.83 1.46 75 1.07 0.78 1.47 
Height category 5 126 1.23 0.97 1.55 69 1.49 1.1 2.03 57 0.97 0.69 1.38 
 
Fully adjusted model
3 
            
Continuous
2
  (per 10cm) 634 1.10 0.98 1.24 371 1.13 0.96 1.33 263 1.06 0.90 1.26 
Height category 1 71 1.09 0.80 1.49 48 1.29 0.88 1.88 23 0.79 0.44 1.40 
Height category 2 86 0.74 0.55 1.01 54 0.80 0.55 1.16 32 0.64 0.38 1.09 
Height category 3 182 1.00   106 1.00   76 1.00   
Height category 4 169 1.12 0.88 1.42 94 1.08 0.79 1.47 75 1.17 0.81 1.69 
Height category 5 126 1.10 0.84 1.44 69 1.38 0.97 1.96 57 0.82 0.53 1.26 
1
Model adjusted for age or age and sex for total cohort 
2
Height modelled as a linear term per 10cm increase  
3
Model adjusted for age, sex, education status, smoking, history of sunburn as a teenager, and cumulative lifetime sun exposure 
 
Definition of height (cm) categories in men 
Category 1: height < 170  
Category 2: 170 <= height <175  
Category 3: 175<= height <180   
Category 4: 180 <= height<185 
Category 5: height >= 185 
 
Definition of height (cm) categories in women 
Category 1: height < 155 
Category 2: 155 <= height <160 
Category 3: 160<= height <165 
Category 4: 165 <= height <170 
Category 5: height >= 170
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DISCUSSION 
We investigated the association between adult height and risk of melanoma using two different 
analytical approaches. We first evaluated this association using Mendelian randomisation 
techniques in a dataset comprising 12 874 melanoma cases and 23 203 controls. Subsequently, we 
performed a prospective observational study of height and melanoma using data from a population-
based cohort study of skin cancer. In the Mendelian randomisation analyses, we found that 
genetically-predicted height was associated with a significantly increased risk of melanoma. In our 
observational dataset, we found a non-significant linear association between increasing height and 
melanoma risk in men but not in women. Taken further, this analysis showed a highly significant 
nonlinear association for men but not for women.  
 
The different findings obtained from Mendelian randomisation analysis compared with QSkin 
observational data were unexpected. Mendelian randomisation is a strong tool for assessing possible 
causal associations between exposures and health outcomes as it minimises several limitations 
inherent to observational studies (assuming several important conditions are met). In this study, we 
conducted 3 separate Mendelian randomisation analyses using different sources of instruments. We 
also performed additional sensitivity analyses to assess the validity of our instruments and assess 
the possibility of directional pleiotropy. All of the Mendelian randomisation analyses were 
consistent with an increased risk of melanoma among taller individuals. Unfortunately, we were 
unable to assess sex-specific associations using the Mendelian randomisation approach, since the 
melanoma consortium has not yet published sex-specific GWAS summary estimates, and so this 
line of inquiry remains closed for the present. A limitation common to all Mendelian randomisation 
analyses relates to potential pleiotropy, whereby a genetic variant is independently associated with 
the outcome, but not through the exposure of interest. We assessed for pleiotropy using the MR-
Egger method but observed no evidence that the exclusion restriction criteria assumption was 
violated. While it is also possible that some of the variants used in the analysis might be associated 
with confounders of height and melanoma association, such an effect would likely be small because 
our genetic instrument was generated from more than 3000 variants explaining ~19% of variance in 
height, which further reduces the likelihood of bias from violating Mendelian randomisation 
assumptions [417]. Thus, while there are some limitations to Mendelian randomisation analyses, it 
seems unlikely that the strong, statistically-significant linear association observed here has arisen 
through bias or chance. Moreover, it is notable that the findings from the Mendelian randomisation 
analysis accord with most previous observational studies that have reported significant linear 
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associations between increasing height and melanoma risk [138, 306, 308, 309]. Thus, it would 
seem that the findings from the QSkin Study are the source of discord.  
 
Could information bias explain the discordant findings in QSkin? As for most previous 
epidemiologic studies, height was self-reported, however repeatability of this measure was near-
perfect [intraclass correlation coefficient=0.99] [321] and the mean heights for men and women in 
QSkin were similar to the general population (QSkin: men 177 cm, women 163 cm; population: 
men 176 cm, women 162 cm) [418]. Follow-up for melanoma events was through record linkage to 
the cancer registry (registration of melanoma is mandatory in Queensland), so it highly unlikely that 
any losses to follow-up occurred, let alone introduced bias. Moreover, unlike most previous cohort 
studies, the QSkin Study captured extensive data on key skin cancer risk factors at baseline, 
allowing arguably better control of confounding than previous reports.   
 
Is it possible that there are different pathways through which height influences melanoma risk, 
which manifest to greater or lesser extent depending on the setting? Adult height is determined by 
various growth mechanisms, as well as by childhood environment, any of which may influence 
melanoma risk.  Previous investigators have speculated that height is a proxy for the total number of 
cells (including stem cells) in the body, which presumably increases the probability of mutations 
and hence malignancy [139]. Various hormones implicated in childhood growth, such as insulin-
like growth factor (IGF)-I  [313], also regulate cell turnover, apoptosis and tumour progression 
[140], and thus could be implicated in cancer development. These mechanisms are presumably 
largely under genetic control, and the genetic associations between height and melanoma might be 
mediated through these pathways. ‘Biological’ mechanisms to explain the association between 
height and melanoma have intuitive appeal, but it is also possible that height might increase 
melanoma risk through other pathways, at least in some populations. Recently, a Mendelian 
randomisation study conducted within the UK BioBank (using very similar instruments to those that 
we used) reported that genetically predicted height was significantly associated with four different 
measures of socioeconomic status, with strong positive associations observed for job class and 
annual household income [419]. Previous observational studies, particularly those conducted in 
settings of low ambient sunlight (such as northern Europe), have reported significantly higher 
melanoma incidence among people in high SES categories compared to those in low SES 
categories. In those settings, it has been postulated that greater affluence has given greater access to 
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holidays in sunny locations and sunburns, thereby conferring an increased risk of melanoma [420-
422].  Occupational studies from the UK [423] and Sweden [424] corroborate this hypothesis, 
showing that indoor workers have significantly higher risks of melanoma than outdoor workers in 
those countries. Thus, at a population-level, it is possible to causally associate genetically-
determined height with melanoma through a pathway of social class and sun exposure. We could 
not conduct mediation analyses to explore this further as measures of social class and sun exposure 
were not available from the Melanoma GWAS meta-analysis, but this would be a worthwhile 
pursuit. 
 
The link between height and social class might also partly explain the complex associations 
between height and melanoma observed in QSkin. In the highly sun-exposed population of 
Queensland, higher social class is associated with adoption of early detection activities and higher 
likelihood of a melanoma diagnosis. Lower social class is associated with outdoor work, which in 
Queensland, increases the risk of melanoma. Thus, it is plausible that both lower and greater height 
could confer increased risks of melanoma, and that these complex associations likely depend on the 
setting. 
 
In conclusion, this large-scale Mendelian randomisation analysis supports the findings of earlier 
observational studies and provides strong evidence that height is a risk factor for melanoma. The 
observational arm of our study found some evidence for an association between height and 
melanoma in men but not women. In reality, these apparently discordant findings between genetic 
and observational analyses probably reflect the varying proportions of contributing risk factors, for 
which the magnitude of their attributable fractions depends on the setting in which the participants 
were recruited. While some might conclude that the Mendelian randomisation result implies 
causality, we are not yet ready to assert a directly causal effect. We can imagine various pathways 
through which genetically predicted height might lead to an increased risk of melanoma, some of 
which might include sun exposure and increased detection. Untangling these potential causal 
pathways is the focus of our continuing research.  
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7  Summary and Conclusions  
7.1 Introduction  
Skin cancers are the most frequently occurring form of all cancers diagnosed in Australia each year 
[22, 104]. The three most common forms of skin cancer are basal cell carcinoma (BCC), squamous 
cell carcinoma (cSCC) and cutaneous melanoma (CM) [7]. It is expected that approximately two in 
three Australian will be diagnosed with a skin cancer before the age of 70 [22]. The cost of 
managing skin cancer is the highest for all cancers and imposes a considerable burden to the 
Australian health system [425]. Exposure to ultra-violet radiation and having a sun-sensitive 
phenotype are established as the major causal factors for skin cancer [144] [122, 125], but other 
factors have been implicated. Understanding which risk factors play a role in skin cancer 
development is essential for both understanding disease biology and in developing effective 
preventive interventions.  
 
Cigarette smoking, obesity and height have been shown to be etiologically related to several cancers 
in humans. However, their role in the development of skin cancer is poorly understood despite 
extensive investigations. Previous epidemiological studies evaluating the potential roles of these 
factors in altering risks of skin cancer have had numerous potential limitations that rendered them 
open to questions of bias and confounding. The body of work presented in this thesis attempted to 
investigate these associations by using various epidemiological and statistical techniques aiming to 
overcome some of the limitations of previous studies. This final Chapter recapitulates the key 
findings and significance of the work included in this thesis, compares the findings with those from 
previous studies and explores the evidence for causality for exposure-outcome pairs where a 
significant association was observed. The public health implications of the findings and 
opportunities for future research are also discussed. 
 
7.2 Summary of key findings 
7.2.1 Smoking and risk of skin cancer 
The International Agency for Research on Cancer (IARC) has declared smoking a cause of 18 
cancers [260]. Currently, no cancer of the skin is included in this list. Tobacco smoke contains 
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many mutagenic compounds that are thought to have an effect on skin through DNA damage [268, 
426] or through impaired immune function [427]. In this thesis the role of cigarette smoking in the 
development of skin cancer was investigated using data from a large population-based cohort study 
(QSkin) purpose-designed to investigate skin cancer outcomes. 
 
The association between cigarette smoking and risk of BCC, cSCC and melanoma was evaluated 
and described in Chapter 4 and Chapter 5. Using observational data from the QSkin cohort, it was 
found that current smokers were less likely than never smokers to be diagnosed with a new BCC 
but were significantly more likely to be diagnosed with a new cSCC. Current smoking was not 
associated with melanoma risk. Former smokers had similar risks of BCC and cSCC as never 
smokers but had a lower risk of melanoma. For all three skin cancer types, no dose-response trends 
were observed with duration of smoking or intensity, except for melanoma where risks were lower 
with greater quantity of cigarettes smoked. 
 
The lower risks of BCC and melanoma observed among current smokers are largely similar to those 
of previous prospective studies that reported a moderately reduced risk of BCC and melanoma 
among smokers [264, 338, 348, 354, 362]. It was important to consider whether other explanations, 
such as bias or residual confounding, might underlie the inverse association with smoking. For 
BCC, the lower risk was possibly a result of lower healthcare utilisation among smokers, which 
influenced the likelihood of skin cancer detection. The data described in Chapter 4 show that never 
smokers tend to be more highly educated and more likely to have private health insurance than 
smokers.  High educational attainment and private health insurance are proxies of high socio-
economic status (SES), and high SES has been shown to have a direct impact on the frequency of 
doctor’s appointments [428, 429]. Hence, the higher incidence of BCC among never smokers might 
be a result of increased opportunities for screening for skin cancer in this group. To account for 
possible biases arising as a result of disparities in health care utilization, further analyses stratified 
by history of prior physician skin examinations was conducted. In these analyses, the inverse 
association between current smoking and BCC was only observed among those with a history of 
physician skin checks; current smokers with no such history had the same risk of BCC as never 
smokers. In summary, the inverse association between current smoking and BCC was likely 
explained by detection bias whereby never smokers had regular medical check-ups and procedures, 
thus increasing the likelihood of BCC detection.   
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As for BCC, stratified analyses were performed to explore the possible role of detection bias in 
contributing to the observed effect of current smoking on cSCC risk. Current smokers had 
significantly higher risks of cSCC than never smokers regardless of prior skin examination history, 
although risks were attenuated among those who had previously had their skin examined by a 
doctor. However, the test for interaction showed that these estimates were not statistically different.  
Thus, in comparison with BCC, the incidence of cSCC was not substantially affected by regular 
skin examinations [340]. This may be because cSCC almost always occurs on easily visible body 
sites, and lesions come to patient’s attention readily, leading to timely diagnosis. In addition, BCCs 
are slow-growing tumours with a longer preclinical period, and frequent skin examinations can 
therefore provide a relatively greater opportunity to detect more indolent BCCs than cSCCs.  
 
Unlike other cancers for which clear dose-response relationships with increasing duration and 
intensity of smoking exposure are observed [347], no significant dose-response trends were found 
with either duration or intensity of smoking and any of the three skin cancer types. The absence of a 
dose-response trend does not rule out causality, however, and other criteria support a potential 
causal effect of smoking on cSCC. The effect of current smoking on cSCC was very strong and 
remained stable even after adjustment and stratification. The finding was in accordance with most 
previous observational studies that had reported significantly increased risk of cSCC among current 
smokers [263, 350, 353]. The cohort data ensured temporal sequence of exposure and outcome 
measurements. There are analogies with stronger findings for other cancers and finally, there is a 
number of biologically plausible pathways that may underlie the association. Collectively, these 
concordant observations provide strong evidence that the association between smoking and cSCC is 
most likely causal. A deeper assessment of causality follows [see section 1.3].  
 
For the association between smoking and melanoma, a higher incidence of melanoma amongst 
never smokers might be a result of increased opportunities for melanoma detection as well, thereby 
creating a spurious inverse association with smoking status. The analyses stratified by history of 
skin examination could not be carried out however, because of small numbers of melanoma cases. 
Longer follow-up of the cohort would resolve this unanswered question. 
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7.2.2 Body mass index and risk of melanoma  
Epidemiological studies have reported a positive association been obesity, as measured by body 
mass index, and risk of cancer at a number of different sites [129]. The molecular mechanisms 
through which obesity confers a higher risk of cancer are poorly understood, however; various 
hormonal and inflammatory pathways are implicated [130, 131]. Previous studies examining the 
potential role of obesity in altering the risk of melanoma had yielded heterogeneous findings [129, 
132, 307] [293]. Given the growing epidemic of obesity prevalence worldwide [11] and rapid 
increase in the incidence of melanoma observed in many populations [12], understanding the 
epidemiological link between obesity and melanoma can help elucidate disease biology and may 
have implications for melanoma control.  
 
To resolve the inconsistency seen in earlier studies, three separate analyses were conducted to test 
whether obesity (as determined by BMI) is related to melanoma risk. This association was first 
evaluated using data from the QSkin cohort. Subsequently, a dose-response meta-analysis 
comprising 14 prospective cohort studies (including QSkin) was conducted. Finally, instrumental 
variables derived from the very large international GWAS datasets of BMI and melanoma were 
used to perform Mendelian randomisation analyses. 
 
Overall, the three separate analyses found little evidence that obesity is a risk factor for melanoma, 
although observational data revealed a possible non-linear association in women. This finding is 
contrary to earlier observational studies that reported increased risks of melanoma among 
overweight and obese people [129, 293, 309, 397]. While observational studies can identify 
associations, they cannot always establish whether the relationship is causal, notably in instances 
where confounding is believed to be present but is not fully controlled for. For example, many 
epidemiological studies rely on self-reported weight and height measurements [308] [132, 134] 
which are subject to sex-specific misclassification [294, 295]. In addition, few studies had adjusted 
for confounding effect of sun exposure [131, 430], the major risk factor for melanoma. Therefore, it 
is possible that residual confounding inherent to observational studies explained, at least in part, the 
increased risk of melanoma among obese people reported in earlier studies.  
 
The Mendelian randomisation analyses employed to test whether genetically predicted BMI is a risk 
factor for melanoma can be regarded as a natural RCT because genetic variants associated with 
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BMI are randomly assigned at conception and highly unlikely to be confounded by other traits.  
Consistent with the observational data, the MR analyses showed no evidence that genetically 
predicted BMI was associated with the risk of melanoma. Sex-specific associations could not be 
examined however, because the currently published melanoma GWAS meta-analysis did not report 
sex-specific estimates. Therefore, the apparent non-linear effect seen among women based on 
observational data, could not be confirmed using Mendelian randomisation analyses. On balance, 
and based on three separate epidemiological approaches, the null findings presented here suggest 
that the association between BMI and melanoma is unlikely to be causal.  In future, the availability 
of sex-specific summary data from melanoma GWAS studies would facilitate sex-specific 
Mendelian randomisation analyses in order to rule out differential effects by sex. 
 
7.2.3 Height and risk of melanoma  
A number of previous studies have shown that tall people are more prone to various cancers 
including melanoma [138, 306-309]. However, most studies relied on self-reported height 
measurements with known potential for misclassification. In additional, information regarding 
earlier-life childhood illness and nutrition status, which are potential modifiable factors for height, 
were unavailable for all studies. In Chapter 7, Mendelian randomisation analyses were employed to 
assess whether the increased risk of melanoma reported in earlier studies represents a true causal 
relationship or is simply due to bias or confounding. Mendelian randomisation is less prone to 
confounding because environmental factors cannot change inherited genes and measurement error 
is relatively trivial because the contemporary advanced methods of genotyping provide precise 
measurements of genetic variants. Using more than 3000 instrumental variables for height derived 
from the largest international GWAS meta-analysis, the analyses showed that genetically-predicted 
height was significantly associated with an increased risk of melanoma.  
 
A subsequent analysis using data from the QSkin cohort was conducted to attempt to replicate 
findings from Mendelian randomisation analysis. Despite the limitations inherent to observational 
studies as discussed in previous sections of this Chapter, the QSkin cohort presented several 
strengths relative to earlier studies. For example, the cohort was purposely designed to evaluate skin 
cancer outcomes and the most common skin cancer risk factors were essentially collected at 
baseline. In the QSkin cohort, a modest positive association between increasing height and 
melanoma risk was seen when height was used as a linear term, and the linear association was 
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similar in magnitude to that of Mendelian randomisation analysis. This association was not 
statistically significant however, possibly because the study was underpowered due to a limited 
number of melanoma cases. In further investigations, a highly significant non-linear association was 
seen for men but not for women, suggesting that the association between height and melanoma may 
be non-linear and possibly restricted to men. This finding could not be replicated using Mendelian 
randomisation analysis however, because the current melanoma GWAS dataset does not include 
estimates by sex. Moreover, in Mendelian randomisation analysis, the effect of the exposure on the 
outcome is assumed to be strictly linear or log-linear in case of a binary outcome [431]. In 
comparison to findings described in earlier sections where increased incidence of BCC and cSCC 
was observed among never smokers compared to smokers, it is also possible that the association of 
height and melanoma could be partially due to the increased skin examinations among taller 
individuals.  As shown previously in Chapter 7, taller individuals tend to be highly educated and 
more likely to have private health insurance, similarly to never smokers, thereby conferring 
increased detection and higher chance for melanoma diagnosis. Nevertheless, this study supported 
evidence from earlier studies that height might be an independent causal factor for cutaneous 
melanoma. 
 
In this thesis, we first evaluated the association between genetically predicated BMI and melanoma 
risk. Subsequent and using similar methods, height was evaluated separately to assess whether 
genetically predicted height was independently associated with melanoma risk. Overall, the 
association between height and adiposity-related genetic variants with melanoma risk, revealed 
some evidence that genetically elevated height was associated with increased risk of melanoma, 
while little evidence was found that genetically elevated BMI was associated with melanoma risk. 
These findings suggest that the increased risks of melanoma among obese people reported in earlier 
studies were possibly driven by height related genetic variants.  
 
7.3 Evaluating the causal role of smoking in cSCC 
7.3.1 Consistency with other studies 
The findings presented in this thesis are broadly consistent with the published literature that 
reported increased risk of cSCC among smokers. Two previous meta-analyses reported moderately 
positive associations between current smoking and cSCC risk. The first meta-analysis, restricted to 
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prospective cohort studies, reported that ever smokers had slightly increased risk of cSCC compared 
with never smokers [263].  The second meta-analysis including cohort and case-control studies 
reported a 50% increased risk of cSCC among smokers [186]. Since completion of this analysis 
described in detail in Chapter 4, another meta-analysis including QSkin data was published [264]. 
Overall, the results from that meta-analysis were consistent with evidence presented in this thesis 
and showed a 20% increased risk of cSCC among current smokers compared with never smokers.  
 
Unlike earlier studies for which significant dose-response relationships with increasing duration and 
intensity of smoking exposure were reported [264, 347], no significant dose-response trends were 
seen with either duration or intensity of smoking. Although, in accordance with most previous 
studies, after quitting smoking, the risk of cSCC was reduced to the same level as someone who had 
never smoked, explaining partially the lack of association among former smokers.  
 
7.3.2 The potential role of bias and confounding 
Randomised controlled trials (RCTs) are regarded as gold standard to test for scientific hypothesis 
with reliable evidence [432]. In RCTs, the random allocation of the intervention ensure that 
comparable groups are obtained. However, their use is limited by ethical and practical concerns. 
Alternatively, a well-designed and thoroughly analysed observational studies can mimic RCTs and 
yield reliable estimates. However, confounding and bias are potential threats to validity of causal 
inference in observational studies [433]. Therefore, it is important to discuss the role of bias and 
confounding before a causal relationship can be entertained.  
 
Primarily, the highly significant association between current smoking and cSCC observed, and the 
magnitude of the association suggests that chance alone is unlikely to explain these findings. With 
regards to information bias, data on smoking history was obtained through self-reported 
questionnaires and recall bias and misclassification cannot be entirely excluded. This bias is, 
however, less likely to have affected these results as a validation study of this cohort showed that 
the repeatability for smoking measures was nearly perfect [321].  In addition, any bias arising as a 
result of misclassification of self-reported smoking information would be non-differential and 
would have biased estimates towards no association. The effect of current smoking on cSCC was 
more than 2-fold and if such a bias existed, the true causal effect may have been underestimated. 
The fact that all cSCCs diagnoses were histologically confirmed also reduced the likelihood of 
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potential outcome misclassification.  However, a reasonably high proportion of missing pathology 
data has been found among participants who reported having undergone treatment for KC. Three 
sets of sensitivity analyses were conducted to test the effect of missing cSCC outcome data, and 
none of these analyses resulted in remarkable change to the estimates. Additional sources of bias, 
such as detection bias have been explored by conducting subgroup analyses. Finally, it is unlikely 
that the associations reported here are due to confounding because the most common risk factors for 
skin cancer such as sun exposure and phenotypic characteristics have been adjusted for in 
multivariable analyses. However, the effect of residual confounding cannot be completely ruled out. 
For example, the measures of phenotypic characteristics showed a moderate to high repeatability 
whereas lower levels of agreement were seen for measures of sun exposure [321].  
 
7.3.3 Potential mechanisms of action 
Tobacco smoke contains more than 8000 compounds [434]. Among these, more than 70 have been 
classified by the  International Agency for Research on Cancer (IARC) as carcinogenic in humans 
and animals [267]. Many of these carcinogens are associated with multiple cancers which occur 
more frequently in smokers than non-smokers [260]. Multiple studies have demonstrated that 
tobacco smoke carcinogens interact with DNA, particularly though DNA methylation, and cause 
genetic changes [268, 426]. Tobacco smoke induced epigenetic alternations are accepted to form 
the central basis of smoking related carcinogenesis. For smoking and risk of cSCC, it is believed 
that nicotine, the main constituent of the cigarette smoke, has epigenetic properties which inhibit the 
Notch signalling pathway, a tumour suppressor gene in mammalian [435, 436]. The deletion of 
Notch in epidermal keratinocytes has been associated with increased skin carcinogenesis [437]. 
 
Immunosuppression is also a recognised risk factor for cSCC [194, 195]. Experimental studies have 
shown that chronically nicotine exposed animals express absence of the normal immune response 
activation [427, 438], indicating the immunosuppressive effects of tobacco smoke.  
 
7.4 Evaluating the causal role of height in melanoma 
7.4.1 Consistency with other studies 
The findings from the Mendelian randomisation analysis described in this thesis in relation to height 
and melanoma generally agree with the literature. In the UK Million Women Study, a 30% 
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increased risk of melanoma per 10cm increase in height was reported [138]. A large Norwegian 
cohort also observed a 50% increased melanoma risk for men and women in the fifth quintile of 
height versus first quintile [309].  A pooled analysis comprising 8 case-control studies provided 
additional support for the existence of associations of height with melanoma in women.  
 
In analyses examining for linear associations, a modestly increased risk was found between 
increasing height and melanoma. The results from the QSkin cohort suggested a slightly increased 
linear association between height and melanoma. This analysis did not reach a statistical 
significance however, possibly because of limited number of melanoma cases. Overall, the 
magnitude of associations for Mendelian randomisation and the QSkin cohort analyses was smaller 
compared to other studies, possibly because the high levels of ambient sun exposure in Queensland 
may have overridden the effect of height on melanoma.  
 
7.4.2 The potential role of bias and confounding 
In the QSkin cohort, height measurements were self-reported. Self-reported information tends to be 
overestimated in shorter individuals, particularly among men [439]. While self-reported information 
can be a threat to the validity of observational studies, the repeatability of height measurements in 
this cohort was virtually perfect [321]. Moreover, the mean height of men and women in the cohort 
was quite similar to the general population in Queensland. Therefore, misclassification is unlikely 
to have influenced these findings. Attrition bias was highly unlikely as well because follow-up for 
melanoma events was through record linkage to the cancer registry (registration of melanoma is 
mandatory in Queensland).  
 
The current study, and some of the earlier observational studies, may have been limited by the lack 
of information on factors related to childhood illness and socioeconomic status. These factors are 
regarded as potential modifiable determinants of growth during childhood. However, the heritability 
of human height is extremely high (~90%) [414], and the extent of bias due to residual confounding 
is arguably trivial. Furthermore, results from Mendelian randomisation analyses support the 
evidence from observational studies and any residual confounding would not have remarkably 
affected these results.  
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7.4.3 Potential mechanisms of action  
Height as a proxy for the total number of cell in the body 
A number of previous studies have shown that height is a proxy for the total number of cells 
(including stem cells) in the body. They hypothesised that cancer risk increases with tissue size as  
more cells provide more targets for oncogenic mutations leading to malignancy [312] [139]. 
However, this hypothesis seems counterintuitive because cancer incidence does not necessarily 
increase with body size across different species. For example, the risk of cancer is much higher in 
humans than in the largest living mammals such as blue whales [440]. Similarly, increased cancer 
susceptibility has been seen in mice than in humans [440]. The lack of correlation between body 
size and cancer risk across species is known as Peto’s Paradox [441], interest in which has provided 
new insights for cancer prevention. Some of the postulated solutions suggest that larger organisms 
might have evolved cancer suppressing mechanisms to live longer [442]. For example, a recent 
study has shown that the genome of an elephant has 20 copies of the P53 tumour suppressor gene 
whereas humans have only one [88]. Cell size is another proposed key factor underlying the 
paradox. Larger organisms have bigger cells and larger cells have lower mitotic rates than smaller 
ones [443]. Therefore, body size is presumably an imperfect proxy of the total number of cells in an 
organism across species, but cancer risk and body size are positively correlated within members of 
the same species [138, 306, 308, 309]. Collectively, these solutions provide some evidence that the 
link between body size and cancer risk is plausible.  
 
Height as a proxy marker of growth factors 
Adult height is a result of various growth process from conception to adulthood. This process is 
influenced not only by genetic factors but also growth factors and hormones. Previous studies have 
shown that various growth hormones such as insulin-like growth factors (IGFs), in particular IGF-1 
[314], are positively correlated with adult height [315, 316]. IGF-1 is known to regulate apoptosis 
and tumour progression [140] and could be implicated in cancer development. IGF-1 may also 
influence cancer development directly through increased mitotic rates observed among people with 
high IGF-1 levels [312].  Therefore, height itself is unlikely to increase cancer risk, but instead, 
height may be a marker of the growth processes that are linked to cancer risk.  
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Height as a predictor of socio-economic class 
The association between height and melanoma has also been previously speculated to be indirectly 
mediated through socioeconomic class. Recently, a Mendelian randomisation study conducted 
within the UK BioBank reported that genetically predicted height was associated with 
socioeconomic status (SES) [419]. Increased risk of melanoma has been reported among people 
with high SES compared to those with low SES, although the risk was greatly dependent on the 
geographical location. For example, in settings with low levels of ambient sunlight such as Northern 
Europe, higher SES provided more travelling opportunities that could potentially have led to 
increased sun exposure and sunburns, thereby conferring an increased risk of melanoma [420-422]. 
In high ambient sunlight settings such as Queensland, high SES is associated with increased skin 
cancer awareness and screening, resulting in a higher chance of melanoma detection. Lower SES is 
also associated with outdoor work, which in Queensland, does increase the risk of melanoma. Thus, 
it is plausible that both lower and greater height could confer increased risks of melanoma, and that 
these complex associations likely depend on the setting. 
 
7.5 Directions for future research 
The body of work presented in this thesis has generated sufficient evidence to suggest causal 
relationships between smoking and cSCC; and height and melanoma. Little evidence was found that 
smoking or BMI were risk factors for melanoma. While studies included in this thesis presented 
several strengths to generate a high level of evidence, there are still some gaps in knowledge that 
warrant further investigation 1) A causal link between smoking and cSCC is plausible, however, no 
compelling biologic mechanisms are as yet known to support this evidence.  Experimental studies 
to elucidate mechanistic processes underpinning this association are recommended. For example, it 
is worthwhile to explore potential molecular changes induced by cigarette smoke and how these 
changes contribute to skin carcinogenesis. 2) The association between smoking and melanoma was 
underpowered due to limited number of melanoma cases. As a result, stratified analyses by history 
of skin checks could not be carried out to rule out potential detection biases. Longer follow-up of 
the QSkin cohort would resolve this question, since more melanomas cases would be eventually 
diagnosed, allowing several subgroup analyses. 3) In this thesis, the Mendelian randomisation 
analyses employed to assess for the association between BMI, height and melanoma presented two 
potential limitations. First, the two sample Mendelian randomisation analyses methods employed 
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could not test for nonlinear associations.  Thus, the availability of individual level data from 
melanoma GWAS consortium would allow nonlinear Mendelian randomisation analyses to be 
conducted in future. Secondly, the lack of sex-specific GWAS summary data could not allow sex-
specific Mendelian randomisation analyses. While findings reported in this thesis suggest that a 
causal association between obesity and melanoma is unlikely, sex-specific Mendelian 
randomisation studies are needed before a lack of effect can be confirmed conclusively. 
Additionally, height has been previously reported as a potential explanatory factor for sex 
differences in cancer risk, with more than 50% excess risk for men mediated by height [444]. As 
more GWAS data become publicly available, future research should focus on sex-specific 
Mendelian randomisation analyses to disentangle height and melanoma associations by gender.  
 
7.6 Public health implications 
In 2015, it was estimated that over 1.1 billion people worldwide smoked tobacco, with higher 
prevalence reported for men than for women [445]. The prevalence of current smoking in Australia 
was reported as 14.5% (2.6 million) in 2015 [256], a decline from 28% in 1990 [257], reflecting 
concerted action over the past two decades. Tobacco smoking remains the leading preventable 
cause of cancer worldwide, with the International Agency for Research on Cancer (IARC) declaring 
tobacco as a cause for 18 human cancers [260]. Although no cancers of the skin are currently 
included on the list of tobacco-associated cancers, the findings reported in this thesis provided a 
compelling evidence that smoking is a potential cause of cutaneous cSCC. Previous policies of the 
Australian government in banning tobacco promotion have been successful in reducing tobacco use. 
cSCC should be considered as a possible tobacco-associated cancer likely. As the number of 
cancers attributable to tobacco smoking continues to increase, continued efforts to promote smoke-
free lifestyles are imperative.  
 
Tall stature is another highly prevalent risk factor for several cancers. Over the last two centuries, 
human height has steadily increased as result of improvements in health and nutrition [446]. While 
the most effective way to reduce cancer risks involves elimination of causal risk factor, adult height 
is a non-modifiable factor. Therefore, modifying height to target cancer prevention is not practically 
feasible. However, understanding the mechanisms underlying this association may provide valuable 
understanding of carcinogenesis processes. Further research is needed, but it is possible that height 
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may also contribute to future risk stratification algorithms which could be used to target people for 
early detection activities.   
 
7.7 Conclusion 
In summary, the findings of this thesis suggest that smoking is not a risk factor for BCC or 
melanoma. The apparent lower risks of BCC or melanoma may reflect less health-conscious 
smokers being less likely to undergo skin screening and procedures resulting in lower incidence of 
these tumours rather than a truly protective effect. The significantly increased risk of cSCC among 
current smokers reported may be causal, because the association is consistent with evidence from 
other cohort studies and other essential criteria for causation such as temporality, strength of 
association and biological plausibility have been demonstrated. Finally, higher BMI was not 
associated with melanoma risk, but in accordance with earlier studies, height was found to be 
strongly associated with melanoma. Mechanisms through which greater height might lead to 
increased risk of melanoma remain unclear, and it is possible that the effect are mediated through 
hormonal and genetic pathways or through social class and sun exposure.   
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9 Appendixes 
9.1  Appendix A: QSkin cohort study questionnaire  
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9.2 Appendix B: MBS item numbers for treatment of skin cancer 
 
Service Item Numbers Total number 
of claims  
Surgical 
excision 
Keratinocyte cancer 
(including keratoacanthoma), 
Primary Surgical Excision 
(KCm) 
31255, 31260, 31265, 31270, 
31275, 31280, 31285, 31290 
4830 
Residual and Recurrent 
keratinocyte cancer, 
previously treated surgically 
(Otherm) 
31256, 31261, 31266, 31271, 
31276, 31281, 31286, 31291, 
31257, 31262, 31267, 31272, 
31277, 31282, 31287, 31292, 
31258, 31263, 31268, 31273, 
31278, 31283, 31288, 31293,  
173 
Residual and Recurrent 
keratinocyte cancer, 
previously treated non- 
surgically (Otherm) 
31295 
Melanoma (Otherm)                                31300, 31305, 31310, 31315, 
31320, 31325, 31330, 31335 
274 
Biopsy  30071 6636 
Other 
treatment  
(cryotherapy 
or serial 
curettage) 
Malignant Event (Otherm) 
 
30196, 30197, 30202, 30203, 
30205 
1876 
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9.3 Appendix C: Pathology reports data collection instrument  
QSKIN PATHOLOGY DATA ENTRY  
(MS Access) 
 
 
DATA ENTRY: PAGEVIEW 
Section 1. Pathology report 
Section 2. Data entry window 
Section 3. Medicare record 
DATA ENTRY WINDOW (Variables) 
ID (RecordNumber) - Pathology record number  
UID (ID) – QSkin unique ID. 
DateDx (DateDx) - Date of collection of pathology specimen.  
LesionNumber (LesionNumber) - Records per pathology report. 
Diagnosis (Diagnosis 1) – Primary diagnosis of keratinocyte tumour. 
Subtype (Diagnosis 2) - Subtypes of BCC. 
Site (Site) - Anatomical site of lesion. 
Site Face (SiteFace) – Anatomical subdivisions of face. 
Procedure (Excision OR Biopsy) – Treatment procedure, whether total excision of lesion or biopsy of lesion. 
Initial/Recurrent/ residual – Primary, recurrent or residual lesion 
MedicareMatching– whether or not the treatment procedure stated in pathology record matches with the Medicare 
claim. 
MedicareRecordNumber - Medicare Record Numbers are entered if a corresponding Medicare Record is available for 
the participant’s pathology report. 
MatchedRecordNumber / MatchedLesionNumber– matched record numbers and lesion numbers were entered if a 
biopsy was done prior to a surgical excision of the same lesion or where a re-excision was carried out (to prevent 
duplication of the records). i.e. the matching lesions were given one another’s record number (ID on pathology report) 
and lesion number.  
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DIAGNOSIS 1 
Code Diagnosis Notes 
Malignant Lesions 
11 BCC Most common subtypes of BCC 
 Nodular 
 Superficial  
 Pigmented  
 Sclerosing 
 Cystic  
 Others 
12 cSCC  
13 Melanoma See 44 –lentigo maligna 
Pre-Malignant Lesions 
21 Keratoacanthoma (KA)  
22 Intraepidermal carcinoma (IEC) Intraepidermal cSCC, in-situ cSCC 
23 Bowen’s disease Bowenoid solar keratosis 
Bowenoid seb. keratosis 
24 Solar keratosis lichenoid solar keratosis 
actinic keratosis 
focal acantholytic solar keratosis 
cSCC lesions arising from. 
210 KA giving rise to cSCC  
220 IEC  giving rise to cSCC  
230 Bowen’s dis.  giving rise to cSCC  
unconfirmed Squamous lesions 
65 Squamo-proliferative lesions Lesions with unconfirmed differential diagnosis 
of cSCC, KA,IEC and BD 
44 Lentigo maligna Entered as melanoma if reported as type 1 LM 
Hutchinson's melanotic freckle 
Re-Excisions with no residual lesions 
61 BCC re-excision - clear  
62 cSCC re-excision - clear  
63 IEC re-excision - clear  
64 Melanoma re-excision - clear  
Non-malignant lesion 
88 Non-malignant lesion Non-malignant lesions (except AK, which is 
classified under pre-malignant) 
Other malignant skin lesions  
89 Other malignant skin lesions  
Non-skin lesions 
99 Non-skin Non-skin lesions 
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SITE (anatomical sites) 
Code Body site Notes 
1 Face  sub-division entered under SiteFace 
2 Scalp 
Vertex,temporal, mastoid, superior to 
superior sternomastoid (inserted into 
mastoid process), hair line 
3 Ears concha, helix, (post /pre auricle) 
4 Neck 
scm, behind ear, sternomastoid,under the 
chin, submandibular 
5 Shoulders 
clavicle, deltoid, supraclavicular, anterior 
trapezius 
6 Upper chest/ Sternoclavicular 
supra sternal notch, inferior to clavicle, 
proximal sternum 
7 Breast 
lower chest, chest, pectoral area, central 
chest, anterior chest, posterolateral thorax, 
between breast,axilla, peristernal 
8 Abdomen 
flank, perineum, xiphoid area, epigastrium, 
groin, suprapubic, loin  
9 Back/ NOS trapezius 
10 Buttock  
11 UpperArm Biceps, arm 
12 Forarm, Elbow, Wrist lower arm, cubital fossa 
13 Back Of Hand metacarpal 
14 Palmer Skin, Fingers thenar eminance 
15 Finger nail  
16 Thigh  
17 Lower Leg, Ankle, Knee 
Proximal leg, upper leg, leg, malleolus, 
tibia, leg, gaiter area, LL 
18 Top of feet Instep, calcaneum 
19 Plantar Skin, Toes  
20 Toe nail  
21 Illegible  
22 No record  
31 Upper back 
Upper posterior trunk, level above tip  of 
scapula (lower end), T1 – T7, shoulder 
blade, mid back superior 
32 Lower back 
Lower posterior trunk mid back, ASIS, mid 
back inferior  
33 Trunk/NOS Upper/Lower trunk,  
51 Perineum Vulva 
52 Hip  
88 Skin/NOS  
99 Non-Skin  
 
SITE FACE (SUBDIVISION) 
Code Site Notes 
1 Skin of orbit/ eyelid canthus, near the eyes 
2 Nose  alar groove, alar crease, nasion 
3 Lips philtrum, below nostrils, vermillion 
4 Cheeks zygoma, maxilla, malar, Face, side of face 
(R/face, L/face), Infra-orbital 
5 Chin/ Jaw Mandible, infra-auricular, mental crease, 
inferior face, lower face, lower parotid 
6 Forehead  eye brow, glabella, supraorbital, upper face, 
superior face 
7 Temple   
8 Face/NOS  
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PROCEDURES 
Code  Procedure Notes 
1 Excision Ellipse,  other descriptions if reported as excision 
complete (except punch/shave) 
2 Biopsy-Punch Cylindrical portion, core biopsy 
3 Biopsy-Shave  
4 Curette C&C 
11 Other  
99 Uncertain  
 
INITIAL/RECURRENT 
Code  Procedure Notes 
1 Initial  
2 Recurrent  
3 Residual Re-excisions and wide-excisions; biopsy results 
reported as residual lesion  
 
 
 
 
